#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Aberrant salience network functional connectivity in auditory verbal hallucinations: a first episode psychosis sample
#Text=Auditory verbal hallucinations (AVH) often lead to distress and functional disability, and are frequently associated with psychotic illness.
1-1	0-8	Aberrant	_	
1-2	9-17	salience	_	
1-3	18-25	network	_	
1-4	26-36	functional	_	
1-5	37-49	connectivity	_	
1-6	50-52	in	_	
1-7	53-61	auditory	_	
1-8	62-68	verbal	_	
1-9	69-83	hallucinations	_	
1-10	83-84	:	_	
1-11	85-86	a	_	
1-12	87-92	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-13	93-100	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-14	101-110	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-15	111-117	sample	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-16	118-126	Auditory	_	
1-17	127-133	verbal	_	
1-18	134-148	hallucinations	_	
1-19	149-150	(	_	
1-20	150-153	AVH	_	
1-21	153-154	)	_	
1-22	155-160	often	_	
1-23	161-165	lead	_	
1-24	166-168	to	_	
1-25	169-177	distress	_	
1-26	178-181	and	_	
1-27	182-192	functional	_	
1-28	193-203	disability	_	
1-29	203-204	,	_	
1-30	205-208	and	_	
1-31	209-212	are	_	
1-32	213-223	frequently	_	
1-33	224-234	associated	_	
1-34	235-239	with	_	
1-35	240-249	psychotic	_	
1-36	250-257	illness	_	
1-37	257-258	.	_	

#Text=Previously both state and trait magnetic resonance imaging (MRI) studies of AVH have identified activity in brain regions involving auditory processing, language, memory and areas of default mode network (DMN) and salience network (SN).
2-1	259-269	Previously	_	
2-2	270-274	both	_	
2-3	275-280	state	_	
2-4	281-284	and	_	
2-5	285-290	trait	_	
2-6	291-299	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-7	300-309	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-8	310-317	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-9	318-319	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-10	319-322	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-11	322-323	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-12	324-331	studies	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[2]	
2-13	332-334	of	_	
2-14	335-338	AVH	_	
2-15	339-343	have	_	
2-16	344-354	identified	_	
2-17	355-363	activity	_	
2-18	364-366	in	_	
2-19	367-372	brain	_	
2-20	373-380	regions	_	
2-21	381-390	involving	_	
2-22	391-399	auditory	_	
2-23	400-410	processing	_	
2-24	410-411	,	_	
2-25	412-420	language	_	
2-26	420-421	,	_	
2-27	422-428	memory	_	
2-28	429-432	and	_	
2-29	433-438	areas	_	
2-30	439-441	of	_	
2-31	442-449	default	_	
2-32	450-454	mode	_	
2-33	455-462	network	_	
2-34	463-464	(	_	
2-35	464-467	DMN	_	
2-36	467-468	)	_	
2-37	469-472	and	_	
2-38	473-481	salience	_	
2-39	482-489	network	_	
2-40	490-491	(	_	
2-41	491-493	SN	_	
2-42	493-494	)	_	
2-43	494-495	.	_	

#Text=Current evidence is clouded by research mainly in participants on long-term medication, with chronic illness and by choice of seed regions made ‘a priori’.
3-1	496-503	Current	_	
3-2	504-512	evidence	_	
3-3	513-515	is	_	
3-4	516-523	clouded	_	
3-5	524-526	by	_	
3-6	527-535	research	_	
3-7	536-542	mainly	_	
3-8	543-545	in	_	
3-9	546-558	participants	_	
3-10	559-561	on	_	
3-11	562-571	long-term	_	
3-12	572-582	medication	_	
3-13	582-583	,	_	
3-14	584-588	with	_	
3-15	589-596	chronic	_	
3-16	597-604	illness	_	
3-17	605-608	and	_	
3-18	609-611	by	_	
3-19	612-618	choice	_	
3-20	619-621	of	_	
3-21	622-626	seed	_	
3-22	627-634	regions	_	
3-23	635-639	made	_	
3-24	640-641	‘	_	
3-25	641-642	a	_	
3-26	643-649	priori	_	
3-27	649-650	’	_	
3-28	650-651	.	_	

#Text=Thus, the aim of this study was to elucidate the intrinsic functional connectivity in patients presenting with first episode psychosis (FEP).
4-1	652-656	Thus	_	
4-2	656-657	,	_	
4-3	658-661	the	_	
4-4	662-665	aim	_	
4-5	666-668	of	_	
4-6	669-673	this	_	
4-7	674-679	study	_	
4-8	680-683	was	_	
4-9	684-686	to	_	
4-10	687-696	elucidate	_	
4-11	697-700	the	_	
4-12	701-710	intrinsic	_	
4-13	711-721	functional	_	
4-14	722-734	connectivity	_	
4-15	735-737	in	_	
4-16	738-746	patients	_	
4-17	747-757	presenting	_	
4-18	758-762	with	_	
4-19	763-768	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-20	769-776	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-21	777-786	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-22	787-788	(	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-23	788-791	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-24	791-792	)	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
4-25	792-793	.	_	

#Text=Resting state functional MRI data were available from 18 FEP patients, 9 of whom also experienced AVH of sufficient duration in the scanner and had symptom capture functional MRI (sc fMRI), together with 18 healthy controls.
5-1	794-801	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
5-2	802-807	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
5-3	808-818	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
5-4	819-822	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
5-5	823-827	data	_	
5-6	828-832	were	_	
5-7	833-842	available	_	
5-8	843-847	from	_	
5-9	848-850	18	_	
5-10	851-854	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
5-11	855-863	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
5-12	863-864	,	_	
5-13	865-866	9	_	
5-14	867-869	of	_	
5-15	870-874	whom	_	
5-16	875-879	also	_	
5-17	880-891	experienced	_	
5-18	892-895	AVH	_	
5-19	896-898	of	_	
5-20	899-909	sufficient	_	
5-21	910-918	duration	_	
5-22	919-921	in	_	
5-23	922-925	the	_	
5-24	926-933	scanner	_	
5-25	934-937	and	_	
5-26	938-941	had	_	
5-27	942-949	symptom	_	
5-28	950-957	capture	_	
5-29	958-968	functional	_	
5-30	969-972	MRI	_	
5-31	973-974	(	_	
5-32	974-976	sc	_	
5-33	977-981	fMRI	_	
5-34	981-982	)	_	
5-35	982-983	,	_	
5-36	984-992	together	_	
5-37	993-997	with	_	
5-38	998-1000	18	_	
5-39	1001-1008	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-40	1009-1017	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-41	1017-1018	.	_	

#Text=Symptom capture results were used to accurately identify specific brain regions active during AVH; including the superior temporal cortex, insula, precuneus, posterior cingulate and parahippocampal complex.
6-1	1019-1026	Symptom	_	
6-2	1027-1034	capture	_	
6-3	1035-1042	results	_	
6-4	1043-1047	were	_	
6-5	1048-1052	used	_	
6-6	1053-1055	to	_	
6-7	1056-1066	accurately	_	
6-8	1067-1075	identify	_	
6-9	1076-1084	specific	_	
6-10	1085-1090	brain	_	
6-11	1091-1098	regions	_	
6-12	1099-1105	active	_	
6-13	1106-1112	during	_	
6-14	1113-1116	AVH	_	
6-15	1116-1117	;	_	
6-16	1118-1127	including	_	
6-17	1128-1131	the	_	
6-18	1132-1140	superior	_	
6-19	1141-1149	temporal	_	
6-20	1150-1156	cortex	_	
6-21	1156-1157	,	_	
6-22	1158-1164	insula	_	
6-23	1164-1165	,	_	
6-24	1166-1175	precuneus	_	
6-25	1175-1176	,	_	
6-26	1177-1186	posterior	_	
6-27	1187-1196	cingulate	_	
6-28	1197-1200	and	_	
6-29	1201-1216	parahippocampal	_	
6-30	1217-1224	complex	_	
6-31	1224-1225	.	_	

#Text=Using these as seed regions, patients with FEP and AVH showed increased resting sb-FC between parts of the SN and the DMN and between the SN and the cerebellum, but reduced sb-FC between the claustrum and the insula, compared to healthy controls.It is possible that aberrant activity within the DMN and SN complex may be directly linked to impaired salience appraisal of internal activity and AVH generation.
7-1	1226-1231	Using	_	
7-2	1232-1237	these	_	
7-3	1238-1240	as	_	
7-4	1241-1245	seed	_	
7-5	1246-1253	regions	_	
7-6	1253-1254	,	_	
7-7	1255-1263	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
7-8	1264-1268	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
7-9	1269-1272	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
7-10	1273-1276	and	_	
7-11	1277-1280	AVH	_	
7-12	1281-1287	showed	_	
7-13	1288-1297	increased	_	
7-14	1298-1305	resting	_	
7-15	1306-1311	sb-FC	_	
7-16	1312-1319	between	_	
7-17	1320-1325	parts	_	
7-18	1326-1328	of	_	
7-19	1329-1332	the	_	
7-20	1333-1335	SN	_	
7-21	1336-1339	and	_	
7-22	1340-1343	the	_	
7-23	1344-1347	DMN	_	
7-24	1348-1351	and	_	
7-25	1352-1359	between	_	
7-26	1360-1363	the	_	
7-27	1364-1366	SN	_	
7-28	1367-1370	and	_	
7-29	1371-1374	the	_	
7-30	1375-1385	cerebellum	_	
7-31	1385-1386	,	_	
7-32	1387-1390	but	_	
7-33	1391-1398	reduced	_	
7-34	1399-1404	sb-FC	_	
7-35	1405-1412	between	_	
7-36	1413-1416	the	_	
7-37	1417-1426	claustrum	_	
7-38	1427-1430	and	_	
7-39	1431-1434	the	_	
7-40	1435-1441	insula	_	
7-41	1441-1442	,	_	
7-42	1443-1451	compared	_	
7-43	1452-1454	to	_	
7-44	1455-1462	healthy	_	
7-45	1463-1474	controls.It	_	
7-46	1475-1477	is	_	
7-47	1478-1486	possible	_	
7-48	1487-1491	that	_	
7-49	1492-1500	aberrant	_	
7-50	1501-1509	activity	_	
7-51	1510-1516	within	_	
7-52	1517-1520	the	_	
7-53	1521-1524	DMN	_	
7-54	1525-1528	and	_	
7-55	1529-1531	SN	_	
7-56	1532-1539	complex	_	
7-57	1540-1543	may	_	
7-58	1544-1546	be	_	
7-59	1547-1555	directly	_	
7-60	1556-1562	linked	_	
7-61	1563-1565	to	_	
7-62	1566-1574	impaired	_	
7-63	1575-1583	salience	_	
7-64	1584-1593	appraisal	_	
7-65	1594-1596	of	_	
7-66	1597-1605	internal	_	
7-67	1606-1614	activity	_	
7-68	1615-1618	and	_	
7-69	1619-1622	AVH	_	
7-70	1623-1633	generation	_	
7-71	1633-1634	.	_	

#Text=Furthermore, decreased intrinsic functional connectivity between the claustrum and the insula may lead to compensatory over activity in parts of the auditory network including areas involved in DMN, auditory processing, language and memory, potentially related to the complex and individual content of AVH when they occur.
8-1	1635-1646	Furthermore	_	
8-2	1646-1647	,	_	
8-3	1648-1657	decreased	_	
8-4	1658-1667	intrinsic	_	
8-5	1668-1678	functional	_	
8-6	1679-1691	connectivity	_	
8-7	1692-1699	between	_	
8-8	1700-1703	the	_	
8-9	1704-1713	claustrum	_	
8-10	1714-1717	and	_	
8-11	1718-1721	the	_	
8-12	1722-1728	insula	_	
8-13	1729-1732	may	_	
8-14	1733-1737	lead	_	
8-15	1738-1740	to	_	
8-16	1741-1753	compensatory	_	
8-17	1754-1758	over	_	
8-18	1759-1767	activity	_	
8-19	1768-1770	in	_	
8-20	1771-1776	parts	_	
8-21	1777-1779	of	_	
8-22	1780-1783	the	_	
8-23	1784-1792	auditory	_	
8-24	1793-1800	network	_	
8-25	1801-1810	including	_	
8-26	1811-1816	areas	_	
8-27	1817-1825	involved	_	
8-28	1826-1828	in	_	
8-29	1829-1832	DMN	_	
8-30	1832-1833	,	_	
8-31	1834-1842	auditory	_	
8-32	1843-1853	processing	_	
8-33	1853-1854	,	_	
8-34	1855-1863	language	_	
8-35	1864-1867	and	_	
8-36	1868-1874	memory	_	
8-37	1874-1875	,	_	
8-38	1876-1887	potentially	_	
8-39	1888-1895	related	_	
8-40	1896-1898	to	_	
8-41	1899-1902	the	_	
8-42	1903-1910	complex	_	
8-43	1911-1914	and	_	
8-44	1915-1925	individual	_	
8-45	1926-1933	content	_	
8-46	1934-1936	of	_	
8-47	1937-1940	AVH	_	
8-48	1941-1945	when	_	
8-49	1946-1950	they	_	
8-50	1951-1956	occur	_	
8-51	1956-1957	.	_	

#Text=Introduction
#Text=Auditory verbal hallucinations (AVH) are commonly linked to schizophrenia and occur in over 75% of the patients with First Episode Psychosis (FEP).
9-1	1958-1970	Introduction	_	
9-2	1971-1979	Auditory	_	
9-3	1980-1986	verbal	_	
9-4	1987-2001	hallucinations	_	
9-5	2002-2003	(	_	
9-6	2003-2006	AVH	_	
9-7	2006-2007	)	_	
9-8	2008-2011	are	_	
9-9	2012-2020	commonly	_	
9-10	2021-2027	linked	_	
9-11	2028-2030	to	_	
9-12	2031-2044	schizophrenia	_	
9-13	2045-2048	and	_	
9-14	2049-2054	occur	_	
9-15	2055-2057	in	_	
9-16	2058-2062	over	_	
9-17	2063-2066	75%	_	
9-18	2067-2069	of	_	
9-19	2070-2073	the	_	
9-20	2074-2082	patients	_	
9-21	2083-2087	with	_	
9-22	2088-2093	First	_	
9-23	2094-2101	Episode	_	
9-24	2102-2111	Psychosis	_	
9-25	2112-2113	(	_	
9-26	2113-2116	FEP	_	
9-27	2116-2117	)	_	
9-28	2117-2118	.	_	

#Text=Current biological models of AVH can be grouped into those based on abnormal brain activation, source-monitoring deficits, or errors in prediction, .
10-1	2119-2126	Current	_	
10-2	2127-2137	biological	_	
10-3	2138-2144	models	_	
10-4	2145-2147	of	_	
10-5	2148-2151	AVH	_	
10-6	2152-2155	can	_	
10-7	2156-2158	be	_	
10-8	2159-2166	grouped	_	
10-9	2167-2171	into	_	
10-10	2172-2177	those	_	
10-11	2178-2183	based	_	
10-12	2184-2186	on	_	
10-13	2187-2195	abnormal	_	
10-14	2196-2201	brain	_	
10-15	2202-2212	activation	_	
10-16	2212-2213	,	_	
10-17	2214-2231	source-monitoring	_	
10-18	2232-2240	deficits	_	
10-19	2240-2241	,	_	
10-20	2242-2244	or	_	
10-21	2245-2251	errors	_	
10-22	2252-2254	in	_	
10-23	2255-2265	prediction	_	
10-24	2265-2266	,	_	
10-25	2267-2268	.	_	

#Text=The abnormal activation theory proposes that AVH arise from spontaneous activation in the primary auditory, superior temporal cortex and related memory areas.
11-1	2269-2272	The	_	
11-2	2273-2281	abnormal	_	
11-3	2282-2292	activation	_	
11-4	2293-2299	theory	_	
11-5	2300-2308	proposes	_	
11-6	2309-2313	that	_	
11-7	2314-2317	AVH	_	
11-8	2318-2323	arise	_	
11-9	2324-2328	from	_	
11-10	2329-2340	spontaneous	_	
11-11	2341-2351	activation	_	
11-12	2352-2354	in	_	
11-13	2355-2358	the	_	
11-14	2359-2366	primary	_	
11-15	2367-2375	auditory	_	
11-16	2375-2376	,	_	
11-17	2377-2385	superior	_	
11-18	2386-2394	temporal	_	
11-19	2395-2401	cortex	_	
11-20	2402-2405	and	_	
11-21	2406-2413	related	_	
11-22	2414-2420	memory	_	
11-23	2421-2426	areas	_	
11-24	2426-2427	.	_	

#Text=According to source monitoring accounts, AVH results from failure to accurately monitor one’s own internal speech, which is then attributed to an external source.
12-1	2428-2437	According	_	
12-2	2438-2440	to	_	
12-3	2441-2447	source	_	
12-4	2448-2458	monitoring	_	
12-5	2459-2467	accounts	_	
12-6	2467-2468	,	_	
12-7	2469-2472	AVH	_	
12-8	2473-2480	results	_	
12-9	2481-2485	from	_	
12-10	2486-2493	failure	_	
12-11	2494-2496	to	_	
12-12	2497-2507	accurately	_	
12-13	2508-2515	monitor	_	
12-14	2516-2519	one	_	
12-15	2519-2520	’	_	
12-16	2520-2521	s	_	
12-17	2522-2525	own	_	
12-18	2526-2534	internal	_	
12-19	2535-2541	speech	_	
12-20	2541-2542	,	_	
12-21	2543-2548	which	_	
12-22	2549-2551	is	_	
12-23	2552-2556	then	_	
12-24	2557-2567	attributed	_	
12-25	2568-2570	to	_	
12-26	2571-2573	an	_	
12-27	2574-2582	external	_	
12-28	2583-2589	source	_	
12-29	2589-2590	.	_	

#Text=Prediction error models are based on the Bayesian framework that proposes positive symptoms of psychosis including hallucinations arise due to a mismatch between prior expectations and incoming sensory information, leading to a prediction error and voice perception.
13-1	2591-2601	Prediction	_	
13-2	2602-2607	error	_	
13-3	2608-2614	models	_	
13-4	2615-2618	are	_	
13-5	2619-2624	based	_	
13-6	2625-2627	on	_	
13-7	2628-2631	the	_	
13-8	2632-2640	Bayesian	_	
13-9	2641-2650	framework	_	
13-10	2651-2655	that	_	
13-11	2656-2664	proposes	_	
13-12	2665-2673	positive	_	
13-13	2674-2682	symptoms	_	
13-14	2683-2685	of	_	
13-15	2686-2695	psychosis	_	
13-16	2696-2705	including	_	
13-17	2706-2720	hallucinations	_	
13-18	2721-2726	arise	_	
13-19	2727-2730	due	_	
13-20	2731-2733	to	_	
13-21	2734-2735	a	_	
13-22	2736-2744	mismatch	_	
13-23	2745-2752	between	_	
13-24	2753-2758	prior	_	
13-25	2759-2771	expectations	_	
13-26	2772-2775	and	_	
13-27	2776-2784	incoming	_	
13-28	2785-2792	sensory	_	
13-29	2793-2804	information	_	
13-30	2804-2805	,	_	
13-31	2806-2813	leading	_	
13-32	2814-2816	to	_	
13-33	2817-2818	a	_	
13-34	2819-2829	prediction	_	
13-35	2830-2835	error	_	
13-36	2836-2839	and	_	
13-37	2840-2845	voice	_	
13-38	2846-2856	perception	_	
13-39	2856-2857	.	_	

#Text=These models are not mutually exclusive and some commonality exists, for example prediction error can be implicated in source monitoring deficits.
14-1	2858-2863	These	_	
14-2	2864-2870	models	_	
14-3	2871-2874	are	_	
14-4	2875-2878	not	_	
14-5	2879-2887	mutually	_	
14-6	2888-2897	exclusive	_	
14-7	2898-2901	and	_	
14-8	2902-2906	some	_	
14-9	2907-2918	commonality	_	
14-10	2919-2925	exists	_	
14-11	2925-2926	,	_	
14-12	2927-2930	for	_	
14-13	2931-2938	example	_	
14-14	2939-2949	prediction	_	
14-15	2950-2955	error	_	
14-16	2956-2959	can	_	
14-17	2960-2962	be	_	
14-18	2963-2973	implicated	_	
14-19	2974-2976	in	_	
14-20	2977-2983	source	_	
14-21	2984-2994	monitoring	_	
14-22	2995-3003	deficits	_	
14-23	3003-3004	.	_	

#Text=Study of brain activity during hallucination itself (symptom capture) allows direct evidence of regions active during hallucinations, and studies using this method show these regions include areas important for auditory perception (primary auditory cortex, and middle and superior temporal cortex), language (inferior frontal gyrus), and memory (hippocampus and parahippocampus).
15-1	3005-3010	Study	_	
15-2	3011-3013	of	_	
15-3	3014-3019	brain	_	
15-4	3020-3028	activity	_	
15-5	3029-3035	during	_	
15-6	3036-3049	hallucination	_	
15-7	3050-3056	itself	_	
15-8	3057-3058	(	_	
15-9	3058-3065	symptom	_	
15-10	3066-3073	capture	_	
15-11	3073-3074	)	_	
15-12	3075-3081	allows	_	
15-13	3082-3088	direct	_	
15-14	3089-3097	evidence	_	
15-15	3098-3100	of	_	
15-16	3101-3108	regions	_	
15-17	3109-3115	active	_	
15-18	3116-3122	during	_	
15-19	3123-3137	hallucinations	_	
15-20	3137-3138	,	_	
15-21	3139-3142	and	_	
15-22	3143-3150	studies	_	
15-23	3151-3156	using	_	
15-24	3157-3161	this	_	
15-25	3162-3168	method	_	
15-26	3169-3173	show	_	
15-27	3174-3179	these	_	
15-28	3180-3187	regions	_	
15-29	3188-3195	include	_	
15-30	3196-3201	areas	_	
15-31	3202-3211	important	_	
15-32	3212-3215	for	_	
15-33	3216-3224	auditory	_	
15-34	3225-3235	perception	_	
15-35	3236-3237	(	_	
15-36	3237-3244	primary	_	
15-37	3245-3253	auditory	_	
15-38	3254-3260	cortex	_	
15-39	3260-3261	,	_	
15-40	3262-3265	and	_	
15-41	3266-3272	middle	_	
15-42	3273-3276	and	_	
15-43	3277-3285	superior	_	
15-44	3286-3294	temporal	_	
15-45	3295-3301	cortex	_	
15-46	3301-3302	)	_	
15-47	3302-3303	,	_	
15-48	3304-3312	language	_	
15-49	3313-3314	(	_	
15-50	3314-3322	inferior	_	
15-51	3323-3330	frontal	_	
15-52	3331-3336	gyrus	_	
15-53	3336-3337	)	_	
15-54	3337-3338	,	_	
15-55	3339-3342	and	_	
15-56	3343-3349	memory	_	
15-57	3350-3351	(	_	
15-58	3351-3362	hippocampus	_	
15-59	3363-3366	and	_	
15-60	3367-3382	parahippocampus	_	
15-61	3382-3383	)	_	
15-62	3383-3384	.	_	

#Text=However, there remains a lack of detailed modelling that explains the spontaneous, complex and transient nature of AVH, and how the aberrant activity in these brain regions is triggered in the absence of an external stimuli.
16-1	3385-3392	However	_	
16-2	3392-3393	,	_	
16-3	3394-3399	there	_	
16-4	3400-3407	remains	_	
16-5	3408-3409	a	_	
16-6	3410-3414	lack	_	
16-7	3415-3417	of	_	
16-8	3418-3426	detailed	_	
16-9	3427-3436	modelling	_	
16-10	3437-3441	that	_	
16-11	3442-3450	explains	_	
16-12	3451-3454	the	_	
16-13	3455-3466	spontaneous	_	
16-14	3466-3467	,	_	
16-15	3468-3475	complex	_	
16-16	3476-3479	and	_	
16-17	3480-3489	transient	_	
16-18	3490-3496	nature	_	
16-19	3497-3499	of	_	
16-20	3500-3503	AVH	_	
16-21	3503-3504	,	_	
16-22	3505-3508	and	_	
16-23	3509-3512	how	_	
16-24	3513-3516	the	_	
16-25	3517-3525	aberrant	_	
16-26	3526-3534	activity	_	
16-27	3535-3537	in	_	
16-28	3538-3543	these	_	
16-29	3544-3549	brain	_	
16-30	3550-3557	regions	_	
16-31	3558-3560	is	_	
16-32	3561-3570	triggered	_	
16-33	3571-3573	in	_	
16-34	3574-3577	the	_	
16-35	3578-3585	absence	_	
16-36	3586-3588	of	_	
16-37	3589-3591	an	_	
16-38	3592-3600	external	_	
16-39	3601-3608	stimuli	_	
16-40	3608-3609	.	_	

#Text=Thus the key question of how the brain generates AVH remains unanswered.
17-1	3610-3614	Thus	_	
17-2	3615-3618	the	_	
17-3	3619-3622	key	_	
17-4	3623-3631	question	_	
17-5	3632-3634	of	_	
17-6	3635-3638	how	_	
17-7	3639-3642	the	_	
17-8	3643-3648	brain	_	
17-9	3649-3658	generates	_	
17-10	3659-3662	AVH	_	
17-11	3663-3670	remains	_	
17-12	3671-3681	unanswered	_	
17-13	3681-3682	.	_	

#Text=Recently, theories of abnormal integration have been proposed to explain symptoms of schizophrenia, including delusions and hallucinations, with a central abnormality being aberrant activity in intrinsic brain networks such as the default mode network (DMN) or the salience network (SN).
18-1	3683-3691	Recently	_	
18-2	3691-3692	,	_	
18-3	3693-3701	theories	_	
18-4	3702-3704	of	_	
18-5	3705-3713	abnormal	_	
18-6	3714-3725	integration	_	
18-7	3726-3730	have	_	
18-8	3731-3735	been	_	
18-9	3736-3744	proposed	_	
18-10	3745-3747	to	_	
18-11	3748-3755	explain	_	
18-12	3756-3764	symptoms	_	
18-13	3765-3767	of	_	
18-14	3768-3781	schizophrenia	_	
18-15	3781-3782	,	_	
18-16	3783-3792	including	_	
18-17	3793-3802	delusions	_	
18-18	3803-3806	and	_	
18-19	3807-3821	hallucinations	_	
18-20	3821-3822	,	_	
18-21	3823-3827	with	_	
18-22	3828-3829	a	_	
18-23	3830-3837	central	_	
18-24	3838-3849	abnormality	_	
18-25	3850-3855	being	_	
18-26	3856-3864	aberrant	_	
18-27	3865-3873	activity	_	
18-28	3874-3876	in	_	
18-29	3877-3886	intrinsic	_	
18-30	3887-3892	brain	_	
18-31	3893-3901	networks	_	
18-32	3902-3906	such	_	
18-33	3907-3909	as	_	
18-34	3910-3913	the	_	
18-35	3914-3921	default	_	
18-36	3922-3926	mode	_	
18-37	3927-3934	network	_	
18-38	3935-3936	(	_	
18-39	3936-3939	DMN	_	
18-40	3939-3940	)	_	
18-41	3941-3943	or	_	
18-42	3944-3947	the	_	
18-43	3948-3956	salience	_	
18-44	3957-3964	network	_	
18-45	3965-3966	(	_	
18-46	3966-3968	SN	_	
18-47	3968-3969	)	_	
18-48	3969-3970	.	_	

#Text=Northoff proposed that AVH may result from abnormally elevated resting state activity in auditory cortex or from the default-mode network, with a ‘neural confusion’ between auditory resting state stimulus-induced activity, while Jardri et al. proposed that hallucinations occur during spontaneous DMN withdrawal.
19-1	3971-3979	Northoff	_	
19-2	3980-3988	proposed	_	
19-3	3989-3993	that	_	
19-4	3994-3997	AVH	_	
19-5	3998-4001	may	_	
19-6	4002-4008	result	_	
19-7	4009-4013	from	_	
19-8	4014-4024	abnormally	_	
19-9	4025-4033	elevated	_	
19-10	4034-4041	resting	_	
19-11	4042-4047	state	_	
19-12	4048-4056	activity	_	
19-13	4057-4059	in	_	
19-14	4060-4068	auditory	_	
19-15	4069-4075	cortex	_	
19-16	4076-4078	or	_	
19-17	4079-4083	from	_	
19-18	4084-4087	the	_	
19-19	4088-4100	default-mode	_	
19-20	4101-4108	network	_	
19-21	4108-4109	,	_	
19-22	4110-4114	with	_	
19-23	4115-4116	a	_	
19-24	4117-4118	‘	_	
19-25	4118-4124	neural	_	
19-26	4125-4134	confusion	_	
19-27	4134-4135	’	_	
19-28	4136-4143	between	_	
19-29	4144-4152	auditory	_	
19-30	4153-4160	resting	_	
19-31	4161-4166	state	_	
19-32	4167-4183	stimulus-induced	_	
19-33	4184-4192	activity	_	
19-34	4192-4193	,	_	
19-35	4194-4199	while	_	
19-36	4200-4206	Jardri	_	
19-37	4207-4209	et	_	
19-38	4210-4212	al	_	
19-39	4212-4213	.	_	
19-40	4214-4222	proposed	_	
19-41	4223-4227	that	_	
19-42	4228-4242	hallucinations	_	
19-43	4243-4248	occur	_	
19-44	4249-4255	during	_	
19-45	4256-4267	spontaneous	_	
19-46	4268-4271	DMN	_	
19-47	4272-4282	withdrawal	_	
19-48	4282-4283	.	_	

#Text=Disordered connectivity has also been implicated in schizophrenia, with mechanism of aberrant SN co-ordination of DMN and other brain regions .
20-1	4284-4294	Disordered	_	
20-2	4295-4307	connectivity	_	
20-3	4308-4311	has	_	
20-4	4312-4316	also	_	
20-5	4317-4321	been	_	
20-6	4322-4332	implicated	_	
20-7	4333-4335	in	_	
20-8	4336-4349	schizophrenia	_	
20-9	4349-4350	,	_	
20-10	4351-4355	with	_	
20-11	4356-4365	mechanism	_	
20-12	4366-4368	of	_	
20-13	4369-4377	aberrant	_	
20-14	4378-4380	SN	_	
20-15	4381-4394	co-ordination	_	
20-16	4395-4397	of	_	
20-17	4398-4401	DMN	_	
20-18	4402-4405	and	_	
20-19	4406-4411	other	_	
20-20	4412-4417	brain	_	
20-21	4418-4425	regions	_	
20-22	4426-4427	.	_	

#Text=Thus, there is growing evidence of aberrant DMN and SN activity in schizophrenia, and a failure of integration or altered connectivity within brain networks that may explain positive symptoms including delusions and hallucinations.
21-1	4428-4432	Thus	_	
21-2	4432-4433	,	_	
21-3	4434-4439	there	_	
21-4	4440-4442	is	_	
21-5	4443-4450	growing	_	
21-6	4451-4459	evidence	_	
21-7	4460-4462	of	_	
21-8	4463-4471	aberrant	_	
21-9	4472-4475	DMN	_	
21-10	4476-4479	and	_	
21-11	4480-4482	SN	_	
21-12	4483-4491	activity	_	
21-13	4492-4494	in	_	
21-14	4495-4508	schizophrenia	_	
21-15	4508-4509	,	_	
21-16	4510-4513	and	_	
21-17	4514-4515	a	_	
21-18	4516-4523	failure	_	
21-19	4524-4526	of	_	
21-20	4527-4538	integration	_	
21-21	4539-4541	or	_	
21-22	4542-4549	altered	_	
21-23	4550-4562	connectivity	_	
21-24	4563-4569	within	_	
21-25	4570-4575	brain	_	
21-26	4576-4584	networks	_	
21-27	4585-4589	that	_	
21-28	4590-4593	may	_	
21-29	4594-4601	explain	_	
21-30	4602-4610	positive	_	
21-31	4611-4619	symptoms	_	
21-32	4620-4629	including	_	
21-33	4630-4639	delusions	_	
21-34	4640-4643	and	_	
21-35	4644-4658	hallucinations	_	
21-36	4658-4659	.	_	

#Text=However, additional evidence is needed to elucidate the relationship of this activity to hallucinations in particular.
22-1	4660-4667	However	_	
22-2	4667-4668	,	_	
22-3	4669-4679	additional	_	
22-4	4680-4688	evidence	_	
22-5	4689-4691	is	_	
22-6	4692-4698	needed	_	
22-7	4699-4701	to	_	
22-8	4702-4711	elucidate	_	
22-9	4712-4715	the	_	
22-10	4716-4728	relationship	_	
22-11	4729-4731	of	_	
22-12	4732-4736	this	_	
22-13	4737-4745	activity	_	
22-14	4746-4748	to	_	
22-15	4749-4763	hallucinations	_	
22-16	4764-4766	in	_	
22-17	4767-4777	particular	_	
22-18	4777-4778	.	_	

#Text=Previous investigations of AVH, predominantly in patients with schizophrenia and long standing illness, assessing functional connectivity (FC) have used a seed-based approach (sb-FC) based on the three hypotheses outlined above, with seed placement in brain areas responsible for auditory processing, language, and memory; the striatum, and in areas of DMN.
23-1	4779-4787	Previous	_	
23-2	4788-4802	investigations	_	
23-3	4803-4805	of	_	
23-4	4806-4809	AVH	_	
23-5	4809-4810	,	_	
23-6	4811-4824	predominantly	_	
23-7	4825-4827	in	_	
23-8	4828-4836	patients	_	
23-9	4837-4841	with	_	
23-10	4842-4855	schizophrenia	_	
23-11	4856-4859	and	_	
23-12	4860-4864	long	_	
23-13	4865-4873	standing	_	
23-14	4874-4881	illness	_	
23-15	4881-4882	,	_	
23-16	4883-4892	assessing	_	
23-17	4893-4903	functional	_	
23-18	4904-4916	connectivity	_	
23-19	4917-4918	(	_	
23-20	4918-4920	FC	_	
23-21	4920-4921	)	_	
23-22	4922-4926	have	_	
23-23	4927-4931	used	_	
23-24	4932-4933	a	_	
23-25	4934-4944	seed-based	_	
23-26	4945-4953	approach	_	
23-27	4954-4955	(	_	
23-28	4955-4960	sb-FC	_	
23-29	4960-4961	)	_	
23-30	4962-4967	based	_	
23-31	4968-4970	on	_	
23-32	4971-4974	the	_	
23-33	4975-4980	three	_	
23-34	4981-4991	hypotheses	_	
23-35	4992-5000	outlined	_	
23-36	5001-5006	above	_	
23-37	5006-5007	,	_	
23-38	5008-5012	with	_	
23-39	5013-5017	seed	_	
23-40	5018-5027	placement	_	
23-41	5028-5030	in	_	
23-42	5031-5036	brain	_	
23-43	5037-5042	areas	_	
23-44	5043-5054	responsible	_	
23-45	5055-5058	for	_	
23-46	5059-5067	auditory	_	
23-47	5068-5078	processing	_	
23-48	5078-5079	,	_	
23-49	5080-5088	language	_	
23-50	5088-5089	,	_	
23-51	5090-5093	and	_	
23-52	5094-5100	memory	_	
23-53	5100-5101	;	_	
23-54	5102-5105	the	_	
23-55	5106-5114	striatum	_	
23-56	5114-5115	,	_	
23-57	5116-5119	and	_	
23-58	5120-5122	in	_	
23-59	5123-5128	areas	_	
23-60	5129-5131	of	_	
23-61	5132-5135	DMN	_	
23-62	5135-5136	.	_	

#Text=These have generated some conflicting results, possibly because of the varying seed placement and failure to control confounding factors such as length of illness and psychotropic medication.
24-1	5137-5142	These	_	
24-2	5143-5147	have	_	
24-3	5148-5157	generated	_	
24-4	5158-5162	some	_	
24-5	5163-5174	conflicting	_	
24-6	5175-5182	results	_	
24-7	5182-5183	,	_	
24-8	5184-5192	possibly	_	
24-9	5193-5200	because	_	
24-10	5201-5203	of	_	
24-11	5204-5207	the	_	
24-12	5208-5215	varying	_	
24-13	5216-5220	seed	_	
24-14	5221-5230	placement	_	
24-15	5231-5234	and	_	
24-16	5235-5242	failure	_	
24-17	5243-5245	to	_	
24-18	5246-5253	control	_	
24-19	5254-5265	confounding	_	
24-20	5266-5273	factors	_	
24-21	5274-5278	such	_	
24-22	5279-5281	as	_	
24-23	5282-5288	length	_	
24-24	5289-5291	of	_	
24-25	5292-5299	illness	_	
24-26	5300-5303	and	_	
24-27	5304-5316	psychotropic	_	
24-28	5317-5327	medication	_	
24-29	5327-5328	.	_	

#Text=The aim of the current study was to address these confounding factors by investigating the intrinsic FC in FEP patients with AVH.
25-1	5329-5332	The	_	
25-2	5333-5336	aim	_	
25-3	5337-5339	of	_	
25-4	5340-5343	the	_	
25-5	5344-5351	current	_	
25-6	5352-5357	study	_	
25-7	5358-5361	was	_	
25-8	5362-5364	to	_	
25-9	5365-5372	address	_	
25-10	5373-5378	these	_	
25-11	5379-5390	confounding	_	
25-12	5391-5398	factors	_	
25-13	5399-5401	by	_	
25-14	5402-5415	investigating	_	
25-15	5416-5419	the	_	
25-16	5420-5429	intrinsic	_	
25-17	5430-5432	FC	_	
25-18	5433-5435	in	_	
25-19	5436-5439	FEP	_	
25-20	5440-5448	patients	_	
25-21	5449-5453	with	_	
25-22	5454-5457	AVH	_	
25-23	5457-5458	.	_	

#Text=We further aimed to improve selection of seed regions by identifying brain areas activated during AVH itself in the same sample.
26-1	5459-5461	We	_	
26-2	5462-5469	further	_	
26-3	5470-5475	aimed	_	
26-4	5476-5478	to	_	
26-5	5479-5486	improve	_	
26-6	5487-5496	selection	_	
26-7	5497-5499	of	_	
26-8	5500-5504	seed	_	
26-9	5505-5512	regions	_	
26-10	5513-5515	by	_	
26-11	5516-5527	identifying	_	
26-12	5528-5533	brain	_	
26-13	5534-5539	areas	_	
26-14	5540-5549	activated	_	
26-15	5550-5556	during	_	
26-16	5557-5560	AVH	_	
26-17	5561-5567	itself	_	
26-18	5568-5570	in	_	
26-19	5571-5574	the	_	
26-20	5575-5579	same	_	
26-21	5580-5586	sample	_	
26-22	5586-5587	.	_	

#Text=Based on previous literature in participants with chronic AVH outlined above, we hypothesised that symptom capture in FEP patients would identify areas active in AVH including but not limited to primary auditory cortex, inferior frontal gyrus and the insula and that patients would show aberrant resting state FC between areas of the DMN and SN and these areas.
27-1	5588-5593	Based	_	
27-2	5594-5596	on	_	
27-3	5597-5605	previous	_	
27-4	5606-5616	literature	_	
27-5	5617-5619	in	_	
27-6	5620-5632	participants	_	
27-7	5633-5637	with	_	
27-8	5638-5645	chronic	_	
27-9	5646-5649	AVH	_	
27-10	5650-5658	outlined	_	
27-11	5659-5664	above	_	
27-12	5664-5665	,	_	
27-13	5666-5668	we	_	
27-14	5669-5681	hypothesised	_	
27-15	5682-5686	that	_	
27-16	5687-5694	symptom	_	
27-17	5695-5702	capture	_	
27-18	5703-5705	in	_	
27-19	5706-5709	FEP	_	
27-20	5710-5718	patients	_	
27-21	5719-5724	would	_	
27-22	5725-5733	identify	_	
27-23	5734-5739	areas	_	
27-24	5740-5746	active	_	
27-25	5747-5749	in	_	
27-26	5750-5753	AVH	_	
27-27	5754-5763	including	_	
27-28	5764-5767	but	_	
27-29	5768-5771	not	_	
27-30	5772-5779	limited	_	
27-31	5780-5782	to	_	
27-32	5783-5790	primary	_	
27-33	5791-5799	auditory	_	
27-34	5800-5806	cortex	_	
27-35	5806-5807	,	_	
27-36	5808-5816	inferior	_	
27-37	5817-5824	frontal	_	
27-38	5825-5830	gyrus	_	
27-39	5831-5834	and	_	
27-40	5835-5838	the	_	
27-41	5839-5845	insula	_	
27-42	5846-5849	and	_	
27-43	5850-5854	that	_	
27-44	5855-5863	patients	_	
27-45	5864-5869	would	_	
27-46	5870-5874	show	_	
27-47	5875-5883	aberrant	_	
27-48	5884-5891	resting	_	
27-49	5892-5897	state	_	
27-50	5898-5900	FC	_	
27-51	5901-5908	between	_	
27-52	5909-5914	areas	_	
27-53	5915-5917	of	_	
27-54	5918-5921	the	_	
27-55	5922-5925	DMN	_	
27-56	5926-5929	and	_	
27-57	5930-5932	SN	_	
27-58	5933-5936	and	_	
27-59	5937-5942	these	_	
27-60	5943-5948	areas	_	
27-61	5948-5949	.	_	

#Text=Materials and methods
#Text=Participants
#Text=Eighteen individuals diagnosed with FEP were recruited from the Early Intervention Service and Youth Service, Birmingham and Solihull Mental Health NHS Foundation Trust within 12 months of initial diagnosis and treatment onset.
28-1	5950-5959	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-2	5960-5963	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-3	5964-5971	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-4	5972-5984	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-5	5985-5993	Eighteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-6	5994-6005	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[10]	
28-7	6006-6015	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[10]	
28-8	6016-6020	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[10]	
28-9	6021-6024	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[10]	
28-10	6025-6029	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-11	6030-6039	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-12	6040-6044	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-13	6045-6048	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-14	6049-6054	Early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-15	6055-6067	Intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-16	6068-6075	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-17	6076-6079	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-18	6080-6085	Youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-19	6086-6093	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-20	6093-6094	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-21	6095-6105	Birmingham	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-22	6106-6109	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-23	6110-6118	Solihull	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-24	6119-6125	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-25	6126-6132	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-26	6133-6136	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-27	6137-6147	Foundation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-28	6148-6153	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-29	6154-6160	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-30	6161-6163	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-31	6164-6170	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-32	6171-6173	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-33	6174-6181	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-34	6182-6191	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-35	6192-6195	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-36	6196-6205	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-37	6206-6211	onset	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-38	6211-6212	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=FEP was defined as the first presentation of DSM-IV schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder not otherwise specified, confirmed using M.I.N.I.
29-1	6213-6216	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-2	6217-6220	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-3	6221-6228	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-4	6229-6231	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-5	6232-6235	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-6	6236-6241	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-7	6242-6254	presentation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-8	6255-6257	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-9	6258-6264	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-10	6265-6278	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-11	6278-6279	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-12	6280-6296	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-13	6297-6305	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-14	6305-6306	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-15	6307-6322	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-16	6323-6331	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-17	6332-6334	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-18	6335-6344	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-19	6345-6353	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-20	6354-6357	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-21	6358-6367	otherwise	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-22	6368-6377	specified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-23	6377-6378	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-24	6379-6388	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-25	6389-6394	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-26	6395-6402	M.I.N.I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
29-27	6402-6403	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=International Neuropsychiatric Interview (M.I.N.I. 6.0).
30-1	6404-6417	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-2	6418-6434	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-3	6435-6444	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-4	6445-6446	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-5	6446-6453	M.I.N.I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-6	6453-6454	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-7	6455-6458	6.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-8	6458-6459	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
30-9	6459-6460	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=All had at least one episode of AVH every other day.
31-1	6461-6464	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-2	6465-6468	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-3	6469-6471	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-4	6472-6477	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-5	6478-6481	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-6	6482-6489	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-7	6490-6492	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-8	6493-6496	AVH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-9	6497-6502	every	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-10	6503-6508	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-11	6509-6512	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-12	6512-6513	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Age, gender and handedness matched healthy controls (HC) (n = 18) were recruited from the local community via advertisements.
32-1	6514-6517	Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-2	6517-6518	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-3	6519-6525	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-4	6526-6529	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-5	6530-6540	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-6	6541-6548	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
32-7	6549-6556	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
32-8	6557-6565	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
32-9	6566-6567	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-10	6567-6569	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-11	6569-6570	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-12	6571-6572	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-13	6572-6573	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-14	6574-6575	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-15	6576-6578	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-16	6578-6579	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-17	6580-6584	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-18	6585-6594	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-19	6595-6599	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-20	6600-6603	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-21	6604-6609	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-22	6610-6619	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
32-23	6620-6623	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-24	6624-6638	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-25	6638-6639	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=HC had no personal history of mental illness or current mental health problems, and no first-degree relative with a history of psychotic disorder as defined by self-report.
33-1	6640-6642	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-2	6643-6646	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-3	6647-6649	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-4	6650-6658	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-5	6659-6666	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-6	6667-6669	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-7	6670-6676	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-8	6677-6684	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-9	6685-6687	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-10	6688-6695	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-11	6696-6702	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-12	6703-6709	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-13	6710-6718	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-14	6718-6719	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-15	6720-6723	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-16	6724-6726	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-17	6727-6739	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-18	6740-6748	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-19	6749-6753	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-20	6754-6755	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-21	6756-6763	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-22	6764-6766	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-23	6767-6776	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-24	6777-6785	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-25	6786-6788	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-26	6789-6796	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-27	6797-6799	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-28	6800-6811	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
33-29	6811-6812	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Exclusion criteria for both groups included a history of any neurological disorder, seizures, or significant head injury, any contraindications for MRI and any significant risk history including suicide risk and violence (as assessed by the clinical team).
34-1	6813-6822	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-2	6823-6831	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-3	6832-6835	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-4	6836-6840	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-5	6841-6847	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-6	6848-6856	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-7	6857-6858	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-8	6859-6866	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-9	6867-6869	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-10	6870-6873	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-11	6874-6886	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-12	6887-6895	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-13	6895-6896	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-14	6897-6905	seizures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-15	6905-6906	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-16	6907-6909	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-17	6910-6921	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-18	6922-6926	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-19	6927-6933	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-20	6933-6934	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-21	6935-6938	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-22	6939-6956	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-23	6957-6960	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-24	6961-6964	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-25	6965-6968	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-26	6969-6972	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-27	6973-6984	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-28	6985-6989	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-29	6990-6997	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-30	6998-7007	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-31	7008-7015	suicide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-32	7016-7020	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-33	7021-7024	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-34	7025-7033	violence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-35	7034-7035	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-36	7035-7037	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-37	7038-7046	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-38	7047-7049	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-39	7050-7053	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-40	7054-7062	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-41	7063-7067	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-42	7067-7068	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
34-43	7068-7069	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Ethical approval was obtained from the NHS HRA (reference 13/WM/0277) Ethics Committee.
35-1	7070-7077	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-2	7078-7086	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-3	7087-7090	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-4	7091-7099	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-5	7100-7104	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-6	7105-7108	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-7	7109-7112	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-8	7113-7116	HRA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-9	7117-7118	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-10	7118-7127	reference	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-11	7128-7130	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-12	7130-7131	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-13	7131-7133	WM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-14	7133-7134	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-15	7134-7138	0277	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-16	7138-7139	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-17	7140-7146	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-18	7147-7156	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-19	7156-7157	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=All participants provided written informed consent to participate in the study.
36-1	7158-7161	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-2	7162-7174	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-3	7175-7183	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-4	7184-7191	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-5	7192-7200	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-6	7201-7208	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-7	7209-7211	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-8	7212-7223	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-9	7224-7226	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-10	7227-7230	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-11	7231-7236	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
36-12	7236-7237	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Procedure, MRI acquisition and preprocessing
#Text=Information on demographic and clinical variables including age, gender, marital status, duration of treated and untreated psychosis, and current medication was recorded for patients.
37-1	7238-7247	Procedure	_	
37-2	7247-7248	,	_	
37-3	7249-7252	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
37-4	7253-7264	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
37-5	7265-7268	and	_	
37-6	7269-7282	preprocessing	_	
37-7	7283-7294	Information	_	
37-8	7295-7297	on	_	
37-9	7298-7309	demographic	_	
37-10	7310-7313	and	_	
37-11	7314-7322	clinical	_	
37-12	7323-7332	variables	_	
37-13	7333-7342	including	_	
37-14	7343-7346	age	_	
37-15	7346-7347	,	_	
37-16	7348-7354	gender	_	
37-17	7354-7355	,	_	
37-18	7356-7363	marital	_	
37-19	7364-7370	status	_	
37-20	7370-7371	,	_	
37-21	7372-7380	duration	_	
37-22	7381-7383	of	_	
37-23	7384-7391	treated	_	
37-24	7392-7395	and	_	
37-25	7396-7405	untreated	_	
37-26	7406-7415	psychosis	_	
37-27	7415-7416	,	_	
37-28	7417-7420	and	_	
37-29	7421-7428	current	_	
37-30	7429-7439	medication	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus	
37-31	7440-7443	was	_	
37-32	7444-7452	recorded	_	
37-33	7453-7456	for	_	
37-34	7457-7465	patients	_	
37-35	7465-7466	.	_	

#Text=AVH were comprehensively assessed for both frequency and quality using the Beliefs about Voices Questionnaire—Revised (BAVQ-R), Topography of Voices Rating Scale (TVRS), Voice Power Differential Scale (VPD), and Auditory Hallucinations Subscale of Psychotic Symptoms Rating Scale (PSYRATS).
38-1	7467-7470	AVH	_	
38-2	7471-7475	were	_	
38-3	7476-7491	comprehensively	_	
38-4	7492-7500	assessed	_	
38-5	7501-7504	for	_	
38-6	7505-7509	both	_	
38-7	7510-7519	frequency	_	
38-8	7520-7523	and	_	
38-9	7524-7531	quality	_	
38-10	7532-7537	using	_	
38-11	7538-7541	the	_	
38-12	7542-7549	Beliefs	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-13	7550-7555	about	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-14	7556-7562	Voices	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-15	7563-7584	Questionnaire—Revised	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-16	7585-7586	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-17	7586-7592	BAVQ-R	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-18	7592-7593	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-19	7593-7594	,	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-20	7595-7605	Topography	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-21	7606-7608	of	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-22	7609-7615	Voices	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-23	7616-7622	Rating	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-24	7623-7628	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-25	7629-7630	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-26	7630-7634	TVRS	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-27	7634-7635	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-28	7635-7636	,	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-29	7637-7642	Voice	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-30	7643-7648	Power	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-31	7649-7661	Differential	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-32	7662-7667	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-33	7668-7669	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-34	7669-7672	VPD	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-35	7672-7673	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-36	7673-7674	,	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-37	7675-7678	and	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	
38-38	7679-7687	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-39	7688-7702	Hallucinations	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-40	7703-7711	Subscale	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-41	7712-7714	of	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-42	7715-7724	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-43	7725-7733	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-44	7734-7740	Rating	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-45	7741-7746	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-46	7747-7748	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-47	7748-7755	PSYRATS	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-48	7755-7756	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]|http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[20]	
38-49	7756-7757	.	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[19]	

#Text=MRI acquisition
#Text=Patients underwent neuroimaging including fMRI-symptom capture, resting state and structural MRI at the Birmingham University Imaging Centre using a 3 T Philips Achieva MRI scanner, whilst the HC completed the resting state and structural scan.
39-1	7758-7761	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
39-2	7762-7773	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
39-3	7774-7782	Patients	_	
39-4	7783-7792	underwent	_	
39-5	7793-7805	neuroimaging	_	
39-6	7806-7815	including	_	
39-7	7816-7828	fMRI-symptom	_	
39-8	7829-7836	capture	_	
39-9	7836-7837	,	_	
39-10	7838-7845	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
39-11	7846-7851	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
39-12	7852-7855	and	_	
39-13	7856-7866	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[23]	
39-14	7867-7870	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[23]	
39-15	7871-7873	at	_	
39-16	7874-7877	the	_	
39-17	7878-7888	Birmingham	_	
39-18	7889-7899	University	_	
39-19	7900-7907	Imaging	_	
39-20	7908-7914	Centre	_	
39-21	7915-7920	using	_	
39-22	7921-7922	a	_	
39-23	7923-7924	3	_	
39-24	7925-7926	T	_	
39-25	7927-7934	Philips	_	
39-26	7935-7942	Achieva	_	
39-27	7943-7946	MRI	_	
39-28	7947-7954	scanner	_	
39-29	7954-7955	,	_	
39-30	7956-7962	whilst	_	
39-31	7963-7966	the	_	
39-32	7967-7969	HC	_	
39-33	7970-7979	completed	_	
39-34	7980-7983	the	_	
39-35	7984-7991	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
39-36	7992-7997	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
39-37	7998-8001	and	_	
39-38	8002-8012	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[25]	
39-39	8013-8017	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[25]	
39-40	8017-8018	.	_	

#Text=Patients completed a 10-min fMRI symptom capture run wherein 200 volumes of BOLD-fMRI were acquired (TE = 30 ms, whole-brain coverage, TR = 3 s, voxel size 3 mm × 3 mm × 2 mm, field of view 192 × 192 × 100, flip angle 90°, matrix 64 × 64).
40-1	8019-8027	Patients	_	
40-2	8028-8037	completed	_	
40-3	8038-8039	a	_	
40-4	8040-8042	10	_	
40-5	8042-8043	-	_	
40-6	8043-8046	min	_	
40-7	8047-8051	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	
40-8	8052-8059	symptom	_	
40-9	8060-8067	capture	_	
40-10	8068-8071	run	_	
40-11	8072-8079	wherein	_	
40-12	8080-8083	200	_	
40-13	8084-8091	volumes	_	
40-14	8092-8094	of	_	
40-15	8095-8104	BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	
40-16	8105-8109	were	_	
40-17	8110-8118	acquired	_	
40-18	8119-8120	(	_	
40-19	8120-8122	TE	_	
40-20	8123-8124	=	_	
40-21	8125-8127	30	_	
40-22	8128-8130	ms	_	
40-23	8130-8131	,	_	
40-24	8132-8143	whole-brain	_	
40-25	8144-8152	coverage	_	
40-26	8152-8153	,	_	
40-27	8154-8156	TR	_	
40-28	8157-8158	=	_	
40-29	8159-8160	3	_	
40-30	8161-8162	s	_	
40-31	8162-8163	,	_	
40-32	8164-8169	voxel	_	
40-33	8170-8174	size	_	
40-34	8175-8176	3	_	
40-35	8177-8179	mm	_	
40-36	8180-8181	×	_	
40-37	8182-8183	3	_	
40-38	8184-8186	mm	_	
40-39	8187-8188	×	_	
40-40	8189-8190	2	_	
40-41	8191-8193	mm	_	
40-42	8193-8194	,	_	
40-43	8195-8200	field	_	
40-44	8201-8203	of	_	
40-45	8204-8208	view	_	
40-46	8209-8212	192	_	
40-47	8213-8214	×	_	
40-48	8215-8218	192	_	
40-49	8219-8220	×	_	
40-50	8221-8224	100	_	
40-51	8224-8225	,	_	
40-52	8226-8230	flip	_	
40-53	8231-8236	angle	_	
40-54	8237-8239	90	_	
40-55	8239-8240	°	_	
40-56	8240-8241	,	_	
40-57	8242-8248	matrix	_	
40-58	8249-8251	64	_	
40-59	8252-8253	×	_	
40-60	8254-8256	64	_	
40-61	8256-8257	)	_	
40-62	8257-8258	.	_	

#Text=Throughout this scan, participants had their right thumb resting on a button; and they were instructed to press and hold this for the duration of any AVHs experienced.
41-1	8259-8269	Throughout	_	
41-2	8270-8274	this	_	
41-3	8275-8279	scan	_	
41-4	8279-8280	,	_	
41-5	8281-8293	participants	_	
41-6	8294-8297	had	_	
41-7	8298-8303	their	_	
41-8	8304-8309	right	_	
41-9	8310-8315	thumb	_	
41-10	8316-8323	resting	_	
41-11	8324-8326	on	_	
41-12	8327-8328	a	_	
41-13	8329-8335	button	_	
41-14	8335-8336	;	_	
41-15	8337-8340	and	_	
41-16	8341-8345	they	_	
41-17	8346-8350	were	_	
41-18	8351-8361	instructed	_	
41-19	8362-8364	to	_	
41-20	8365-8370	press	_	
41-21	8371-8374	and	_	
41-22	8375-8379	hold	_	
41-23	8380-8384	this	_	
41-24	8385-8388	for	_	
41-25	8389-8392	the	_	
41-26	8393-8401	duration	_	
41-27	8402-8404	of	_	
41-28	8405-8408	any	_	
41-29	8409-8413	AVHs	_	
41-30	8414-8425	experienced	_	
41-31	8425-8426	.	_	

#Text=Participants completed a 10-min resting state scan when they were in the scanner in a state of wakeful rest with their eyes closed.
42-1	8427-8439	Participants	_	
42-2	8440-8449	completed	_	
42-3	8450-8451	a	_	
42-4	8452-8454	10	_	
42-5	8454-8455	-	_	
42-6	8455-8458	min	_	
42-7	8459-8466	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
42-8	8467-8472	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
42-9	8473-8477	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
42-10	8478-8482	when	_	
42-11	8483-8487	they	_	
42-12	8488-8492	were	_	
42-13	8493-8495	in	_	
42-14	8496-8499	the	_	
42-15	8500-8507	scanner	_	
42-16	8508-8510	in	_	
42-17	8511-8512	a	_	
42-18	8513-8518	state	_	
42-19	8519-8521	of	_	
42-20	8522-8529	wakeful	_	
42-21	8530-8534	rest	_	
42-22	8535-8539	with	_	
42-23	8540-8545	their	_	
42-24	8546-8550	eyes	_	
42-25	8551-8557	closed	_	
42-26	8557-8558	.	_	

#Text=Two hundred volumes of BOLD-fMRI were acquired (TE = 30 ms, whole-brain coverage, TR = 3 s, voxel size 3 mm × 3 mm × 2 mm, field of view 192 × 192 × 100, flip angle 90°, matrix 64 × 64).
43-1	8559-8562	Two	_	
43-2	8563-8570	hundred	_	
43-3	8571-8578	volumes	_	
43-4	8579-8581	of	_	
43-5	8582-8591	BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	
43-6	8592-8596	were	_	
43-7	8597-8605	acquired	_	
43-8	8606-8607	(	_	
43-9	8607-8609	TE	_	
43-10	8610-8611	=	_	
43-11	8612-8614	30	_	
43-12	8615-8617	ms	_	
43-13	8617-8618	,	_	
43-14	8619-8630	whole-brain	_	
43-15	8631-8639	coverage	_	
43-16	8639-8640	,	_	
43-17	8641-8643	TR	_	
43-18	8644-8645	=	_	
43-19	8646-8647	3	_	
43-20	8648-8649	s	_	
43-21	8649-8650	,	_	
43-22	8651-8656	voxel	_	
43-23	8657-8661	size	_	
43-24	8662-8663	3	_	
43-25	8664-8666	mm	_	
43-26	8667-8668	×	_	
43-27	8669-8670	3	_	
43-28	8671-8673	mm	_	
43-29	8674-8675	×	_	
43-30	8676-8677	2	_	
43-31	8678-8680	mm	_	
43-32	8680-8681	,	_	
43-33	8682-8687	field	_	
43-34	8688-8690	of	_	
43-35	8691-8695	view	_	
43-36	8696-8699	192	_	
43-37	8700-8701	×	_	
43-38	8702-8705	192	_	
43-39	8706-8707	×	_	
43-40	8708-8711	100	_	
43-41	8711-8712	,	_	
43-42	8713-8717	flip	_	
43-43	8718-8723	angle	_	
43-44	8724-8726	90	_	
43-45	8726-8727	°	_	
43-46	8727-8728	,	_	
43-47	8729-8735	matrix	_	
43-48	8736-8738	64	_	
43-49	8739-8740	×	_	
43-50	8741-8743	64	_	
43-51	8743-8744	)	_	
43-52	8744-8745	.	_	

#Text=T1-weighted images (TR = 8.4 ms, TE = 3.8 ms, flip angle = 8°, FOV = 288 × 232 × 175 mm, voxel size 1mm3) were acquired for each participant for image registration.
44-1	8746-8748	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
44-2	8748-8749	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
44-3	8749-8757	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
44-4	8758-8764	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
44-5	8765-8766	(	_	
44-6	8766-8768	TR	_	
44-7	8769-8770	=	_	
44-8	8771-8774	8.4	_	
44-9	8775-8777	ms	_	
44-10	8777-8778	,	_	
44-11	8779-8781	TE	_	
44-12	8782-8783	=	_	
44-13	8784-8787	3.8	_	
44-14	8788-8790	ms	_	
44-15	8790-8791	,	_	
44-16	8792-8796	flip	_	
44-17	8797-8802	angle	_	
44-18	8803-8804	=	_	
44-19	8805-8806	8	_	
44-20	8806-8807	°	_	
44-21	8807-8808	,	_	
44-22	8809-8812	FOV	_	
44-23	8813-8814	=	_	
44-24	8815-8818	288	_	
44-25	8819-8820	×	_	
44-26	8821-8824	232	_	
44-27	8825-8826	×	_	
44-28	8827-8830	175	_	
44-29	8831-8833	mm	_	
44-30	8833-8834	,	_	
44-31	8835-8840	voxel	_	
44-32	8841-8845	size	_	
44-33	8846-8850	1mm3	_	
44-34	8850-8851	)	_	
44-35	8852-8856	were	_	
44-36	8857-8865	acquired	_	
44-37	8866-8869	for	_	
44-38	8870-8874	each	_	
44-39	8875-8886	participant	_	
44-40	8887-8890	for	_	
44-41	8891-8896	image	_	
44-42	8897-8909	registration	_	
44-43	8909-8910	.	_	

#Text=Participants wore headphones and earplugs throughout both scan runs to attenuate the noise of the scanner.
45-1	8911-8923	Participants	_	
45-2	8924-8928	wore	_	
45-3	8929-8939	headphones	_	
45-4	8940-8943	and	_	
45-5	8944-8952	earplugs	_	
45-6	8953-8963	throughout	_	
45-7	8964-8968	both	_	
45-8	8969-8973	scan	_	
45-9	8974-8978	runs	_	
45-10	8979-8981	to	_	
45-11	8982-8991	attenuate	_	
45-12	8992-8995	the	_	
45-13	8996-9001	noise	_	
45-14	9002-9004	of	_	
45-15	9005-9008	the	_	
45-16	9009-9016	scanner	_	
45-17	9016-9017	.	_	

#Text=Preprocessing
#Text=Anatomical and functional MRI scans were preprocessed with statistical parametric mapping software (SPM 8, Friston, The Welcome Department of Cognitive Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm) and the Data Processing Assistant for Resting-State fMRI Advanced Edition (DPARSFA) V3.1 (http://rfmri.org/DPARSF).
46-1	9018-9031	Preprocessing	_	
46-2	9032-9042	Anatomical	_	
46-3	9043-9046	and	_	
46-4	9047-9057	functional	_	
46-5	9058-9061	MRI	_	
46-6	9062-9067	scans	_	
46-7	9068-9072	were	_	
46-8	9073-9085	preprocessed	_	
46-9	9086-9090	with	_	
46-10	9091-9102	statistical	_	
46-11	9103-9113	parametric	_	
46-12	9114-9121	mapping	_	
46-13	9122-9130	software	_	
46-14	9131-9132	(	_	
46-15	9132-9135	SPM	_	
46-16	9136-9137	8	_	
46-17	9137-9138	,	_	
46-18	9139-9146	Friston	_	
46-19	9146-9147	,	_	
46-20	9148-9151	The	_	
46-21	9152-9159	Welcome	_	
46-22	9160-9170	Department	_	
46-23	9171-9173	of	_	
46-24	9174-9183	Cognitive	_	
46-25	9184-9193	Neurology	_	
46-26	9193-9194	,	_	
46-27	9195-9201	London	_	
46-28	9201-9202	,	_	
46-29	9203-9205	UK	_	
46-30	9205-9206	;	_	
46-31	9207-9211	http	_	
46-32	9211-9212	:	_	
46-33	9212-9213	/	_	
46-34	9213-9214	/	_	
46-35	9214-9235	www.fil.ion.ucl.ac.uk	_	
46-36	9235-9236	/	_	
46-37	9236-9239	spm	_	
46-38	9239-9240	)	_	
46-39	9241-9244	and	_	
46-40	9245-9248	the	_	
46-41	9249-9253	Data	_	
46-42	9254-9264	Processing	_	
46-43	9265-9274	Assistant	_	
46-44	9275-9278	for	_	
46-45	9279-9292	Resting-State	_	
46-46	9293-9297	fMRI	_	
46-47	9298-9306	Advanced	_	
46-48	9307-9314	Edition	_	
46-49	9315-9316	(	_	
46-50	9316-9323	DPARSFA	_	
46-51	9323-9324	)	_	
46-52	9325-9329	V3.1	_	
46-53	9330-9331	(	_	
46-54	9331-9335	http	_	
46-55	9335-9336	:	_	
46-56	9336-9337	/	_	
46-57	9337-9338	/	_	
46-58	9338-9347	rfmri.org	_	
46-59	9347-9348	/	_	
46-60	9348-9354	DPARSF	_	
46-61	9354-9355	)	_	
46-62	9355-9356	.	_	

#Text=Preprocessing of symptom capture data: Preprocessing of the acquired images included slice time correction, realignment, co-registration with the anatomical image, spatial normalisation using a Montreal Neurological Institute template scan, and smoothing using 8-mm full-width-at-half-maximum 3D Gaussian kernel.
47-1	9357-9370	Preprocessing	_	
47-2	9371-9373	of	_	
47-3	9374-9381	symptom	_	
47-4	9382-9389	capture	_	
47-5	9390-9394	data	_	
47-6	9394-9395	:	_	
47-7	9396-9409	Preprocessing	_	
47-8	9410-9412	of	_	
47-9	9413-9416	the	_	
47-10	9417-9425	acquired	_	
47-11	9426-9432	images	_	
47-12	9433-9441	included	_	
47-13	9442-9447	slice	_	
47-14	9448-9452	time	_	
47-15	9453-9463	correction	_	
47-16	9463-9464	,	_	
47-17	9465-9476	realignment	_	
47-18	9476-9477	,	_	
47-19	9478-9493	co-registration	_	
47-20	9494-9498	with	_	
47-21	9499-9502	the	_	
47-22	9503-9513	anatomical	_	
47-23	9514-9519	image	_	
47-24	9519-9520	,	_	
47-25	9521-9528	spatial	_	
47-26	9529-9542	normalisation	_	
47-27	9543-9548	using	_	
47-28	9549-9550	a	_	
47-29	9551-9559	Montreal	_	
47-30	9560-9572	Neurological	_	
47-31	9573-9582	Institute	_	
47-32	9583-9591	template	_	
47-33	9592-9596	scan	_	
47-34	9596-9597	,	_	
47-35	9598-9601	and	_	
47-36	9602-9611	smoothing	_	
47-37	9612-9617	using	_	
47-38	9618-9619	8	_	
47-39	9619-9620	-	_	
47-40	9620-9622	mm	_	
47-41	9623-9649	full-width-at-half-maximum	_	
47-42	9650-9652	3D	_	
47-43	9653-9661	Gaussian	_	
47-44	9662-9668	kernel	_	
47-45	9668-9669	.	_	

#Text=If excessive movement was noted of realignment, defined as a translation of > 1 voxel (3 mm × 3 mm × 2 mm) or rotation of >2 degrees, artefact repair was performed to correct for it using the ArtRepair toolbox.
48-1	9670-9672	If	_	
48-2	9673-9682	excessive	_	
48-3	9683-9691	movement	_	
48-4	9692-9695	was	_	
48-5	9696-9701	noted	_	
48-6	9702-9704	of	_	
48-7	9705-9716	realignment	_	
48-8	9716-9717	,	_	
48-9	9718-9725	defined	_	
48-10	9726-9728	as	_	
48-11	9729-9730	a	_	
48-12	9731-9742	translation	_	
48-13	9743-9745	of	_	
48-14	9746-9747	>	_	
48-15	9748-9749	1	_	
48-16	9750-9755	voxel	_	
48-17	9756-9757	(	_	
48-18	9757-9758	3	_	
48-19	9759-9761	mm	_	
48-20	9762-9763	×	_	
48-21	9764-9765	3	_	
48-22	9766-9768	mm	_	
48-23	9769-9770	×	_	
48-24	9771-9772	2	_	
48-25	9773-9775	mm	_	
48-26	9775-9776	)	_	
48-27	9777-9779	or	_	
48-28	9780-9788	rotation	_	
48-29	9789-9791	of	_	
48-30	9792-9793	>	_	
48-31	9793-9794	2	_	
48-32	9795-9802	degrees	_	
48-33	9802-9803	,	_	
48-34	9804-9812	artefact	_	
48-35	9813-9819	repair	_	
48-36	9820-9823	was	_	
48-37	9824-9833	performed	_	
48-38	9834-9836	to	_	
48-39	9837-9844	correct	_	
48-40	9845-9848	for	_	
48-41	9849-9851	it	_	
48-42	9852-9857	using	_	
48-43	9858-9861	the	_	
48-44	9862-9871	ArtRepair	_	
48-45	9872-9879	toolbox	_	
48-46	9879-9880	.	_	

#Text=Preprocessing of resting state scans: The first ten volumes from each scan were excluded as dummy scans to allow stability of longitudinal magnetisation.
49-1	9881-9894	Preprocessing	_	
49-2	9895-9897	of	_	
49-3	9898-9905	resting	_	
49-4	9906-9911	state	_	
49-5	9912-9917	scans	_	
49-6	9917-9918	:	_	
49-7	9919-9922	The	_	
49-8	9923-9928	first	_	
49-9	9929-9932	ten	_	
49-10	9933-9940	volumes	_	
49-11	9941-9945	from	_	
49-12	9946-9950	each	_	
49-13	9951-9955	scan	_	
49-14	9956-9960	were	_	
49-15	9961-9969	excluded	_	
49-16	9970-9972	as	_	
49-17	9973-9978	dummy	_	
49-18	9979-9984	scans	_	
49-19	9985-9987	to	_	
49-20	9988-9993	allow	_	
49-21	9994-10003	stability	_	
49-22	10004-10006	of	_	
49-23	10007-10019	longitudinal	_	
49-24	10020-10033	magnetisation	_	
49-25	10033-10034	.	_	

#Text=The images were then reoriented and corrected for slice timing differences, with the middle slice being used as a reference slice.
50-1	10035-10038	The	_	
50-2	10039-10045	images	_	
50-3	10046-10050	were	_	
50-4	10051-10055	then	_	
50-5	10056-10066	reoriented	_	
50-6	10067-10070	and	_	
50-7	10071-10080	corrected	_	
50-8	10081-10084	for	_	
50-9	10085-10090	slice	_	
50-10	10091-10097	timing	_	
50-11	10098-10109	differences	_	
50-12	10109-10110	,	_	
50-13	10111-10115	with	_	
50-14	10116-10119	the	_	
50-15	10120-10126	middle	_	
50-16	10127-10132	slice	_	
50-17	10133-10138	being	_	
50-18	10139-10143	used	_	
50-19	10144-10146	as	_	
50-20	10147-10148	a	_	
50-21	10149-10158	reference	_	
50-22	10159-10164	slice	_	
50-23	10164-10165	.	_	

#Text=Both the T1 and the functional images were reoriented in order to improve co-registration accuracy.
51-1	10166-10170	Both	_	
51-2	10171-10174	the	_	
51-3	10175-10177	T1	_	
51-4	10178-10181	and	_	
51-5	10182-10185	the	_	
51-6	10186-10196	functional	_	
51-7	10197-10203	images	_	
51-8	10204-10208	were	_	
51-9	10209-10219	reoriented	_	
51-10	10220-10222	in	_	
51-11	10223-10228	order	_	
51-12	10229-10231	to	_	
51-13	10232-10239	improve	_	
51-14	10240-10255	co-registration	_	
51-15	10256-10264	accuracy	_	
51-16	10264-10265	.	_	

#Text=Brain extraction was then performed on the T1 images in order to remove the skull before co-registration to the functional images and to improve the co-registration algorithm.
52-1	10266-10271	Brain	_	
52-2	10272-10282	extraction	_	
52-3	10283-10286	was	_	
52-4	10287-10291	then	_	
52-5	10292-10301	performed	_	
52-6	10302-10304	on	_	
52-7	10305-10308	the	_	
52-8	10309-10311	T1	_	
52-9	10312-10318	images	_	
52-10	10319-10321	in	_	
52-11	10322-10327	order	_	
52-12	10328-10330	to	_	
52-13	10331-10337	remove	_	
52-14	10338-10341	the	_	
52-15	10342-10347	skull	_	
52-16	10348-10354	before	_	
52-17	10355-10370	co-registration	_	
52-18	10371-10373	to	_	
52-19	10374-10377	the	_	
52-20	10378-10388	functional	_	
52-21	10389-10395	images	_	
52-22	10396-10399	and	_	
52-23	10400-10402	to	_	
52-24	10403-10410	improve	_	
52-25	10411-10414	the	_	
52-26	10415-10430	co-registration	_	
52-27	10431-10440	algorithm	_	
52-28	10440-10441	.	_	

#Text=The T1 images were then coregistered to the functional images and segmented into grey matter, white matter (WM), and cerebrospinal fluid (CSF) partitions.
53-1	10442-10445	The	_	
53-2	10446-10448	T1	_	
53-3	10449-10455	images	_	
53-4	10456-10460	were	_	
53-5	10461-10465	then	_	
53-6	10466-10478	coregistered	_	
53-7	10479-10481	to	_	
53-8	10482-10485	the	_	
53-9	10486-10496	functional	_	
53-10	10497-10503	images	_	
53-11	10504-10507	and	_	
53-12	10508-10517	segmented	_	
53-13	10518-10522	into	_	
53-14	10523-10527	grey	_	
53-15	10528-10534	matter	_	
53-16	10534-10535	,	_	
53-17	10536-10541	white	_	
53-18	10542-10548	matter	_	
53-19	10549-10550	(	_	
53-20	10550-10552	WM	_	
53-21	10552-10553	)	_	
53-22	10553-10554	,	_	
53-23	10555-10558	and	_	
53-24	10559-10572	cerebrospinal	_	
53-25	10573-10578	fluid	_	
53-26	10579-10580	(	_	
53-27	10580-10583	CSF	_	
53-28	10583-10584	)	_	
53-29	10585-10595	partitions	_	
53-30	10595-10596	.	_	

#Text=The Friston 24-parameter model was then used to obtain six head motion parameters, six head motion parameters one time-point before, and the 12 corresponding squared items and input them into our model as nuisance regressors.
54-1	10597-10600	The	_	
54-2	10601-10608	Friston	_	
54-3	10609-10611	24	_	
54-4	10611-10612	-	_	
54-5	10612-10621	parameter	_	
54-6	10622-10627	model	_	
54-7	10628-10631	was	_	
54-8	10632-10636	then	_	
54-9	10637-10641	used	_	
54-10	10642-10644	to	_	
54-11	10645-10651	obtain	_	
54-12	10652-10655	six	_	
54-13	10656-10660	head	_	
54-14	10661-10667	motion	_	
54-15	10668-10678	parameters	_	
54-16	10678-10679	,	_	
54-17	10680-10683	six	_	
54-18	10684-10688	head	_	
54-19	10689-10695	motion	_	
54-20	10696-10706	parameters	_	
54-21	10707-10710	one	_	
54-22	10711-10721	time-point	_	
54-23	10722-10728	before	_	
54-24	10728-10729	,	_	
54-25	10730-10733	and	_	
54-26	10734-10737	the	_	
54-27	10738-10740	12	_	
54-28	10741-10754	corresponding	_	
54-29	10755-10762	squared	_	
54-30	10763-10768	items	_	
54-31	10769-10772	and	_	
54-32	10773-10778	input	_	
54-33	10779-10783	them	_	
54-34	10784-10788	into	_	
54-35	10789-10792	our	_	
54-36	10793-10798	model	_	
54-37	10799-10801	as	_	
54-38	10802-10810	nuisance	_	
54-39	10811-10821	regressors	_	
54-40	10821-10822	.	_	

#Text=Any time-points that had a framewise displacement of more than 0.5 as well as one time-point before them and two time-points after them were regressed out.
55-1	10823-10826	Any	_	
55-2	10827-10838	time-points	_	
55-3	10839-10843	that	_	
55-4	10844-10847	had	_	
55-5	10848-10849	a	_	
55-6	10850-10859	framewise	_	
55-7	10860-10872	displacement	_	
55-8	10873-10875	of	_	
55-9	10876-10880	more	_	
55-10	10881-10885	than	_	
55-11	10886-10889	0.5	_	
55-12	10890-10892	as	_	
55-13	10893-10897	well	_	
55-14	10898-10900	as	_	
55-15	10901-10904	one	_	
55-16	10905-10915	time-point	_	
55-17	10916-10922	before	_	
55-18	10923-10927	them	_	
55-19	10928-10931	and	_	
55-20	10932-10935	two	_	
55-21	10936-10947	time-points	_	
55-22	10948-10953	after	_	
55-23	10954-10958	them	_	
55-24	10959-10963	were	_	
55-25	10964-10973	regressed	_	
55-26	10974-10977	out	_	
55-27	10977-10978	.	_	

#Text=The WM and the CSF masks that were created during segmentation were then combined and their time series was calculated.
56-1	10979-10982	The	_	
56-2	10983-10985	WM	_	
56-3	10986-10989	and	_	
56-4	10990-10993	the	_	
56-5	10994-10997	CSF	_	
56-6	10998-11003	masks	_	
56-7	11004-11008	that	_	
56-8	11009-11013	were	_	
56-9	11014-11021	created	_	
56-10	11022-11028	during	_	
56-11	11029-11041	segmentation	_	
56-12	11042-11046	were	_	
56-13	11047-11051	then	_	
56-14	11052-11060	combined	_	
56-15	11061-11064	and	_	
56-16	11065-11070	their	_	
56-17	11071-11075	time	_	
56-18	11076-11082	series	_	
56-19	11083-11086	was	_	
56-20	11087-11097	calculated	_	
56-21	11097-11098	.	_	

#Text=Then, their first five principal components were calculated and entered as nuisance regressors in the model (CompCor).
57-1	11099-11103	Then	_	
57-2	11103-11104	,	_	
57-3	11105-11110	their	_	
57-4	11111-11116	first	_	
57-5	11117-11121	five	_	
57-6	11122-11131	principal	_	
57-7	11132-11142	components	_	
57-8	11143-11147	were	_	
57-9	11148-11158	calculated	_	
57-10	11159-11162	and	_	
57-11	11163-11170	entered	_	
57-12	11171-11173	as	_	
57-13	11174-11182	nuisance	_	
57-14	11183-11193	regressors	_	
57-15	11194-11196	in	_	
57-16	11197-11200	the	_	
57-17	11201-11206	model	_	
57-18	11207-11208	(	_	
57-19	11208-11215	CompCor	_	
57-20	11215-11216	)	_	
57-21	11216-11217	.	_	

#Text=Diffeomorphic Anatomical Registration using Exponentiated Algebra (DARTEL) was used to create a group specific template to which all of the images were normalised to.
58-1	11218-11231	Diffeomorphic	_	
58-2	11232-11242	Anatomical	_	
58-3	11243-11255	Registration	_	
58-4	11256-11261	using	_	
58-5	11262-11275	Exponentiated	_	
58-6	11276-11283	Algebra	_	
58-7	11284-11285	(	_	
58-8	11285-11291	DARTEL	_	
58-9	11291-11292	)	_	
58-10	11293-11296	was	_	
58-11	11297-11301	used	_	
58-12	11302-11304	to	_	
58-13	11305-11311	create	_	
58-14	11312-11313	a	_	
58-15	11314-11319	group	_	
58-16	11320-11328	specific	_	
58-17	11329-11337	template	_	
58-18	11338-11340	to	_	
58-19	11341-11346	which	_	
58-20	11347-11350	all	_	
58-21	11351-11353	of	_	
58-22	11354-11357	the	_	
58-23	11358-11364	images	_	
58-24	11365-11369	were	_	
58-25	11370-11380	normalised	_	
58-26	11381-11383	to	_	
58-27	11383-11384	.	_	

#Text=An affine transformation of the images to the Montreal Neurological Institute (MNI) stereotactic space using the parameters estimated in DARTEL was performed.
59-1	11385-11387	An	_	
59-2	11388-11394	affine	_	
59-3	11395-11409	transformation	_	
59-4	11410-11412	of	_	
59-5	11413-11416	the	_	
59-6	11417-11423	images	_	
59-7	11424-11426	to	_	
59-8	11427-11430	the	_	
59-9	11431-11439	Montreal	_	
59-10	11440-11452	Neurological	_	
59-11	11453-11462	Institute	_	
59-12	11463-11464	(	_	
59-13	11464-11467	MNI	_	
59-14	11467-11468	)	_	
59-15	11469-11481	stereotactic	_	
59-16	11482-11487	space	_	
59-17	11488-11493	using	_	
59-18	11494-11497	the	_	
59-19	11498-11508	parameters	_	
59-20	11509-11518	estimated	_	
59-21	11519-11521	in	_	
59-22	11522-11528	DARTEL	_	
59-23	11529-11532	was	_	
59-24	11533-11542	performed	_	
59-25	11542-11543	.	_	

#Text=Finally, the images were smoothed with a Gaussian kernel of 8 mm full-width at half maximum.
60-1	11544-11551	Finally	_	
60-2	11551-11552	,	_	
60-3	11553-11556	the	_	
60-4	11557-11563	images	_	
60-5	11564-11568	were	_	
60-6	11569-11577	smoothed	_	
60-7	11578-11582	with	_	
60-8	11583-11584	a	_	
60-9	11585-11593	Gaussian	_	
60-10	11594-11600	kernel	_	
60-11	11601-11603	of	_	
60-12	11604-11605	8	_	
60-13	11606-11608	mm	_	
60-14	11609-11619	full-width	_	
60-15	11620-11622	at	_	
60-16	11623-11627	half	_	
60-17	11628-11635	maximum	_	
60-18	11635-11636	.	_	

#Text=Data analysis
#Text=Statistical analyses of demographic and clinical data were performed using SPSS (SPSS version 24, Chicago, IL, USA).
61-1	11637-11641	Data	_	
61-2	11642-11650	analysis	_	
61-3	11651-11662	Statistical	_	
61-4	11663-11671	analyses	_	
61-5	11672-11674	of	_	
61-6	11675-11686	demographic	_	
61-7	11687-11690	and	_	
61-8	11691-11699	clinical	_	
61-9	11700-11704	data	_	
61-10	11705-11709	were	_	
61-11	11710-11719	performed	_	
61-12	11720-11725	using	_	
61-13	11726-11730	SPSS	_	
61-14	11731-11732	(	_	
61-15	11732-11736	SPSS	_	
61-16	11737-11744	version	_	
61-17	11745-11747	24	_	
61-18	11747-11748	,	_	
61-19	11749-11756	Chicago	_	
61-20	11756-11757	,	_	
61-21	11758-11760	IL	_	
61-22	11760-11761	,	_	
61-23	11762-11765	USA	_	
61-24	11765-11766	)	_	
61-25	11766-11767	.	_	

#Text=After testing for the normality of the distributions, continuous variables were compared using t-tests and categorical variables were compared using chi-square tests.
62-1	11768-11773	After	_	
62-2	11774-11781	testing	_	
62-3	11782-11785	for	_	
62-4	11786-11789	the	_	
62-5	11790-11799	normality	_	
62-6	11800-11802	of	_	
62-7	11803-11806	the	_	
62-8	11807-11820	distributions	_	
62-9	11820-11821	,	_	
62-10	11822-11832	continuous	_	
62-11	11833-11842	variables	_	
62-12	11843-11847	were	_	
62-13	11848-11856	compared	_	
62-14	11857-11862	using	_	
62-15	11863-11870	t-tests	_	
62-16	11871-11874	and	_	
62-17	11875-11886	categorical	_	
62-18	11887-11896	variables	_	
62-19	11897-11901	were	_	
62-20	11902-11910	compared	_	
62-21	11911-11916	using	_	
62-22	11917-11927	chi-square	_	
62-23	11928-11933	tests	_	
62-24	11933-11934	.	_	

#Text=Significance was set at p < 0.05.
63-1	11935-11947	Significance	_	
63-2	11948-11951	was	_	
63-3	11952-11955	set	_	
63-4	11956-11958	at	_	
63-5	11959-11960	p	_	
63-6	11961-11962	<	_	
63-7	11963-11967	0.05	_	
63-8	11967-11968	.	_	

#Text=Symptom capture analysis
#Text=General linear model analysis was used on the pre-processed images.
64-1	11969-11976	Symptom	_	
64-2	11977-11984	capture	_	
64-3	11985-11993	analysis	_	
64-4	11994-12001	General	_	
64-5	12002-12008	linear	_	
64-6	12009-12014	model	_	
64-7	12015-12023	analysis	_	
64-8	12024-12027	was	_	
64-9	12028-12032	used	_	
64-10	12033-12035	on	_	
64-11	12036-12039	the	_	
64-12	12040-12053	pre-processed	_	
64-13	12054-12060	images	_	
64-14	12060-12061	.	_	

#Text=For each subject, one contrast vector (AVH minus rest) was specified to evaluate the effect of AVH (button pressed) relative to the baseline (button not pressed) with the six movement parameters (three translation and three rotation) from pre-processing entered as nuisance regressors.
65-1	12062-12065	For	_	
65-2	12066-12070	each	_	
65-3	12071-12078	subject	_	
65-4	12078-12079	,	_	
65-5	12080-12083	one	_	
65-6	12084-12092	contrast	_	
65-7	12093-12099	vector	_	
65-8	12100-12101	(	_	
65-9	12101-12104	AVH	_	
65-10	12105-12110	minus	_	
65-11	12111-12115	rest	_	
65-12	12115-12116	)	_	
65-13	12117-12120	was	_	
65-14	12121-12130	specified	_	
65-15	12131-12133	to	_	
65-16	12134-12142	evaluate	_	
65-17	12143-12146	the	_	
65-18	12147-12153	effect	_	
65-19	12154-12156	of	_	
65-20	12157-12160	AVH	_	
65-21	12161-12162	(	_	
65-22	12162-12168	button	_	
65-23	12169-12176	pressed	_	
65-24	12176-12177	)	_	
65-25	12178-12186	relative	_	
65-26	12187-12189	to	_	
65-27	12190-12193	the	_	
65-28	12194-12202	baseline	_	
65-29	12203-12204	(	_	
65-30	12204-12210	button	_	
65-31	12211-12214	not	_	
65-32	12215-12222	pressed	_	
65-33	12222-12223	)	_	
65-34	12224-12228	with	_	
65-35	12229-12232	the	_	
65-36	12233-12236	six	_	
65-37	12237-12245	movement	_	
65-38	12246-12256	parameters	_	
65-39	12257-12258	(	_	
65-40	12258-12263	three	_	
65-41	12264-12275	translation	_	
65-42	12276-12279	and	_	
65-43	12280-12285	three	_	
65-44	12286-12294	rotation	_	
65-45	12294-12295	)	_	
65-46	12296-12300	from	_	
65-47	12301-12315	pre-processing	_	
65-48	12316-12323	entered	_	
65-49	12324-12326	as	_	
65-50	12327-12335	nuisance	_	
65-51	12336-12346	regressors	_	
65-52	12346-12347	.	_	

#Text=This produced a contrast image for each subject that was then entered into a second level, random-effects analysis, using a one-sample t-test.
66-1	12348-12352	This	_	
66-2	12353-12361	produced	_	
66-3	12362-12363	a	_	
66-4	12364-12372	contrast	_	
66-5	12373-12378	image	_	
66-6	12379-12382	for	_	
66-7	12383-12387	each	_	
66-8	12388-12395	subject	_	
66-9	12396-12400	that	_	
66-10	12401-12404	was	_	
66-11	12405-12409	then	_	
66-12	12410-12417	entered	_	
66-13	12418-12422	into	_	
66-14	12423-12424	a	_	
66-15	12425-12431	second	_	
66-16	12432-12437	level	_	
66-17	12437-12438	,	_	
66-18	12439-12453	random-effects	_	
66-19	12454-12462	analysis	_	
66-20	12462-12463	,	_	
66-21	12464-12469	using	_	
66-22	12470-12471	a	_	
66-23	12472-12482	one-sample	_	
66-24	12483-12489	t-test	_	
66-25	12489-12490	.	_	

#Text=A group comparison of activation during AVH and at rest was then conducted.
67-1	12491-12492	A	_	
67-2	12493-12498	group	_	
67-3	12499-12509	comparison	_	
67-4	12510-12512	of	_	
67-5	12513-12523	activation	_	
67-6	12524-12530	during	_	
67-7	12531-12534	AVH	_	
67-8	12535-12538	and	_	
67-9	12539-12541	at	_	
67-10	12542-12546	rest	_	
67-11	12547-12550	was	_	
67-12	12551-12555	then	_	
67-13	12556-12565	conducted	_	
67-14	12565-12566	.	_	

#Text=A cluster was considered as significant at p < 0.01 (uncorrected) and an extent criterion of k = 60 to reduce the likelihood of identifying false positive clusters.
68-1	12567-12568	A	_	
68-2	12569-12576	cluster	_	
68-3	12577-12580	was	_	
68-4	12581-12591	considered	_	
68-5	12592-12594	as	_	
68-6	12595-12606	significant	_	
68-7	12607-12609	at	_	
68-8	12610-12611	p	_	
68-9	12612-12613	<	_	
68-10	12614-12618	0.01	_	
68-11	12619-12620	(	_	
68-12	12620-12631	uncorrected	_	
68-13	12631-12632	)	_	
68-14	12633-12636	and	_	
68-15	12637-12639	an	_	
68-16	12640-12646	extent	_	
68-17	12647-12656	criterion	_	
68-18	12657-12659	of	_	
68-19	12660-12661	k	_	
68-20	12662-12663	=	_	
68-21	12664-12666	60	_	
68-22	12667-12669	to	_	
68-23	12670-12676	reduce	_	
68-24	12677-12680	the	_	
68-25	12681-12691	likelihood	_	
68-26	12692-12694	of	_	
68-27	12695-12706	identifying	_	
68-28	12707-12712	false	_	
68-29	12713-12721	positive	_	
68-30	12722-12730	clusters	_	
68-31	12730-12731	.	_	

#Text=The uncorrected threshold was chosen to reduce the likelihood of type 2 error.
69-1	12732-12735	The	_	
69-2	12736-12747	uncorrected	_	
69-3	12748-12757	threshold	_	
69-4	12758-12761	was	_	
69-5	12762-12768	chosen	_	
69-6	12769-12771	to	_	
69-7	12772-12778	reduce	_	
69-8	12779-12782	the	_	
69-9	12783-12793	likelihood	_	
69-10	12794-12796	of	_	
69-11	12797-12801	type	_	
69-12	12802-12803	2	_	
69-13	12804-12809	error	_	
69-14	12809-12810	.	_	

#Text=Seed-based FC analysis
#Text=The brain regions that were identified in the symptom capture study were included as regions of interest (ROI) for the FC analyses.
70-1	12811-12821	Seed-based	_	
70-2	12822-12824	FC	_	
70-3	12825-12833	analysis	_	
70-4	12834-12837	The	_	
70-5	12838-12843	brain	_	
70-6	12844-12851	regions	_	
70-7	12852-12856	that	_	
70-8	12857-12861	were	_	
70-9	12862-12872	identified	_	
70-10	12873-12875	in	_	
70-11	12876-12879	the	_	
70-12	12880-12887	symptom	_	
70-13	12888-12895	capture	_	
70-14	12896-12901	study	_	
70-15	12902-12906	were	_	
70-16	12907-12915	included	_	
70-17	12916-12918	as	_	
70-18	12919-12926	regions	_	
70-19	12927-12929	of	_	
70-20	12930-12938	interest	_	
70-21	12939-12940	(	_	
70-22	12940-12943	ROI	_	
70-23	12943-12944	)	_	
70-24	12945-12948	for	_	
70-25	12949-12952	the	_	
70-26	12953-12955	FC	_	
70-27	12956-12964	analyses	_	
70-28	12964-12965	.	_	

#Text=ROI were created using spherical peak coordinates with a radius of 4 mm.
71-1	12966-12969	ROI	_	
71-2	12970-12974	were	_	
71-3	12975-12982	created	_	
71-4	12983-12988	using	_	
71-5	12989-12998	spherical	_	
71-6	12999-13003	peak	_	
71-7	13004-13015	coordinates	_	
71-8	13016-13020	with	_	
71-9	13021-13022	a	_	
71-10	13023-13029	radius	_	
71-11	13030-13032	of	_	
71-12	13033-13034	4	_	
71-13	13035-13037	mm	_	
71-14	13037-13038	.	_	

#Text=Four millimetre radius was chosen over 6 mm, more frequently used, in the aim of adding specificity to regions chosen.
72-1	13039-13043	Four	_	
72-2	13044-13054	millimetre	_	
72-3	13055-13061	radius	_	
72-4	13062-13065	was	_	
72-5	13066-13072	chosen	_	
72-6	13073-13077	over	_	
72-7	13078-13079	6	_	
72-8	13080-13082	mm	_	
72-9	13082-13083	,	_	
72-10	13084-13088	more	_	
72-11	13089-13099	frequently	_	
72-12	13100-13104	used	_	
72-13	13104-13105	,	_	
72-14	13106-13108	in	_	
72-15	13109-13112	the	_	
72-16	13113-13116	aim	_	
72-17	13117-13119	of	_	
72-18	13120-13126	adding	_	
72-19	13127-13138	specificity	_	
72-20	13139-13141	to	_	
72-21	13142-13149	regions	_	
72-22	13150-13156	chosen	_	
72-23	13156-13157	.	_	

#Text=Pearson’s correlations coefficients between the time series of each seed region with voxels of the rest of the brain were then calculated for each ROI.
73-1	13158-13165	Pearson	_	
73-2	13165-13166	’	_	
73-3	13166-13167	s	_	
73-4	13168-13180	correlations	_	
73-5	13181-13193	coefficients	_	
73-6	13194-13201	between	_	
73-7	13202-13205	the	_	
73-8	13206-13210	time	_	
73-9	13211-13217	series	_	
73-10	13218-13220	of	_	
73-11	13221-13225	each	_	
73-12	13226-13230	seed	_	
73-13	13231-13237	region	_	
73-14	13238-13242	with	_	
73-15	13243-13249	voxels	_	
73-16	13250-13252	of	_	
73-17	13253-13256	the	_	
73-18	13257-13261	rest	_	
73-19	13262-13264	of	_	
73-20	13265-13268	the	_	
73-21	13269-13274	brain	_	
73-22	13275-13279	were	_	
73-23	13280-13284	then	_	
73-24	13285-13295	calculated	_	
73-25	13296-13299	for	_	
73-26	13300-13304	each	_	
73-27	13305-13308	ROI	_	
73-28	13308-13309	.	_	

#Text=A Fisher transformation was then used to convert these voxel-wise Pearson correlation coefficients into whole-brain z-values for each participant to conduct second-level analyses in SPM8.
74-1	13310-13311	A	_	
74-2	13312-13318	Fisher	_	
74-3	13319-13333	transformation	_	
74-4	13334-13337	was	_	
74-5	13338-13342	then	_	
74-6	13343-13347	used	_	
74-7	13348-13350	to	_	
74-8	13351-13358	convert	_	
74-9	13359-13364	these	_	
74-10	13365-13375	voxel-wise	_	
74-11	13376-13383	Pearson	_	
74-12	13384-13395	correlation	_	
74-13	13396-13408	coefficients	_	
74-14	13409-13413	into	_	
74-15	13414-13425	whole-brain	_	
74-16	13426-13434	z-values	_	
74-17	13435-13438	for	_	
74-18	13439-13443	each	_	
74-19	13444-13455	participant	_	
74-20	13456-13458	to	_	
74-21	13459-13466	conduct	_	
74-22	13467-13479	second-level	_	
74-23	13480-13488	analyses	_	
74-24	13489-13491	in	_	
74-25	13492-13496	SPM8	_	
74-26	13496-13497	.	_	

#Text=The FC maps from individual participants were separately analysed using one-sample t-test for the entire sample with cluster level significance level set at p < 0.05 (family-wise error (FWE) corrected).
75-1	13498-13501	The	_	
75-2	13502-13504	FC	_	
75-3	13505-13509	maps	_	
75-4	13510-13514	from	_	
75-5	13515-13525	individual	_	
75-6	13526-13538	participants	_	
75-7	13539-13543	were	_	
75-8	13544-13554	separately	_	
75-9	13555-13563	analysed	_	
75-10	13564-13569	using	_	
75-11	13570-13580	one-sample	_	
75-12	13581-13587	t-test	_	
75-13	13588-13591	for	_	
75-14	13592-13595	the	_	
75-15	13596-13602	entire	_	
75-16	13603-13609	sample	_	
75-17	13610-13614	with	_	
75-18	13615-13622	cluster	_	
75-19	13623-13628	level	_	
75-20	13629-13641	significance	_	
75-21	13642-13647	level	_	
75-22	13648-13651	set	_	
75-23	13652-13654	at	_	
75-24	13655-13656	p	_	
75-25	13657-13658	<	_	
75-26	13659-13663	0.05	_	
75-27	13664-13665	(	_	
75-28	13665-13676	family-wise	_	
75-29	13677-13682	error	_	
75-30	13683-13684	(	_	
75-31	13684-13687	FWE	_	
75-32	13687-13688	)	_	
75-33	13689-13698	corrected	_	
75-34	13698-13699	)	_	
75-35	13699-13700	.	_	

#Text=The results from the one sample t-test were used to derive search volume masks for the FC to constrain subsequent between group analysis.
76-1	13701-13704	The	_	
76-2	13705-13712	results	_	
76-3	13713-13717	from	_	
76-4	13718-13721	the	_	
76-5	13722-13725	one	_	
76-6	13726-13732	sample	_	
76-7	13733-13739	t-test	_	
76-8	13740-13744	were	_	
76-9	13745-13749	used	_	
76-10	13750-13752	to	_	
76-11	13753-13759	derive	_	
76-12	13760-13766	search	_	
76-13	13767-13773	volume	_	
76-14	13774-13779	masks	_	
76-15	13780-13783	for	_	
76-16	13784-13787	the	_	
76-17	13788-13790	FC	_	
76-18	13791-13793	to	_	
76-19	13794-13803	constrain	_	
76-20	13804-13814	subsequent	_	
76-21	13815-13822	between	_	
76-22	13823-13828	group	_	
76-23	13829-13837	analysis	_	
76-24	13837-13838	.	_	

#Text=The masks represented regions with significant instantaneous positive correlation or anticorrelation with the seed region.
77-1	13839-13842	The	_	
77-2	13843-13848	masks	_	
77-3	13849-13860	represented	_	
77-4	13861-13868	regions	_	
77-5	13869-13873	with	_	
77-6	13874-13885	significant	_	
77-7	13886-13899	instantaneous	_	
77-8	13900-13908	positive	_	
77-9	13909-13920	correlation	_	
77-10	13921-13923	or	_	
77-11	13924-13939	anticorrelation	_	
77-12	13940-13944	with	_	
77-13	13945-13948	the	_	
77-14	13949-13953	seed	_	
77-15	13954-13960	region	_	
77-16	13960-13961	.	_	

#Text=Between group analyses were conducted using an unpaired t-test with significance set at p < 0.05 (FWE corrected).
78-1	13962-13969	Between	_	
78-2	13970-13975	group	_	
78-3	13976-13984	analyses	_	
78-4	13985-13989	were	_	
78-5	13990-13999	conducted	_	
78-6	14000-14005	using	_	
78-7	14006-14008	an	_	
78-8	14009-14017	unpaired	_	
78-9	14018-14024	t-test	_	
78-10	14025-14029	with	_	
78-11	14030-14042	significance	_	
78-12	14043-14046	set	_	
78-13	14047-14049	at	_	
78-14	14050-14051	p	_	
78-15	14052-14053	<	_	
78-16	14054-14058	0.05	_	
78-17	14059-14060	(	_	
78-18	14060-14063	FWE	_	
78-19	14064-14073	corrected	_	
78-20	14073-14074	)	_	
78-21	14074-14075	.	_	

#Text=All group level analyses were carried out using SPM8 software and the toolboxes MarsBar (http://marsbar.sourceforge.net) and xjview (http://www.alivelearn.net/xjview8).
79-1	14076-14079	All	_	
79-2	14080-14085	group	_	
79-3	14086-14091	level	_	
79-4	14092-14100	analyses	_	
79-5	14101-14105	were	_	
79-6	14106-14113	carried	_	
79-7	14114-14117	out	_	
79-8	14118-14123	using	_	
79-9	14124-14128	SPM8	_	
79-10	14129-14137	software	_	
79-11	14138-14141	and	_	
79-12	14142-14145	the	_	
79-13	14146-14155	toolboxes	_	
79-14	14156-14163	MarsBar	_	
79-15	14164-14165	(	_	
79-16	14165-14169	http	_	
79-17	14169-14170	:	_	
79-18	14170-14171	/	_	
79-19	14171-14172	/	_	
79-20	14172-14195	marsbar.sourceforge.net	_	
79-21	14195-14196	)	_	
79-22	14197-14200	and	_	
79-23	14201-14207	xjview	_	
79-24	14208-14209	(	_	
79-25	14209-14213	http	_	
79-26	14213-14214	:	_	
79-27	14214-14215	/	_	
79-28	14215-14216	/	_	
79-29	14216-14234	www.alivelearn.net	_	
79-30	14234-14235	/	_	
79-31	14235-14242	xjview8	_	
79-32	14242-14243	)	_	
79-33	14243-14244	.	_	

#Text=In the patient group, bivariate correlations were used to examine the influence of current antipsychotic medications (chlorpromazine equivalent), and duration of illness on the mean coefficients within the clusters that emerged as significant from the two-sample t-tests.
80-1	14245-14247	In	_	
80-2	14248-14251	the	_	
80-3	14252-14259	patient	_	
80-4	14260-14265	group	_	
80-5	14265-14266	,	_	
80-6	14267-14276	bivariate	_	
80-7	14277-14289	correlations	_	
80-8	14290-14294	were	_	
80-9	14295-14299	used	_	
80-10	14300-14302	to	_	
80-11	14303-14310	examine	_	
80-12	14311-14314	the	_	
80-13	14315-14324	influence	_	
80-14	14325-14327	of	_	
80-15	14328-14335	current	_	
80-16	14336-14349	antipsychotic	_	
80-17	14350-14361	medications	_	
80-18	14362-14363	(	_	
80-19	14363-14377	chlorpromazine	_	
80-20	14378-14388	equivalent	_	
80-21	14388-14389	)	_	
80-22	14389-14390	,	_	
80-23	14391-14394	and	_	
80-24	14395-14403	duration	_	
80-25	14404-14406	of	_	
80-26	14407-14414	illness	_	
80-27	14415-14417	on	_	
80-28	14418-14421	the	_	
80-29	14422-14426	mean	_	
80-30	14427-14439	coefficients	_	
80-31	14440-14446	within	_	
80-32	14447-14450	the	_	
80-33	14451-14459	clusters	_	
80-34	14460-14464	that	_	
80-35	14465-14472	emerged	_	
80-36	14473-14475	as	_	
80-37	14476-14487	significant	_	
80-38	14488-14492	from	_	
80-39	14493-14496	the	_	
80-40	14497-14507	two-sample	_	
80-41	14508-14515	t-tests	_	
80-42	14515-14516	.	_	

#Text=The scores on severity of hallucinations (TVRS, VPD, PSYRATS) were correlated with the mean coefficients within the clusters that were significantly different between patients and controls.
81-1	14517-14520	The	_	
81-2	14521-14527	scores	_	
81-3	14528-14530	on	_	
81-4	14531-14539	severity	_	
81-5	14540-14542	of	_	
81-6	14543-14557	hallucinations	_	
81-7	14558-14559	(	_	
81-8	14559-14563	TVRS	_	
81-9	14563-14564	,	_	
81-10	14565-14568	VPD	_	
81-11	14568-14569	,	_	
81-12	14570-14577	PSYRATS	_	
81-13	14577-14578	)	_	
81-14	14579-14583	were	_	
81-15	14584-14594	correlated	_	
81-16	14595-14599	with	_	
81-17	14600-14603	the	_	
81-18	14604-14608	mean	_	
81-19	14609-14621	coefficients	_	
81-20	14622-14628	within	_	
81-21	14629-14632	the	_	
81-22	14633-14641	clusters	_	
81-23	14642-14646	that	_	
81-24	14647-14651	were	_	
81-25	14652-14665	significantly	_	
81-26	14666-14675	different	_	
81-27	14676-14683	between	_	
81-28	14684-14692	patients	_	
81-29	14693-14696	and	_	
81-30	14697-14705	controls	_	
81-31	14705-14706	.	_	

#Text=The significance level was set at p < 0.05 (FWE corrected across all comparisons).
82-1	14707-14710	The	_	
82-2	14711-14723	significance	_	
82-3	14724-14729	level	_	
82-4	14730-14733	was	_	
82-5	14734-14737	set	_	
82-6	14738-14740	at	_	
82-7	14741-14742	p	_	
82-8	14743-14744	<	_	
82-9	14745-14749	0.05	_	
82-10	14750-14751	(	_	
82-11	14751-14754	FWE	_	
82-12	14755-14764	corrected	_	
82-13	14765-14771	across	_	
82-14	14772-14775	all	_	
82-15	14776-14787	comparisons	_	
82-16	14787-14788	)	_	
82-17	14788-14789	.	_	

#Text=Results
#Text=Demographic and clinical data
#Text=Demographic and clinical characteristics of the sample
#Text=\tFEP patients with persistent AVH (n = 18)\tHealthy controls (n = 18)\tp value\t \tAge (mean ± s.d.)\t27.14 ± 5.66\t26.94 ± 4.31\t0.91\t \tGender (Male/female)\t15/3\t15/3\t0.73\t \tMarital status (single/married)\t18/0\t16/2\t0/492\t \tCPZ equivalents (mean ± s.d.)\t217.85 ± 139.51\t\t\t \tDuration of untreated psychosis (days) (mean ± s.d.)\t323.92 ± 311.23\t\t\t \tBAVQ-R scores\t \t Malevolence (mean ± s.d.)\t11.07 ± 4.54\t\t\t \t Benevolence (mean ± s.d.)\t4.00 ± 3.28\t\t\t \t Omnipotence (mean ± s.d.)\t11.57 ± 4.32\t\t\t \t Resistance (mean ± s.d.)\t19.36 ± 3.67\t\t\t \t Engagement (mean ± s.d.)\t5.21 ± 3.98\t\t\t \t TVRS scores (mean ± s.d.)\t17.71 ± 3.47\t\t\t \t VPDS scores (mean ± s.d.)\t22.93 ± 5.44\t\t\t \tPSYRATS (auditory hallucination subscale)\t \t Total score (mean ± s.d.)\t26.86 ± 4.95\t\t\t \t Emotional domain (mean ± s.d.)\t11.29 ± 3.42\t\t\t \t Cognitive domain (mean ± s.d.)\t8.64 ± 1.82\t\t\t \t Physical domain (mean ± s.d.)\t9.79 ± 1.92\t\t\t \t
#Text=FEP first episode psychosis, AVH auditory verbal hallucinations, CPZ chlorpromazine, BAVQ-R belief about voices questionnaire—revised, TVRS topography of Voices Rating Scale, VPDS Voice Power Differential Scale, PSYRATS Psychotic Symptom Rating Scales
#Text=Clinical data analyses are summarised in Table 1.
83-1	14790-14797	Results	_	
83-2	14798-14809	Demographic	_	
83-3	14810-14813	and	_	
83-4	14814-14822	clinical	_	
83-5	14823-14827	data	_	
83-6	14828-14839	Demographic	_	
83-7	14840-14843	and	_	
83-8	14844-14852	clinical	_	
83-9	14853-14868	characteristics	_	
83-10	14869-14871	of	_	
83-11	14872-14875	the	_	
83-12	14876-14882	sample	_	
83-13	14884-14887	FEP	_	
83-14	14888-14896	patients	_	
83-15	14897-14901	with	_	
83-16	14902-14912	persistent	_	
83-17	14913-14916	AVH	_	
83-18	14917-14918	(	_	
83-19	14918-14919	n	_	
83-20	14920-14921	=	_	
83-21	14922-14924	18	_	
83-22	14924-14925	)	_	
83-23	14926-14933	Healthy	_	
83-24	14934-14942	controls	_	
83-25	14943-14944	(	_	
83-26	14944-14945	n	_	
83-27	14946-14947	=	_	
83-28	14948-14950	18	_	
83-29	14950-14951	)	_	
83-30	14952-14953	p	_	
83-31	14954-14959	value	_	
83-32	14962-14965	Age	_	
83-33	14966-14967	(	_	
83-34	14967-14971	mean	_	
83-35	14972-14973	±	_	
83-36	14974-14977	s.d	_	
83-37	14977-14978	.	_	
83-38	14978-14979	)	_	
83-39	14980-14985	27.14	_	
83-40	14986-14987	±	_	
83-41	14988-14992	5.66	_	
83-42	14993-14998	26.94	_	
83-43	14999-15000	±	_	
83-44	15001-15005	4.31	_	
83-45	15006-15010	0.91	_	
83-46	15013-15019	Gender	_	
83-47	15020-15021	(	_	
83-48	15021-15025	Male	_	
83-49	15025-15026	/	_	
83-50	15026-15032	female	_	
83-51	15032-15033	)	_	
83-52	15034-15036	15	_	
83-53	15036-15037	/	_	
83-54	15037-15038	3	_	
83-55	15039-15041	15	_	
83-56	15041-15042	/	_	
83-57	15042-15043	3	_	
83-58	15044-15048	0.73	_	
83-59	15051-15058	Marital	_	
83-60	15059-15065	status	_	
83-61	15066-15067	(	_	
83-62	15067-15073	single	_	
83-63	15073-15074	/	_	
83-64	15074-15081	married	_	
83-65	15081-15082	)	_	
83-66	15083-15085	18	_	
83-67	15085-15086	/	_	
83-68	15086-15087	0	_	
83-69	15088-15090	16	_	
83-70	15090-15091	/	_	
83-71	15091-15092	2	_	
83-72	15093-15094	0	_	
83-73	15094-15095	/	_	
83-74	15095-15098	492	_	
83-75	15101-15104	CPZ	_	
83-76	15105-15116	equivalents	_	
83-77	15117-15118	(	_	
83-78	15118-15122	mean	_	
83-79	15123-15124	±	_	
83-80	15125-15128	s.d	_	
83-81	15128-15129	.	_	
83-82	15129-15130	)	_	
83-83	15131-15137	217.85	_	
83-84	15138-15139	±	_	
83-85	15140-15146	139.51	_	
83-86	15151-15159	Duration	_	
83-87	15160-15162	of	_	
83-88	15163-15172	untreated	_	
83-89	15173-15182	psychosis	_	
83-90	15183-15184	(	_	
83-91	15184-15188	days	_	
83-92	15188-15189	)	_	
83-93	15190-15191	(	_	
83-94	15191-15195	mean	_	
83-95	15196-15197	±	_	
83-96	15198-15201	s.d	_	
83-97	15201-15202	.	_	
83-98	15202-15203	)	_	
83-99	15204-15210	323.92	_	
83-100	15211-15212	±	_	
83-101	15213-15219	311.23	_	
83-102	15224-15230	BAVQ-R	_	
83-103	15231-15237	scores	_	
83-104	15241-15252	Malevolence	_	
83-105	15253-15254	(	_	
83-106	15254-15258	mean	_	
83-107	15259-15260	±	_	
83-108	15261-15264	s.d	_	
83-109	15264-15265	.	_	
83-110	15265-15266	)	_	
83-111	15267-15272	11.07	_	
83-112	15273-15274	±	_	
83-113	15275-15279	4.54	_	
83-114	15285-15296	Benevolence	_	
83-115	15297-15298	(	_	
83-116	15298-15302	mean	_	
83-117	15303-15304	±	_	
83-118	15305-15308	s.d	_	
83-119	15308-15309	.	_	
83-120	15309-15310	)	_	
83-121	15311-15315	4.00	_	
83-122	15316-15317	±	_	
83-123	15318-15322	3.28	_	
83-124	15328-15339	Omnipotence	_	
83-125	15340-15341	(	_	
83-126	15341-15345	mean	_	
83-127	15346-15347	±	_	
83-128	15348-15351	s.d	_	
83-129	15351-15352	.	_	
83-130	15352-15353	)	_	
83-131	15354-15359	11.57	_	
83-132	15360-15361	±	_	
83-133	15362-15366	4.32	_	
83-134	15372-15382	Resistance	_	
83-135	15383-15384	(	_	
83-136	15384-15388	mean	_	
83-137	15389-15390	±	_	
83-138	15391-15394	s.d	_	
83-139	15394-15395	.	_	
83-140	15395-15396	)	_	
83-141	15397-15402	19.36	_	
83-142	15403-15404	±	_	
83-143	15405-15409	3.67	_	
83-144	15415-15425	Engagement	_	
83-145	15426-15427	(	_	
83-146	15427-15431	mean	_	
83-147	15432-15433	±	_	
83-148	15434-15437	s.d	_	
83-149	15437-15438	.	_	
83-150	15438-15439	)	_	
83-151	15440-15444	5.21	_	
83-152	15445-15446	±	_	
83-153	15447-15451	3.98	_	
83-154	15457-15461	TVRS	_	
83-155	15462-15468	scores	_	
83-156	15469-15470	(	_	
83-157	15470-15474	mean	_	
83-158	15475-15476	±	_	
83-159	15477-15480	s.d	_	
83-160	15480-15481	.	_	
83-161	15481-15482	)	_	
83-162	15483-15488	17.71	_	
83-163	15489-15490	±	_	
83-164	15491-15495	3.47	_	
83-165	15501-15505	VPDS	_	
83-166	15506-15512	scores	_	
83-167	15513-15514	(	_	
83-168	15514-15518	mean	_	
83-169	15519-15520	±	_	
83-170	15521-15524	s.d	_	
83-171	15524-15525	.	_	
83-172	15525-15526	)	_	
83-173	15527-15532	22.93	_	
83-174	15533-15534	±	_	
83-175	15535-15539	5.44	_	
83-176	15544-15551	PSYRATS	_	
83-177	15552-15553	(	_	
83-178	15553-15561	auditory	_	
83-179	15562-15575	hallucination	_	
83-180	15576-15584	subscale	_	
83-181	15584-15585	)	_	
83-182	15589-15594	Total	_	
83-183	15595-15600	score	_	
83-184	15601-15602	(	_	
83-185	15602-15606	mean	_	
83-186	15607-15608	±	_	
83-187	15609-15612	s.d	_	
83-188	15612-15613	.	_	
83-189	15613-15614	)	_	
83-190	15615-15620	26.86	_	
83-191	15621-15622	±	_	
83-192	15623-15627	4.95	_	
83-193	15633-15642	Emotional	_	
83-194	15643-15649	domain	_	
83-195	15650-15651	(	_	
83-196	15651-15655	mean	_	
83-197	15656-15657	±	_	
83-198	15658-15661	s.d	_	
83-199	15661-15662	.	_	
83-200	15662-15663	)	_	
83-201	15664-15669	11.29	_	
83-202	15670-15671	±	_	
83-203	15672-15676	3.42	_	
83-204	15682-15691	Cognitive	_	
83-205	15692-15698	domain	_	
83-206	15699-15700	(	_	
83-207	15700-15704	mean	_	
83-208	15705-15706	±	_	
83-209	15707-15710	s.d	_	
83-210	15710-15711	.	_	
83-211	15711-15712	)	_	
83-212	15713-15717	8.64	_	
83-213	15718-15719	±	_	
83-214	15720-15724	1.82	_	
83-215	15730-15738	Physical	_	
83-216	15739-15745	domain	_	
83-217	15746-15747	(	_	
83-218	15747-15751	mean	_	
83-219	15752-15753	±	_	
83-220	15754-15757	s.d	_	
83-221	15757-15758	.	_	
83-222	15758-15759	)	_	
83-223	15760-15764	9.79	_	
83-224	15765-15766	±	_	
83-225	15767-15771	1.92	_	
83-226	15777-15780	FEP	_	
83-227	15781-15786	first	_	
83-228	15787-15794	episode	_	
83-229	15795-15804	psychosis	_	
83-230	15804-15805	,	_	
83-231	15806-15809	AVH	_	
83-232	15810-15818	auditory	_	
83-233	15819-15825	verbal	_	
83-234	15826-15840	hallucinations	_	
83-235	15840-15841	,	_	
83-236	15842-15845	CPZ	_	
83-237	15846-15860	chlorpromazine	_	
83-238	15860-15861	,	_	
83-239	15862-15868	BAVQ-R	_	
83-240	15869-15875	belief	_	
83-241	15876-15881	about	_	
83-242	15882-15888	voices	_	
83-243	15889-15910	questionnaire—revised	_	
83-244	15910-15911	,	_	
83-245	15912-15916	TVRS	_	
83-246	15917-15927	topography	_	
83-247	15928-15930	of	_	
83-248	15931-15937	Voices	_	
83-249	15938-15944	Rating	_	
83-250	15945-15950	Scale	_	
83-251	15950-15951	,	_	
83-252	15952-15956	VPDS	_	
83-253	15957-15962	Voice	_	
83-254	15963-15968	Power	_	
83-255	15969-15981	Differential	_	
83-256	15982-15987	Scale	_	
83-257	15987-15988	,	_	
83-258	15989-15996	PSYRATS	_	
83-259	15997-16006	Psychotic	_	
83-260	16007-16014	Symptom	_	
83-261	16015-16021	Rating	_	
83-262	16022-16028	Scales	_	
83-263	16029-16037	Clinical	_	
83-264	16038-16042	data	_	
83-265	16043-16051	analyses	_	
83-266	16052-16055	are	_	
83-267	16056-16066	summarised	_	
83-268	16067-16069	in	_	
83-269	16070-16075	Table	_	
83-270	16076-16077	1	_	
83-271	16077-16078	.	_	

#Text=Nine individuals with FEP were diagnosed with schizophrenia, four with psychotic disorder not otherwise specified, one with schizoaffective disorder, four with schizophreniform disorder.
84-1	16079-16083	Nine	_	
84-2	16084-16095	individuals	_	
84-3	16096-16100	with	_	
84-4	16101-16104	FEP	_	
84-5	16105-16109	were	_	
84-6	16110-16119	diagnosed	_	
84-7	16120-16124	with	_	
84-8	16125-16138	schizophrenia	_	
84-9	16138-16139	,	_	
84-10	16140-16144	four	_	
84-11	16145-16149	with	_	
84-12	16150-16159	psychotic	_	
84-13	16160-16168	disorder	_	
84-14	16169-16172	not	_	
84-15	16173-16182	otherwise	_	
84-16	16183-16192	specified	_	
84-17	16192-16193	,	_	
84-18	16194-16197	one	_	
84-19	16198-16202	with	_	
84-20	16203-16218	schizoaffective	_	
84-21	16219-16227	disorder	_	
84-22	16227-16228	,	_	
84-23	16229-16233	four	_	
84-24	16234-16238	with	_	
84-25	16239-16255	schizophreniform	_	
84-26	16256-16264	disorder	_	
84-27	16264-16265	.	_	

#Text=Median dose of antipsychotic medication currently taken in chlorpromazine equivalents was 200 mg (range 0–400 mg).
85-1	16266-16272	Median	_	
85-2	16273-16277	dose	_	
85-3	16278-16280	of	_	
85-4	16281-16294	antipsychotic	_	
85-5	16295-16305	medication	_	
85-6	16306-16315	currently	_	
85-7	16316-16321	taken	_	
85-8	16322-16324	in	_	
85-9	16325-16339	chlorpromazine	_	
85-10	16340-16351	equivalents	_	
85-11	16352-16355	was	_	
85-12	16356-16359	200	_	
85-13	16360-16362	mg	_	
85-14	16363-16364	(	_	
85-15	16364-16369	range	_	
85-16	16370-16371	0	_	
85-17	16371-16372	–	_	
85-18	16372-16375	400	_	
85-19	16376-16378	mg	_	
85-20	16378-16379	)	_	
85-21	16379-16380	.	_	

#Text=Two patients were not on any antipsychotic medication.
86-1	16381-16384	Two	_	
86-2	16385-16393	patients	_	
86-3	16394-16398	were	_	
86-4	16399-16402	not	_	
86-5	16403-16405	on	_	
86-6	16406-16409	any	_	
86-7	16410-16423	antipsychotic	_	
86-8	16424-16434	medication	_	
86-9	16434-16435	.	_	

#Text=The mean duration of treated psychosis was 103 days (median 99, range 0–360) and of untreated psychosis was 226.5 days (range 6–1095 days).
87-1	16436-16439	The	_	
87-2	16440-16444	mean	_	
87-3	16445-16453	duration	_	
87-4	16454-16456	of	_	
87-5	16457-16464	treated	_	
87-6	16465-16474	psychosis	_	
87-7	16475-16478	was	_	
87-8	16479-16482	103	_	
87-9	16483-16487	days	_	
87-10	16488-16489	(	_	
87-11	16489-16495	median	_	
87-12	16496-16498	99	_	
87-13	16498-16499	,	_	
87-14	16500-16505	range	_	
87-15	16506-16507	0	_	
87-16	16507-16508	–	_	
87-17	16508-16511	360	_	
87-18	16511-16512	)	_	
87-19	16513-16516	and	_	
87-20	16517-16519	of	_	
87-21	16520-16529	untreated	_	
87-22	16530-16539	psychosis	_	
87-23	16540-16543	was	_	
87-24	16544-16549	226.5	_	
87-25	16550-16554	days	_	
87-26	16555-16556	(	_	
87-27	16556-16561	range	_	
87-28	16562-16563	6	_	
87-29	16563-16564	–	_	
87-30	16564-16568	1095	_	
87-31	16569-16573	days	_	
87-32	16573-16574	)	_	
87-33	16574-16575	.	_	

#Text=Symptom capture analysis
#Text=Coordinates of brain regions activated during auditory verbal hallucinations (n = 9)
#Text=Region of interest (BA)\tMNI Coordinates (xyz)\tCluster size,\tp value (uncorr)\t \t Cluster 1 (left)\t \t Lingual gyrus (18)\t-24 -58 -4\tk = 121\tp < 0.001**\t \t Lingual gyrus (19)\t-18 -46 -8\t \t Parahippocampal gyrus (19)\t-33 -55 -4\t \t Cluster 2 (left)\t-48 2 -6\tk = 61\tp = 0.013\t \t Insula (22)\t-54 11 -8\t \t Superior temporal gyrus (22)\t-54 -7 -10\t \t Superior temporal gyrus (22)\t\t\t\t \t Cluster 3 (right)\t \t Superior temporal gyrus (22)\t51 -7 -2\tk = 141\tp < 0.001**\t \t Insula\t42 -19 -6\t \t Superior temporal gyrus (22)\t48 -16 -14\t \t Cluster 4 (left)\t \t Claustrum\t-33 -7 -10\tk = 65\tp = 0.010\t \t Insula (13)\t-45 -13 -4\t \t Claustrum\t-39 -1 -8\t \t Cluster 5 (right)\t \t Precuneus (31)\t12 -64 22\tk = 61\tp = 0.013\t \t Precuneus (31)\t24 -70 20\t \t Posterior cingulate cortex (31)\t21 -61 14\t \t
#Text=BA Broadman area
#Text=**significant at FDR < 0.05
#Text=The results of the symptom capture analysis are presented in Table 2.
88-1	16576-16583	Symptom	_	
88-2	16584-16591	capture	_	
88-3	16592-16600	analysis	_	
88-4	16601-16612	Coordinates	_	
88-5	16613-16615	of	_	
88-6	16616-16621	brain	_	
88-7	16622-16629	regions	_	
88-8	16630-16639	activated	_	
88-9	16640-16646	during	_	
88-10	16647-16655	auditory	_	
88-11	16656-16662	verbal	_	
88-12	16663-16677	hallucinations	_	
88-13	16678-16679	(	_	
88-14	16679-16680	n	_	
88-15	16681-16682	=	_	
88-16	16683-16684	9	_	
88-17	16684-16685	)	_	
88-18	16686-16692	Region	_	
88-19	16693-16695	of	_	
88-20	16696-16704	interest	_	
88-21	16705-16706	(	_	
88-22	16706-16708	BA	_	
88-23	16708-16709	)	_	
88-24	16710-16713	MNI	_	
88-25	16714-16725	Coordinates	_	
88-26	16726-16727	(	_	
88-27	16727-16730	xyz	_	
88-28	16730-16731	)	_	
88-29	16732-16739	Cluster	_	
88-30	16740-16744	size	_	
88-31	16744-16745	,	_	
88-32	16746-16747	p	_	
88-33	16748-16753	value	_	
88-34	16754-16755	(	_	
88-35	16755-16761	uncorr	_	
88-36	16761-16762	)	_	
88-37	16766-16773	Cluster	_	
88-38	16774-16775	1	_	
88-39	16776-16777	(	_	
88-40	16777-16781	left	_	
88-41	16781-16782	)	_	
88-42	16786-16793	Lingual	_	
88-43	16794-16799	gyrus	_	
88-44	16800-16801	(	_	
88-45	16801-16803	18	_	
88-46	16803-16804	)	_	
88-47	16805-16806	-	_	
88-48	16806-16808	24	_	
88-49	16809-16810	-	_	
88-50	16810-16812	58	_	
88-51	16813-16814	-	_	
88-52	16814-16815	4	_	
88-53	16816-16817	k	_	
88-54	16818-16819	=	_	
88-55	16820-16823	121	_	
88-56	16824-16825	p	_	
88-57	16826-16827	<	_	
88-58	16828-16833	0.001	_	
88-59	16833-16834	*	_	
88-60	16834-16835	*	_	
88-61	16839-16846	Lingual	_	
88-62	16847-16852	gyrus	_	
88-63	16853-16854	(	_	
88-64	16854-16856	19	_	
88-65	16856-16857	)	_	
88-66	16858-16859	-	_	
88-67	16859-16861	18	_	
88-68	16862-16863	-	_	
88-69	16863-16865	46	_	
88-70	16866-16867	-	_	
88-71	16867-16868	8	_	
88-72	16872-16887	Parahippocampal	_	
88-73	16888-16893	gyrus	_	
88-74	16894-16895	(	_	
88-75	16895-16897	19	_	
88-76	16897-16898	)	_	
88-77	16899-16900	-	_	
88-78	16900-16902	33	_	
88-79	16903-16904	-	_	
88-80	16904-16906	55	_	
88-81	16907-16908	-	_	
88-82	16908-16909	4	_	
88-83	16913-16920	Cluster	_	
88-84	16921-16922	2	_	
88-85	16923-16924	(	_	
88-86	16924-16928	left	_	
88-87	16928-16929	)	_	
88-88	16930-16931	-	_	
88-89	16931-16933	48	_	
88-90	16934-16935	2	_	
88-91	16936-16937	-	_	
88-92	16937-16938	6	_	
88-93	16939-16940	k	_	
88-94	16941-16942	=	_	
88-95	16943-16945	61	_	
88-96	16946-16947	p	_	
88-97	16948-16949	=	_	
88-98	16950-16955	0.013	_	
88-99	16959-16965	Insula	_	
88-100	16966-16967	(	_	
88-101	16967-16969	22	_	
88-102	16969-16970	)	_	
88-103	16971-16972	-	_	
88-104	16972-16974	54	_	
88-105	16975-16977	11	_	
88-106	16978-16979	-	_	
88-107	16979-16980	8	_	
88-108	16984-16992	Superior	_	
88-109	16993-17001	temporal	_	
88-110	17002-17007	gyrus	_	
88-111	17008-17009	(	_	
88-112	17009-17011	22	_	
88-113	17011-17012	)	_	
88-114	17013-17014	-	_	
88-115	17014-17016	54	_	
88-116	17017-17018	-	_	
88-117	17018-17019	7	_	
88-118	17020-17021	-	_	
88-119	17021-17023	10	_	
88-120	17027-17035	Superior	_	
88-121	17036-17044	temporal	_	
88-122	17045-17050	gyrus	_	
88-123	17051-17052	(	_	
88-124	17052-17054	22	_	
88-125	17054-17055	)	_	
88-126	17062-17069	Cluster	_	
88-127	17070-17071	3	_	
88-128	17072-17073	(	_	
88-129	17073-17078	right	_	
88-130	17078-17079	)	_	
88-131	17083-17091	Superior	_	
88-132	17092-17100	temporal	_	
88-133	17101-17106	gyrus	_	
88-134	17107-17108	(	_	
88-135	17108-17110	22	_	
88-136	17110-17111	)	_	
88-137	17112-17114	51	_	
88-138	17115-17116	-	_	
88-139	17116-17117	7	_	
88-140	17118-17119	-	_	
88-141	17119-17120	2	_	
88-142	17121-17122	k	_	
88-143	17123-17124	=	_	
88-144	17125-17128	141	_	
88-145	17129-17130	p	_	
88-146	17131-17132	<	_	
88-147	17133-17138	0.001	_	
88-148	17138-17139	*	_	
88-149	17139-17140	*	_	
88-150	17144-17150	Insula	_	
88-151	17151-17153	42	_	
88-152	17154-17155	-	_	
88-153	17155-17157	19	_	
88-154	17158-17159	-	_	
88-155	17159-17160	6	_	
88-156	17164-17172	Superior	_	
88-157	17173-17181	temporal	_	
88-158	17182-17187	gyrus	_	
88-159	17188-17189	(	_	
88-160	17189-17191	22	_	
88-161	17191-17192	)	_	
88-162	17193-17195	48	_	
88-163	17196-17197	-	_	
88-164	17197-17199	16	_	
88-165	17200-17201	-	_	
88-166	17201-17203	14	_	
88-167	17207-17214	Cluster	_	
88-168	17215-17216	4	_	
88-169	17217-17218	(	_	
88-170	17218-17222	left	_	
88-171	17222-17223	)	_	
88-172	17227-17236	Claustrum	_	
88-173	17237-17238	-	_	
88-174	17238-17240	33	_	
88-175	17241-17242	-	_	
88-176	17242-17243	7	_	
88-177	17244-17245	-	_	
88-178	17245-17247	10	_	
88-179	17248-17249	k	_	
88-180	17250-17251	=	_	
88-181	17252-17254	65	_	
88-182	17255-17256	p	_	
88-183	17257-17258	=	_	
88-184	17259-17264	0.010	_	
88-185	17268-17274	Insula	_	
88-186	17275-17276	(	_	
88-187	17276-17278	13	_	
88-188	17278-17279	)	_	
88-189	17280-17281	-	_	
88-190	17281-17283	45	_	
88-191	17284-17285	-	_	
88-192	17285-17287	13	_	
88-193	17288-17289	-	_	
88-194	17289-17290	4	_	
88-195	17294-17303	Claustrum	_	
88-196	17304-17305	-	_	
88-197	17305-17307	39	_	
88-198	17308-17309	-	_	
88-199	17309-17310	1	_	
88-200	17311-17312	-	_	
88-201	17312-17313	8	_	
88-202	17317-17324	Cluster	_	
88-203	17325-17326	5	_	
88-204	17327-17328	(	_	
88-205	17328-17333	right	_	
88-206	17333-17334	)	_	
88-207	17338-17347	Precuneus	_	
88-208	17348-17349	(	_	
88-209	17349-17351	31	_	
88-210	17351-17352	)	_	
88-211	17353-17355	12	_	
88-212	17356-17357	-	_	
88-213	17357-17359	64	_	
88-214	17360-17362	22	_	
88-215	17363-17364	k	_	
88-216	17365-17366	=	_	
88-217	17367-17369	61	_	
88-218	17370-17371	p	_	
88-219	17372-17373	=	_	
88-220	17374-17379	0.013	_	
88-221	17383-17392	Precuneus	_	
88-222	17393-17394	(	_	
88-223	17394-17396	31	_	
88-224	17396-17397	)	_	
88-225	17398-17400	24	_	
88-226	17401-17402	-	_	
88-227	17402-17404	70	_	
88-228	17405-17407	20	_	
88-229	17411-17420	Posterior	_	
88-230	17421-17430	cingulate	_	
88-231	17431-17437	cortex	_	
88-232	17438-17439	(	_	
88-233	17439-17441	31	_	
88-234	17441-17442	)	_	
88-235	17443-17445	21	_	
88-236	17446-17447	-	_	
88-237	17447-17449	61	_	
88-238	17450-17452	14	_	
88-239	17456-17458	BA	_	
88-240	17459-17467	Broadman	_	
88-241	17468-17472	area	_	
88-242	17473-17474	*	_	
88-243	17474-17475	*	_	
88-244	17475-17486	significant	_	
88-245	17487-17489	at	_	
88-246	17490-17493	FDR	_	
88-247	17494-17495	<	_	
88-248	17496-17500	0.05	_	
88-249	17501-17504	The	_	
88-250	17505-17512	results	_	
88-251	17513-17515	of	_	
88-252	17516-17519	the	_	
88-253	17520-17527	symptom	_	
88-254	17528-17535	capture	_	
88-255	17536-17544	analysis	_	
88-256	17545-17548	are	_	
88-257	17549-17558	presented	_	
88-258	17559-17561	in	_	
88-259	17562-17567	Table	_	
88-260	17568-17569	2	_	
88-261	17569-17570	.	_	

#Text=Twelve of the 18 patients with AVH reported hearing voices during the symptom capture scan.
89-1	17571-17577	Twelve	_	
89-2	17578-17580	of	_	
89-3	17581-17584	the	_	
89-4	17585-17587	18	_	
89-5	17588-17596	patients	_	
89-6	17597-17601	with	_	
89-7	17602-17605	AVH	_	
89-8	17606-17614	reported	_	
89-9	17615-17622	hearing	_	
89-10	17623-17629	voices	_	
89-11	17630-17636	during	_	
89-12	17637-17640	the	_	
89-13	17641-17648	symptom	_	
89-14	17649-17656	capture	_	
89-15	17657-17661	scan	_	
89-16	17661-17662	.	_	

#Text=The number of AVHs experienced by each participant during the scan time ranged from 1-17 with a mean number of 6.22 (SD 6.00) and median of 3 (IQR 10.00).
90-1	17663-17666	The	_	
90-2	17667-17673	number	_	
90-3	17674-17676	of	_	
90-4	17677-17681	AVHs	_	
90-5	17682-17693	experienced	_	
90-6	17694-17696	by	_	
90-7	17697-17701	each	_	
90-8	17702-17713	participant	_	
90-9	17714-17720	during	_	
90-10	17721-17724	the	_	
90-11	17725-17729	scan	_	
90-12	17730-17734	time	_	
90-13	17735-17741	ranged	_	
90-14	17742-17746	from	_	
90-15	17747-17748	1	_	
90-16	17748-17749	-	_	
90-17	17749-17751	17	_	
90-18	17752-17756	with	_	
90-19	17757-17758	a	_	
90-20	17759-17763	mean	_	
90-21	17764-17770	number	_	
90-22	17771-17773	of	_	
90-23	17774-17778	6.22	_	
90-24	17779-17780	(	_	
90-25	17780-17782	SD	_	
90-26	17783-17787	6.00	_	
90-27	17787-17788	)	_	
90-28	17789-17792	and	_	
90-29	17793-17799	median	_	
90-30	17800-17802	of	_	
90-31	17803-17804	3	_	
90-32	17805-17806	(	_	
90-33	17806-17809	IQR	_	
90-34	17810-17815	10.00	_	
90-35	17815-17816	)	_	
90-36	17816-17817	.	_	

#Text=Individual AVH duration ranged from 4.17–154.93 s with a median of 9.06 s (IQR 11.65).
91-1	17818-17828	Individual	_	
91-2	17829-17832	AVH	_	
91-3	17833-17841	duration	_	
91-4	17842-17848	ranged	_	
91-5	17849-17853	from	_	
91-6	17854-17858	4.17	_	
91-7	17858-17859	–	_	
91-8	17859-17865	154.93	_	
91-9	17866-17867	s	_	
91-10	17868-17872	with	_	
91-11	17873-17874	a	_	
91-12	17875-17881	median	_	
91-13	17882-17884	of	_	
91-14	17885-17889	9.06	_	
91-15	17890-17891	s	_	
91-16	17892-17893	(	_	
91-17	17893-17896	IQR	_	
91-18	17897-17902	11.65	_	
91-19	17902-17903	)	_	
91-20	17903-17904	.	_	

#Text=Individual participants’ cumulative duration of AVHs ranged from 4.17–240.83 s with a median of 127.83 s (IQR 121.98).
92-1	17905-17915	Individual	_	
92-2	17916-17928	participants	_	
92-3	17928-17929	’	_	
92-4	17930-17940	cumulative	_	
92-5	17941-17949	duration	_	
92-6	17950-17952	of	_	
92-7	17953-17957	AVHs	_	
92-8	17958-17964	ranged	_	
92-9	17965-17969	from	_	
92-10	17970-17974	4.17	_	
92-11	17974-17975	–	_	
92-12	17975-17981	240.83	_	
92-13	17982-17983	s	_	
92-14	17984-17988	with	_	
92-15	17989-17990	a	_	
92-16	17991-17997	median	_	
92-17	17998-18000	of	_	
92-18	18001-18007	127.83	_	
92-19	18008-18009	s	_	
92-20	18010-18011	(	_	
92-21	18011-18014	IQR	_	
92-22	18015-18021	121.98	_	
92-23	18021-18022	)	_	
92-24	18022-18023	.	_	

#Text=Nine of the 12 patients’ images were used for analysis as 3 patients only had AVH which lasted less than 4 s, thus as the delay in BOLD response is around 8 s, their AVH did not outlast the BOLD response.
93-1	18024-18028	Nine	_	
93-2	18029-18031	of	_	
93-3	18032-18035	the	_	
93-4	18036-18038	12	_	
93-5	18039-18047	patients	_	
93-6	18047-18048	’	_	
93-7	18049-18055	images	_	
93-8	18056-18060	were	_	
93-9	18061-18065	used	_	
93-10	18066-18069	for	_	
93-11	18070-18078	analysis	_	
93-12	18079-18081	as	_	
93-13	18082-18083	3	_	
93-14	18084-18092	patients	_	
93-15	18093-18097	only	_	
93-16	18098-18101	had	_	
93-17	18102-18105	AVH	_	
93-18	18106-18111	which	_	
93-19	18112-18118	lasted	_	
93-20	18119-18123	less	_	
93-21	18124-18128	than	_	
93-22	18129-18130	4	_	
93-23	18131-18132	s	_	
93-24	18132-18133	,	_	
93-25	18134-18138	thus	_	
93-26	18139-18141	as	_	
93-27	18142-18145	the	_	
93-28	18146-18151	delay	_	
93-29	18152-18154	in	_	
93-30	18155-18159	BOLD	_	
93-31	18160-18168	response	_	
93-32	18169-18171	is	_	
93-33	18172-18178	around	_	
93-34	18179-18180	8	_	
93-35	18181-18182	s	_	
93-36	18182-18183	,	_	
93-37	18184-18189	their	_	
93-38	18190-18193	AVH	_	
93-39	18194-18197	did	_	
93-40	18198-18201	not	_	
93-41	18202-18209	outlast	_	
93-42	18210-18213	the	_	
93-43	18214-18218	BOLD	_	
93-44	18219-18227	response	_	
93-45	18227-18228	.	_	

#Text=The brain regions activated during AVH compared to rest included bilateral auditory processing areas (superior temporal cortex), bilateral insula, posterior regions of DMN (precuneus and posterior cingulate cortex) and lingual/ parahippocampal complex (Table 2).
94-1	18229-18232	The	_	
94-2	18233-18238	brain	_	
94-3	18239-18246	regions	_	
94-4	18247-18256	activated	_	
94-5	18257-18263	during	_	
94-6	18264-18267	AVH	_	
94-7	18268-18276	compared	_	
94-8	18277-18279	to	_	
94-9	18280-18284	rest	_	
94-10	18285-18293	included	_	
94-11	18294-18303	bilateral	_	
94-12	18304-18312	auditory	_	
94-13	18313-18323	processing	_	
94-14	18324-18329	areas	_	
94-15	18330-18331	(	_	
94-16	18331-18339	superior	_	
94-17	18340-18348	temporal	_	
94-18	18349-18355	cortex	_	
94-19	18355-18356	)	_	
94-20	18356-18357	,	_	
94-21	18358-18367	bilateral	_	
94-22	18368-18374	insula	_	
94-23	18374-18375	,	_	
94-24	18376-18385	posterior	_	
94-25	18386-18393	regions	_	
94-26	18394-18396	of	_	
94-27	18397-18400	DMN	_	
94-28	18401-18402	(	_	
94-29	18402-18411	precuneus	_	
94-30	18412-18415	and	_	
94-31	18416-18425	posterior	_	
94-32	18426-18435	cingulate	_	
94-33	18436-18442	cortex	_	
94-34	18442-18443	)	_	
94-35	18444-18447	and	_	
94-36	18448-18455	lingual	_	
94-37	18455-18456	/	_	
94-38	18457-18472	parahippocampal	_	
94-39	18473-18480	complex	_	
94-40	18481-18482	(	_	
94-41	18482-18487	Table	_	
94-42	18488-18489	2	_	
94-43	18489-18490	)	_	
94-44	18490-18491	.	_	

#Text=Seed-based FC analysis
#Text=The areas of activations from the symptom capture study formed the 15 ROI seeds (see Table 2) for the FC analysis.
95-1	18492-18502	Seed-based	_	
95-2	18503-18505	FC	_	
95-3	18506-18514	analysis	_	
95-4	18515-18518	The	_	
95-5	18519-18524	areas	_	
95-6	18525-18527	of	_	
95-7	18528-18539	activations	_	
95-8	18540-18544	from	_	
95-9	18545-18548	the	_	
95-10	18549-18556	symptom	_	
95-11	18557-18564	capture	_	
95-12	18565-18570	study	_	
95-13	18571-18577	formed	_	
95-14	18578-18581	the	_	
95-15	18582-18584	15	_	
95-16	18585-18588	ROI	_	
95-17	18589-18594	seeds	_	
95-18	18595-18596	(	_	
95-19	18596-18599	see	_	
95-20	18600-18605	Table	_	
95-21	18606-18607	2	_	
95-22	18607-18608	)	_	
95-23	18609-18612	for	_	
95-24	18613-18616	the	_	
95-25	18617-18619	FC	_	
95-26	18620-18628	analysis	_	
95-27	18628-18629	.	_	

#Text=Four subjects had excessive head motion (translation >2.0 mm and rotation >2°) at pre-processing and were removed from the sb-FC analysis.
96-1	18630-18634	Four	_	
96-2	18635-18643	subjects	_	
96-3	18644-18647	had	_	
96-4	18648-18657	excessive	_	
96-5	18658-18662	head	_	
96-6	18663-18669	motion	_	
96-7	18670-18671	(	_	
96-8	18671-18682	translation	_	
96-9	18683-18684	>	_	
96-10	18684-18687	2.0	_	
96-11	18688-18690	mm	_	
96-12	18691-18694	and	_	
96-13	18695-18703	rotation	_	
96-14	18704-18705	>	_	
96-15	18705-18706	2	_	
96-16	18706-18707	°	_	
96-17	18707-18708	)	_	
96-18	18709-18711	at	_	
96-19	18712-18726	pre-processing	_	
96-20	18727-18730	and	_	
96-21	18731-18735	were	_	
96-22	18736-18743	removed	_	
96-23	18744-18748	from	_	
96-24	18749-18752	the	_	
96-25	18753-18758	sb-FC	_	
96-26	18759-18767	analysis	_	
96-27	18767-18768	.	_	

#Text=Differential functional connectivity (FC) of Insula and Claustrum between patients with AVH (n = 14) and Healthy controls (n = 18)
#Text=Seed region\t\tBrain region (BA)\tMNI coordinates\tCluster size (mm3)\tTmax\tp corr valuea\t \tX\tY\tZ\t \tL Insula\tAVH > HC\tR Posterior cerebellum\t30\t−75\t−45\t406\t5.94\t<0.001\t \tR Posterior cerebellum\t42\t−78\t−33\t \tR Angular gyrus (39)\t57\t−66\t30\t125\t5.06\t0.026\t \tR Angular gyrus (39)\t60\t−57\t30\t \tL Posterior cerebellum\t−21\t−75\t−48\t210\t4.76\t0.003\t \tL Claustrum\tAVH > HC\tL Posterior cerebellum\t−15\t−84\t−42\t121\t4.94\t0.012\t \tL Posterior cerebellum\t−39\t−69\t−39\t \tL Posterior cerebellum\t−48\t−63\t−48\t \tR Postcentral gyrus (5)\t6\t−51\t75\t134\t4.72\t0.007\t \tL Claustrum\tHC > AVH\tL Insula (13)\t−39\t−3\t−6\t101\t4.42\t0.024\t \t
#Text=BA Broadman area, L left, R right
#Text=a Family-wise error (FWE) corrected
#Text=Whole-brain voxel-based comparisons of the Insula/Claustrum functional connectivity in schizophrenia patients with auditory verbal hallucinations (AVH, n = 14) and matched healthy volunteers (HC, n = 18).
97-1	18769-18781	Differential	_	
97-2	18782-18792	functional	_	
97-3	18793-18805	connectivity	_	
97-4	18806-18807	(	_	
97-5	18807-18809	FC	_	
97-6	18809-18810	)	_	
97-7	18811-18813	of	_	
97-8	18814-18820	Insula	_	
97-9	18821-18824	and	_	
97-10	18825-18834	Claustrum	_	
97-11	18835-18842	between	_	
97-12	18843-18851	patients	_	
97-13	18852-18856	with	_	
97-14	18857-18860	AVH	_	
97-15	18861-18862	(	_	
97-16	18862-18863	n	_	
97-17	18864-18865	=	_	
97-18	18866-18868	14	_	
97-19	18868-18869	)	_	
97-20	18870-18873	and	_	
97-21	18874-18881	Healthy	_	
97-22	18882-18890	controls	_	
97-23	18891-18892	(	_	
97-24	18892-18893	n	_	
97-25	18894-18895	=	_	
97-26	18896-18898	18	_	
97-27	18898-18899	)	_	
97-28	18900-18904	Seed	_	
97-29	18905-18911	region	_	
97-30	18913-18918	Brain	_	
97-31	18919-18925	region	_	
97-32	18926-18927	(	_	
97-33	18927-18929	BA	_	
97-34	18929-18930	)	_	
97-35	18931-18934	MNI	_	
97-36	18935-18946	coordinates	_	
97-37	18947-18954	Cluster	_	
97-38	18955-18959	size	_	
97-39	18960-18961	(	_	
97-40	18961-18964	mm3	_	
97-41	18964-18965	)	_	
97-42	18966-18970	Tmax	_	
97-43	18971-18972	p	_	
97-44	18973-18977	corr	_	
97-45	18978-18984	valuea	_	
97-46	18987-18988	X	_	
97-47	18989-18990	Y	_	
97-48	18991-18992	Z	_	
97-49	18995-18996	L	_	
97-50	18997-19003	Insula	_	
97-51	19004-19007	AVH	_	
97-52	19008-19009	>	_	
97-53	19010-19012	HC	_	
97-54	19013-19014	R	_	
97-55	19015-19024	Posterior	_	
97-56	19025-19035	cerebellum	_	
97-57	19036-19038	30	_	
97-58	19039-19040	−	_	
97-59	19040-19042	75	_	
97-60	19043-19044	−	_	
97-61	19044-19046	45	_	
97-62	19047-19050	406	_	
97-63	19051-19055	5.94	_	
97-64	19056-19057	<	_	
97-65	19057-19062	0.001	_	
97-66	19065-19066	R	_	
97-67	19067-19076	Posterior	_	
97-68	19077-19087	cerebellum	_	
97-69	19088-19090	42	_	
97-70	19091-19092	−	_	
97-71	19092-19094	78	_	
97-72	19095-19096	−	_	
97-73	19096-19098	33	_	
97-74	19101-19102	R	_	
97-75	19103-19110	Angular	_	
97-76	19111-19116	gyrus	_	
97-77	19117-19118	(	_	
97-78	19118-19120	39	_	
97-79	19120-19121	)	_	
97-80	19122-19124	57	_	
97-81	19125-19126	−	_	
97-82	19126-19128	66	_	
97-83	19129-19131	30	_	
97-84	19132-19135	125	_	
97-85	19136-19140	5.06	_	
97-86	19141-19146	0.026	_	
97-87	19149-19150	R	_	
97-88	19151-19158	Angular	_	
97-89	19159-19164	gyrus	_	
97-90	19165-19166	(	_	
97-91	19166-19168	39	_	
97-92	19168-19169	)	_	
97-93	19170-19172	60	_	
97-94	19173-19174	−	_	
97-95	19174-19176	57	_	
97-96	19177-19179	30	_	
97-97	19182-19183	L	_	
97-98	19184-19193	Posterior	_	
97-99	19194-19204	cerebellum	_	
97-100	19205-19206	−	_	
97-101	19206-19208	21	_	
97-102	19209-19210	−	_	
97-103	19210-19212	75	_	
97-104	19213-19214	−	_	
97-105	19214-19216	48	_	
97-106	19217-19220	210	_	
97-107	19221-19225	4.76	_	
97-108	19226-19231	0.003	_	
97-109	19234-19235	L	_	
97-110	19236-19245	Claustrum	_	
97-111	19246-19249	AVH	_	
97-112	19250-19251	>	_	
97-113	19252-19254	HC	_	
97-114	19255-19256	L	_	
97-115	19257-19266	Posterior	_	
97-116	19267-19277	cerebellum	_	
97-117	19278-19279	−	_	
97-118	19279-19281	15	_	
97-119	19282-19283	−	_	
97-120	19283-19285	84	_	
97-121	19286-19287	−	_	
97-122	19287-19289	42	_	
97-123	19290-19293	121	_	
97-124	19294-19298	4.94	_	
97-125	19299-19304	0.012	_	
97-126	19307-19308	L	_	
97-127	19309-19318	Posterior	_	
97-128	19319-19329	cerebellum	_	
97-129	19330-19331	−	_	
97-130	19331-19333	39	_	
97-131	19334-19335	−	_	
97-132	19335-19337	69	_	
97-133	19338-19339	−	_	
97-134	19339-19341	39	_	
97-135	19344-19345	L	_	
97-136	19346-19355	Posterior	_	
97-137	19356-19366	cerebellum	_	
97-138	19367-19368	−	_	
97-139	19368-19370	48	_	
97-140	19371-19372	−	_	
97-141	19372-19374	63	_	
97-142	19375-19376	−	_	
97-143	19376-19378	48	_	
97-144	19381-19382	R	_	
97-145	19383-19394	Postcentral	_	
97-146	19395-19400	gyrus	_	
97-147	19401-19402	(	_	
97-148	19402-19403	5	_	
97-149	19403-19404	)	_	
97-150	19405-19406	6	_	
97-151	19407-19408	−	_	
97-152	19408-19410	51	_	
97-153	19411-19413	75	_	
97-154	19414-19417	134	_	
97-155	19418-19422	4.72	_	
97-156	19423-19428	0.007	_	
97-157	19431-19432	L	_	
97-158	19433-19442	Claustrum	_	
97-159	19443-19445	HC	_	
97-160	19446-19447	>	_	
97-161	19448-19451	AVH	_	
97-162	19452-19453	L	_	
97-163	19454-19460	Insula	_	
97-164	19461-19462	(	_	
97-165	19462-19464	13	_	
97-166	19464-19465	)	_	
97-167	19466-19467	−	_	
97-168	19467-19469	39	_	
97-169	19470-19471	−	_	
97-170	19471-19472	3	_	
97-171	19473-19474	−	_	
97-172	19474-19475	6	_	
97-173	19476-19479	101	_	
97-174	19480-19484	4.42	_	
97-175	19485-19490	0.024	_	
97-176	19494-19496	BA	_	
97-177	19497-19505	Broadman	_	
97-178	19506-19510	area	_	
97-179	19510-19511	,	_	
97-180	19512-19513	L	_	
97-181	19514-19518	left	_	
97-182	19518-19519	,	_	
97-183	19520-19521	R	_	
97-184	19522-19527	right	_	
97-185	19528-19529	a	_	
97-186	19530-19541	Family-wise	_	
97-187	19542-19547	error	_	
97-188	19548-19549	(	_	
97-189	19549-19552	FWE	_	
97-190	19552-19553	)	_	
97-191	19554-19563	corrected	_	
97-192	19564-19575	Whole-brain	_	
97-193	19576-19587	voxel-based	_	
97-194	19588-19599	comparisons	_	
97-195	19600-19602	of	_	
97-196	19603-19606	the	_	
97-197	19607-19613	Insula	_	
97-198	19613-19614	/	_	
97-199	19614-19623	Claustrum	_	
97-200	19624-19634	functional	_	
97-201	19635-19647	connectivity	_	
97-202	19648-19650	in	_	
97-203	19651-19664	schizophrenia	_	
97-204	19665-19673	patients	_	
97-205	19674-19678	with	_	
97-206	19679-19687	auditory	_	
97-207	19688-19694	verbal	_	
97-208	19695-19709	hallucinations	_	
97-209	19710-19711	(	_	
97-210	19711-19714	AVH	_	
97-211	19714-19715	,	_	
97-212	19716-19717	n	_	
97-213	19718-19719	=	_	
97-214	19720-19722	14	_	
97-215	19722-19723	)	_	
97-216	19724-19727	and	_	
97-217	19728-19735	matched	_	
97-218	19736-19743	healthy	_	
97-219	19744-19754	volunteers	_	
97-220	19755-19756	(	_	
97-221	19756-19758	HC	_	
97-222	19758-19759	,	_	
97-223	19760-19761	n	_	
97-224	19762-19763	=	_	
97-225	19764-19766	18	_	
97-226	19766-19767	)	_	
97-227	19767-19768	.	_	

#Text=Contrast maps are overlaid on a structural MRI brain (n = 32; Pcorr 0.05).
98-1	19769-19777	Contrast	_	
98-2	19778-19782	maps	_	
98-3	19783-19786	are	_	
98-4	19787-19795	overlaid	_	
98-5	19796-19798	on	_	
98-6	19799-19800	a	_	
98-7	19801-19811	structural	_	
98-8	19812-19815	MRI	_	
98-9	19816-19821	brain	_	
98-10	19822-19823	(	_	
98-11	19823-19824	n	_	
98-12	19825-19826	=	_	
98-13	19827-19829	32	_	
98-14	19829-19830	;	_	
98-15	19831-19836	Pcorr	_	
98-16	19837-19841	0.05	_	
98-17	19841-19842	)	_	
98-18	19842-19843	.	_	

#Text=Increased sb-FC was detected in patients between left Insula and bilateral posterior cerebellum and angular gyrus (a).
99-1	19844-19853	Increased	_	
99-2	19854-19859	sb-FC	_	
99-3	19860-19863	was	_	
99-4	19864-19872	detected	_	
99-5	19873-19875	in	_	
99-6	19876-19884	patients	_	
99-7	19885-19892	between	_	
99-8	19893-19897	left	_	
99-9	19898-19904	Insula	_	
99-10	19905-19908	and	_	
99-11	19909-19918	bilateral	_	
99-12	19919-19928	posterior	_	
99-13	19929-19939	cerebellum	_	
99-14	19940-19943	and	_	
99-15	19944-19951	angular	_	
99-16	19952-19957	gyrus	_	
99-17	19958-19959	(	_	
99-18	19959-19960	a	_	
99-19	19960-19961	)	_	
99-20	19961-19962	.	_	

#Text=Increased sb-FC was detected in patients between left Claustrum and left posterior cerebellum and right post central gyrus (b).
100-1	19963-19972	Increased	_	
100-2	19973-19978	sb-FC	_	
100-3	19979-19982	was	_	
100-4	19983-19991	detected	_	
100-5	19992-19994	in	_	
100-6	19995-20003	patients	_	
100-7	20004-20011	between	_	
100-8	20012-20016	left	_	
100-9	20017-20026	Claustrum	_	
100-10	20027-20030	and	_	
100-11	20031-20035	left	_	
100-12	20036-20045	posterior	_	
100-13	20046-20056	cerebellum	_	
100-14	20057-20060	and	_	
100-15	20061-20066	right	_	
100-16	20067-20071	post	_	
100-17	20072-20079	central	_	
100-18	20080-20085	gyrus	_	
100-19	20086-20087	(	_	
100-20	20087-20088	b	_	
100-21	20088-20089	)	_	
100-22	20089-20090	.	_	

#Text=A decreased sb-FC was measured in patients between left claustrum and left insula (c).
101-1	20091-20092	A	_	
101-2	20093-20102	decreased	_	
101-3	20103-20108	sb-FC	_	
101-4	20109-20112	was	_	
101-5	20113-20121	measured	_	
101-6	20122-20124	in	_	
101-7	20125-20133	patients	_	
101-8	20134-20141	between	_	
101-9	20142-20146	left	_	
101-10	20147-20156	claustrum	_	
101-11	20157-20160	and	_	
101-12	20161-20165	left	_	
101-13	20166-20172	insula	_	
101-14	20173-20174	(	_	
101-15	20174-20175	c	_	
101-16	20175-20176	)	_	
101-17	20176-20177	.	_	

#Text=Colour bars show a scale of t values
#Text=There was a statistically significant difference between patients with AVH and HC in FC on 2 of the 15 seed regions.
102-1	20178-20184	Colour	_	
102-2	20185-20189	bars	_	
102-3	20190-20194	show	_	
102-4	20195-20196	a	_	
102-5	20197-20202	scale	_	
102-6	20203-20205	of	_	
102-7	20206-20207	t	_	
102-8	20208-20214	values	_	
102-9	20215-20220	There	_	
102-10	20221-20224	was	_	
102-11	20225-20226	a	_	
102-12	20227-20240	statistically	_	
102-13	20241-20252	significant	_	
102-14	20253-20263	difference	_	
102-15	20264-20271	between	_	
102-16	20272-20280	patients	_	
102-17	20281-20285	with	_	
102-18	20286-20289	AVH	_	
102-19	20290-20293	and	_	
102-20	20294-20296	HC	_	
102-21	20297-20299	in	_	
102-22	20300-20302	FC	_	
102-23	20303-20305	on	_	
102-24	20306-20307	2	_	
102-25	20308-20310	of	_	
102-26	20311-20314	the	_	
102-27	20315-20317	15	_	
102-28	20318-20322	seed	_	
102-29	20323-20330	regions	_	
102-30	20330-20331	.	_	

#Text=The left insula and left claustrum seeds showed significant differences between patients with AVH and HC (Table 3 and Fig. 1).
103-1	20332-20335	The	_	
103-2	20336-20340	left	_	
103-3	20341-20347	insula	_	
103-4	20348-20351	and	_	
103-5	20352-20356	left	_	
103-6	20357-20366	claustrum	_	
103-7	20367-20372	seeds	_	
103-8	20373-20379	showed	_	
103-9	20380-20391	significant	_	
103-10	20392-20403	differences	_	
103-11	20404-20411	between	_	
103-12	20412-20420	patients	_	
103-13	20421-20425	with	_	
103-14	20426-20429	AVH	_	
103-15	20430-20433	and	_	
103-16	20434-20436	HC	_	
103-17	20437-20438	(	_	
103-18	20438-20443	Table	_	
103-19	20444-20445	3	_	
103-20	20446-20449	and	_	
103-21	20450-20453	Fig	_	
103-22	20453-20454	.	_	
103-23	20455-20456	1	_	
103-24	20456-20457	)	_	
103-25	20457-20458	.	_	

#Text=Patients showed increased FC between left insula and bilateral cerebellum, and angular gyrus; and increased FC between left claustrum and left cerebellum and postcentral gyrus.
104-1	20459-20467	Patients	_	
104-2	20468-20474	showed	_	
104-3	20475-20484	increased	_	
104-4	20485-20487	FC	_	
104-5	20488-20495	between	_	
104-6	20496-20500	left	_	
104-7	20501-20507	insula	_	
104-8	20508-20511	and	_	
104-9	20512-20521	bilateral	_	
104-10	20522-20532	cerebellum	_	
104-11	20532-20533	,	_	
104-12	20534-20537	and	_	
104-13	20538-20545	angular	_	
104-14	20546-20551	gyrus	_	
104-15	20551-20552	;	_	
104-16	20553-20556	and	_	
104-17	20557-20566	increased	_	
104-18	20567-20569	FC	_	
104-19	20570-20577	between	_	
104-20	20578-20582	left	_	
104-21	20583-20592	claustrum	_	
104-22	20593-20596	and	_	
104-23	20597-20601	left	_	
104-24	20602-20612	cerebellum	_	
104-25	20613-20616	and	_	
104-26	20617-20628	postcentral	_	
104-27	20629-20634	gyrus	_	
104-28	20634-20635	.	_	

#Text=There was reduced FC in FEP patients with AVH between left claustrum and left insula compared to HC.
105-1	20636-20641	There	_	
105-2	20642-20645	was	_	
105-3	20646-20653	reduced	_	
105-4	20654-20656	FC	_	
105-5	20657-20659	in	_	
105-6	20660-20663	FEP	_	
105-7	20664-20672	patients	_	
105-8	20673-20677	with	_	
105-9	20678-20681	AVH	_	
105-10	20682-20689	between	_	
105-11	20690-20694	left	_	
105-12	20695-20704	claustrum	_	
105-13	20705-20708	and	_	
105-14	20709-20713	left	_	
105-15	20714-20720	insula	_	
105-16	20721-20729	compared	_	
105-17	20730-20732	to	_	
105-18	20733-20735	HC	_	
105-19	20735-20736	.	_	

#Text=The FC between left insula and left claustrum seeds for patients and HC is shown separately in supplementary information (Tables 1–4 in supplementary information).
106-1	20737-20740	The	_	
106-2	20741-20743	FC	_	
106-3	20744-20751	between	_	
106-4	20752-20756	left	_	
106-5	20757-20763	insula	_	
106-6	20764-20767	and	_	
106-7	20768-20772	left	_	
106-8	20773-20782	claustrum	_	
106-9	20783-20788	seeds	_	
106-10	20789-20792	for	_	
106-11	20793-20801	patients	_	
106-12	20802-20805	and	_	
106-13	20806-20808	HC	_	
106-14	20809-20811	is	_	
106-15	20812-20817	shown	_	
106-16	20818-20828	separately	_	
106-17	20829-20831	in	_	
106-18	20832-20845	supplementary	_	
106-19	20846-20857	information	_	
106-20	20858-20859	(	_	
106-21	20859-20865	Tables	_	
106-22	20866-20867	1	_	
106-23	20867-20868	–	_	
106-24	20868-20869	4	_	
106-25	20870-20872	in	_	
106-26	20873-20886	supplementary	_	
106-27	20887-20898	information	_	
106-28	20898-20899	)	_	
106-29	20899-20900	.	_	

#Text=There were no significant correlations between DUP, dose of antipsychotic medications, and severity of hallucinations and the mean coefficients of clusters that were significantly different between FEP patients and HC.
107-1	20901-20906	There	_	
107-2	20907-20911	were	_	
107-3	20912-20914	no	_	
107-4	20915-20926	significant	_	
107-5	20927-20939	correlations	_	
107-6	20940-20947	between	_	
107-7	20948-20951	DUP	_	
107-8	20951-20952	,	_	
107-9	20953-20957	dose	_	
107-10	20958-20960	of	_	
107-11	20961-20974	antipsychotic	_	
107-12	20975-20986	medications	_	
107-13	20986-20987	,	_	
107-14	20988-20991	and	_	
107-15	20992-21000	severity	_	
107-16	21001-21003	of	_	
107-17	21004-21018	hallucinations	_	
107-18	21019-21022	and	_	
107-19	21023-21026	the	_	
107-20	21027-21031	mean	_	
107-21	21032-21044	coefficients	_	
107-22	21045-21047	of	_	
107-23	21048-21056	clusters	_	
107-24	21057-21061	that	_	
107-25	21062-21066	were	_	
107-26	21067-21080	significantly	_	
107-27	21081-21090	different	_	
107-28	21091-21098	between	_	
107-29	21099-21102	FEP	_	
107-30	21103-21111	patients	_	
107-31	21112-21115	and	_	
107-32	21116-21118	HC	_	
107-33	21118-21119	.	_	

#Text=Discussion
#Text=This is the first study of FC in FEP patients with frequent AVH and matched controls, using seed regions obtained during symptom capture in the same group.
108-1	21120-21130	Discussion	_	
108-2	21131-21135	This	_	
108-3	21136-21138	is	_	
108-4	21139-21142	the	_	
108-5	21143-21148	first	_	
108-6	21149-21154	study	_	
108-7	21155-21157	of	_	
108-8	21158-21160	FC	_	
108-9	21161-21163	in	_	
108-10	21164-21167	FEP	_	
108-11	21168-21176	patients	_	
108-12	21177-21181	with	_	
108-13	21182-21190	frequent	_	
108-14	21191-21194	AVH	_	
108-15	21195-21198	and	_	
108-16	21199-21206	matched	_	
108-17	21207-21215	controls	_	
108-18	21215-21216	,	_	
108-19	21217-21222	using	_	
108-20	21223-21227	seed	_	
108-21	21228-21235	regions	_	
108-22	21236-21244	obtained	_	
108-23	21245-21251	during	_	
108-24	21252-21259	symptom	_	
108-25	21260-21267	capture	_	
108-26	21268-21270	in	_	
108-27	21271-21274	the	_	
108-28	21275-21279	same	_	
108-29	21280-21285	group	_	
108-30	21285-21286	.	_	

#Text=Thus, we report results with reduced confounding factors of chronicity of illness, repeated episodes, long duration of treatment and model based selection of seed regions.
109-1	21287-21291	Thus	_	
109-2	21291-21292	,	_	
109-3	21293-21295	we	_	
109-4	21296-21302	report	_	
109-5	21303-21310	results	_	
109-6	21311-21315	with	_	
109-7	21316-21323	reduced	_	
109-8	21324-21335	confounding	_	
109-9	21336-21343	factors	_	
109-10	21344-21346	of	_	
109-11	21347-21357	chronicity	_	
109-12	21358-21360	of	_	
109-13	21361-21368	illness	_	
109-14	21368-21369	,	_	
109-15	21370-21378	repeated	_	
109-16	21379-21387	episodes	_	
109-17	21387-21388	,	_	
109-18	21389-21393	long	_	
109-19	21394-21402	duration	_	
109-20	21403-21405	of	_	
109-21	21406-21415	treatment	_	
109-22	21416-21419	and	_	
109-23	21420-21425	model	_	
109-24	21426-21431	based	_	
109-25	21432-21441	selection	_	
109-26	21442-21444	of	_	
109-27	21445-21449	seed	_	
109-28	21450-21457	regions	_	
109-29	21457-21458	.	_	

#Text=The results from symptom capture showed that the bilateral superior temporal cortex, precuneus/posterior cingulate cortex, bilateral insula and parahippocampal regions were active during AVH.
110-1	21459-21462	The	_	
110-2	21463-21470	results	_	
110-3	21471-21475	from	_	
110-4	21476-21483	symptom	_	
110-5	21484-21491	capture	_	
110-6	21492-21498	showed	_	
110-7	21499-21503	that	_	
110-8	21504-21507	the	_	
110-9	21508-21517	bilateral	_	
110-10	21518-21526	superior	_	
110-11	21527-21535	temporal	_	
110-12	21536-21542	cortex	_	
110-13	21542-21543	,	_	
110-14	21544-21553	precuneus	_	
110-15	21553-21554	/	_	
110-16	21554-21563	posterior	_	
110-17	21564-21573	cingulate	_	
110-18	21574-21580	cortex	_	
110-19	21580-21581	,	_	
110-20	21582-21591	bilateral	_	
110-21	21592-21598	insula	_	
110-22	21599-21602	and	_	
110-23	21603-21618	parahippocampal	_	
110-24	21619-21626	regions	_	
110-25	21627-21631	were	_	
110-26	21632-21638	active	_	
110-27	21639-21645	during	_	
110-28	21646-21649	AVH	_	
110-29	21649-21650	.	_	

#Text=Using these areas as seed regions, we found that, compared to HC, FEP patients with frequent AVH had increased FC between left insula and bilateral cerebellum and angular gyrus; and increased FC between left claustrum and left cerebellum and postcentral gyrus.
111-1	21651-21656	Using	_	
111-2	21657-21662	these	_	
111-3	21663-21668	areas	_	
111-4	21669-21671	as	_	
111-5	21672-21676	seed	_	
111-6	21677-21684	regions	_	
111-7	21684-21685	,	_	
111-8	21686-21688	we	_	
111-9	21689-21694	found	_	
111-10	21695-21699	that	_	
111-11	21699-21700	,	_	
111-12	21701-21709	compared	_	
111-13	21710-21712	to	_	
111-14	21713-21715	HC	_	
111-15	21715-21716	,	_	
111-16	21717-21720	FEP	_	
111-17	21721-21729	patients	_	
111-18	21730-21734	with	_	
111-19	21735-21743	frequent	_	
111-20	21744-21747	AVH	_	
111-21	21748-21751	had	_	
111-22	21752-21761	increased	_	
111-23	21762-21764	FC	_	
111-24	21765-21772	between	_	
111-25	21773-21777	left	_	
111-26	21778-21784	insula	_	
111-27	21785-21788	and	_	
111-28	21789-21798	bilateral	_	
111-29	21799-21809	cerebellum	_	
111-30	21810-21813	and	_	
111-31	21814-21821	angular	_	
111-32	21822-21827	gyrus	_	
111-33	21827-21828	;	_	
111-34	21829-21832	and	_	
111-35	21833-21842	increased	_	
111-36	21843-21845	FC	_	
111-37	21846-21853	between	_	
111-38	21854-21858	left	_	
111-39	21859-21868	claustrum	_	
111-40	21869-21872	and	_	
111-41	21873-21877	left	_	
111-42	21878-21888	cerebellum	_	
111-43	21889-21892	and	_	
111-44	21893-21904	postcentral	_	
111-45	21905-21910	gyrus	_	
111-46	21910-21911	.	_	

#Text=We also found reduced FC between left claustrum and left insula in FEP with AVH patients compared to HC.
112-1	21912-21914	We	_	
112-2	21915-21919	also	_	
112-3	21920-21925	found	_	
112-4	21926-21933	reduced	_	
112-5	21934-21936	FC	_	
112-6	21937-21944	between	_	
112-7	21945-21949	left	_	
112-8	21950-21959	claustrum	_	
112-9	21960-21963	and	_	
112-10	21964-21968	left	_	
112-11	21969-21975	insula	_	
112-12	21976-21978	in	_	
112-13	21979-21982	FEP	_	
112-14	21983-21987	with	_	
112-15	21988-21991	AVH	_	
112-16	21992-22000	patients	_	
112-17	22001-22009	compared	_	
112-18	22010-22012	to	_	
112-19	22013-22015	HC	_	
112-20	22015-22016	.	_	

#Text=Contrary to our hypotheses, we found no significant sb-FC results from seeds placed in auditory processing areas [bilateral superior temporal gyrus (STG)], areas involved in memory (parahippocampal gyrus and lingual gyrus), or posterior DMN (precuneus and posterior cingulate cortex).
113-1	22017-22025	Contrary	_	
113-2	22026-22028	to	_	
113-3	22029-22032	our	_	
113-4	22033-22043	hypotheses	_	
113-5	22043-22044	,	_	
113-6	22045-22047	we	_	
113-7	22048-22053	found	_	
113-8	22054-22056	no	_	
113-9	22057-22068	significant	_	
113-10	22069-22074	sb-FC	_	
113-11	22075-22082	results	_	
113-12	22083-22087	from	_	
113-13	22088-22093	seeds	_	
113-14	22094-22100	placed	_	
113-15	22101-22103	in	_	
113-16	22104-22112	auditory	_	
113-17	22113-22123	processing	_	
113-18	22124-22129	areas	_	
113-19	22130-22131	[	_	
113-20	22131-22140	bilateral	_	
113-21	22141-22149	superior	_	
113-22	22150-22158	temporal	_	
113-23	22159-22164	gyrus	_	
113-24	22165-22166	(	_	
113-25	22166-22169	STG	_	
113-26	22169-22170	)	_	
113-27	22170-22171	]	_	
113-28	22171-22172	,	_	
113-29	22173-22178	areas	_	
113-30	22179-22187	involved	_	
113-31	22188-22190	in	_	
113-32	22191-22197	memory	_	
113-33	22198-22199	(	_	
113-34	22199-22214	parahippocampal	_	
113-35	22215-22220	gyrus	_	
113-36	22221-22224	and	_	
113-37	22225-22232	lingual	_	
113-38	22233-22238	gyrus	_	
113-39	22238-22239	)	_	
113-40	22239-22240	,	_	
113-41	22241-22243	or	_	
113-42	22244-22253	posterior	_	
113-43	22254-22257	DMN	_	
113-44	22258-22259	(	_	
113-45	22259-22268	precuneus	_	
113-46	22269-22272	and	_	
113-47	22273-22282	posterior	_	
113-48	22283-22292	cingulate	_	
113-49	22293-22299	cortex	_	
113-50	22299-22300	)	_	
113-51	22300-22301	.	_	

#Text=Thus, our main results include increased FC between left insula (a key node of SN) and the angular gyrus, a region which has been consistently identified as a key parietal node of the DMN.
114-1	22302-22306	Thus	_	
114-2	22306-22307	,	_	
114-3	22308-22311	our	_	
114-4	22312-22316	main	_	
114-5	22317-22324	results	_	
114-6	22325-22332	include	_	
114-7	22333-22342	increased	_	
114-8	22343-22345	FC	_	
114-9	22346-22353	between	_	
114-10	22354-22358	left	_	
114-11	22359-22365	insula	_	
114-12	22366-22367	(	_	
114-13	22367-22368	a	_	
114-14	22369-22372	key	_	
114-15	22373-22377	node	_	
114-16	22378-22380	of	_	
114-17	22381-22383	SN	_	
114-18	22383-22384	)	_	
114-19	22385-22388	and	_	
114-20	22389-22392	the	_	
114-21	22393-22400	angular	_	
114-22	22401-22406	gyrus	_	
114-23	22406-22407	,	_	
114-24	22408-22409	a	_	
114-25	22410-22416	region	_	
114-26	22417-22422	which	_	
114-27	22423-22426	has	_	
114-28	22427-22431	been	_	
114-29	22432-22444	consistently	_	
114-30	22445-22455	identified	_	
114-31	22456-22458	as	_	
114-32	22459-22460	a	_	
114-33	22461-22464	key	_	
114-34	22465-22473	parietal	_	
114-35	22474-22478	node	_	
114-36	22479-22481	of	_	
114-37	22482-22485	the	_	
114-38	22486-22489	DMN	_	
114-39	22489-22490	.	_	

#Text=It is possible the pathology of AVH is primarily located in these two regions; the insula and angular gyrus.
115-1	22491-22493	It	_	
115-2	22494-22496	is	_	
115-3	22497-22505	possible	_	
115-4	22506-22509	the	_	
115-5	22510-22519	pathology	_	
115-6	22520-22522	of	_	
115-7	22523-22526	AVH	_	
115-8	22527-22529	is	_	
115-9	22530-22539	primarily	_	
115-10	22540-22547	located	_	
115-11	22548-22550	in	_	
115-12	22551-22556	these	_	
115-13	22557-22560	two	_	
115-14	22561-22568	regions	_	
115-15	22568-22569	;	_	
115-16	22570-22573	the	_	
115-17	22574-22580	insula	_	
115-18	22581-22584	and	_	
115-19	22585-22592	angular	_	
115-20	22593-22598	gyrus	_	
115-21	22598-22599	.	_	

#Text=Our results of both the left insula seed shows connectivity with right insula and anterior cingulate cortex (key regions of SN).
116-1	22600-22603	Our	_	
116-2	22604-22611	results	_	
116-3	22612-22614	of	_	
116-4	22615-22619	both	_	
116-5	22620-22623	the	_	
116-6	22624-22628	left	_	
116-7	22629-22635	insula	_	
116-8	22636-22640	seed	_	
116-9	22641-22646	shows	_	
116-10	22647-22659	connectivity	_	
116-11	22660-22664	with	_	
116-12	22665-22670	right	_	
116-13	22671-22677	insula	_	
116-14	22678-22681	and	_	
116-15	22682-22690	anterior	_	
116-16	22691-22700	cingulate	_	
116-17	22701-22707	cortex	_	
116-18	22708-22709	(	_	
116-19	22709-22712	key	_	
116-20	22713-22720	regions	_	
116-21	22721-22723	of	_	
116-22	22724-22726	SN	_	
116-23	22726-22727	)	_	
116-24	22727-22728	.	_	

#Text=Together with literature from patients with chronic AVH, the suggestion may be that resting state dysconnectivity within the DMN and SN are implicated in the generation of AVH, which during the experience itself will further involve temporal and auditory networks.
117-1	22729-22737	Together	_	
117-2	22738-22742	with	_	
117-3	22743-22753	literature	_	
117-4	22754-22758	from	_	
117-5	22759-22767	patients	_	
117-6	22768-22772	with	_	
117-7	22773-22780	chronic	_	
117-8	22781-22784	AVH	_	
117-9	22784-22785	,	_	
117-10	22786-22789	the	_	
117-11	22790-22800	suggestion	_	
117-12	22801-22804	may	_	
117-13	22805-22807	be	_	
117-14	22808-22812	that	_	
117-15	22813-22820	resting	_	
117-16	22821-22826	state	_	
117-17	22827-22842	dysconnectivity	_	
117-18	22843-22849	within	_	
117-19	22850-22853	the	_	
117-20	22854-22857	DMN	_	
117-21	22858-22861	and	_	
117-22	22862-22864	SN	_	
117-23	22865-22868	are	_	
117-24	22869-22879	implicated	_	
117-25	22880-22882	in	_	
117-26	22883-22886	the	_	
117-27	22887-22897	generation	_	
117-28	22898-22900	of	_	
117-29	22901-22904	AVH	_	
117-30	22904-22905	,	_	
117-31	22906-22911	which	_	
117-32	22912-22918	during	_	
117-33	22919-22922	the	_	
117-34	22923-22933	experience	_	
117-35	22934-22940	itself	_	
117-36	22941-22945	will	_	
117-37	22946-22953	further	_	
117-38	22954-22961	involve	_	
117-39	22962-22970	temporal	_	
117-40	22971-22974	and	_	
117-41	22975-22983	auditory	_	
117-42	22984-22992	networks	_	
117-43	22992-22993	.	_	

#Text=Reduction in left insula volume has been observed in patients with schizophrenia and prominent hallucinations and volumes of the left insula and right STG have been negatively correlated with severity of AVH in a meta-analysis of structural studies.
118-1	22994-23003	Reduction	_	
118-2	23004-23006	in	_	
118-3	23007-23011	left	_	
118-4	23012-23018	insula	_	
118-5	23019-23025	volume	_	
118-6	23026-23029	has	_	
118-7	23030-23034	been	_	
118-8	23035-23043	observed	_	
118-9	23044-23046	in	_	
118-10	23047-23055	patients	_	
118-11	23056-23060	with	_	
118-12	23061-23074	schizophrenia	_	
118-13	23075-23078	and	_	
118-14	23079-23088	prominent	_	
118-15	23089-23103	hallucinations	_	
118-16	23104-23107	and	_	
118-17	23108-23115	volumes	_	
118-18	23116-23118	of	_	
118-19	23119-23122	the	_	
118-20	23123-23127	left	_	
118-21	23128-23134	insula	_	
118-22	23135-23138	and	_	
118-23	23139-23144	right	_	
118-24	23145-23148	STG	_	
118-25	23149-23153	have	_	
118-26	23154-23158	been	_	
118-27	23159-23169	negatively	_	
118-28	23170-23180	correlated	_	
118-29	23181-23185	with	_	
118-30	23186-23194	severity	_	
118-31	23195-23197	of	_	
118-32	23198-23201	AVH	_	
118-33	23202-23204	in	_	
118-34	23205-23206	a	_	
118-35	23207-23220	meta-analysis	_	
118-36	23221-23223	of	_	
118-37	23224-23234	structural	_	
118-38	23235-23242	studies	_	
118-39	23242-23243	.	_	

#Text=Although with a small sample and cross sectional study it is speculative to propose definitive models, our results suggest that AVH possibly begin with dysconnectivity between the DMN and SN.
119-1	23244-23252	Although	_	
119-2	23253-23257	with	_	
119-3	23258-23259	a	_	
119-4	23260-23265	small	_	
119-5	23266-23272	sample	_	
119-6	23273-23276	and	_	
119-7	23277-23282	cross	_	
119-8	23283-23292	sectional	_	
119-9	23293-23298	study	_	
119-10	23299-23301	it	_	
119-11	23302-23304	is	_	
119-12	23305-23316	speculative	_	
119-13	23317-23319	to	_	
119-14	23320-23327	propose	_	
119-15	23328-23338	definitive	_	
119-16	23339-23345	models	_	
119-17	23345-23346	,	_	
119-18	23347-23350	our	_	
119-19	23351-23358	results	_	
119-20	23359-23366	suggest	_	
119-21	23367-23371	that	_	
119-22	23372-23375	AVH	_	
119-23	23376-23384	possibly	_	
119-24	23385-23390	begin	_	
119-25	23391-23395	with	_	
119-26	23396-23411	dysconnectivity	_	
119-27	23412-23419	between	_	
119-28	23420-23423	the	_	
119-29	23424-23427	DMN	_	
119-30	23428-23431	and	_	
119-31	23432-23434	SN	_	
119-32	23434-23435	.	_	

#Text=AVH are then further developed by the incorporation of other regions resulting in a ‘heard’ experience or one associated with memory, as our symptom capture results confirm activation in the superior temporal cortex, and parahippocampal areas during AVH itself.
120-1	23436-23439	AVH	_	
120-2	23440-23443	are	_	
120-3	23444-23448	then	_	
120-4	23449-23456	further	_	
120-5	23457-23466	developed	_	
120-6	23467-23469	by	_	
120-7	23470-23473	the	_	
120-8	23474-23487	incorporation	_	
120-9	23488-23490	of	_	
120-10	23491-23496	other	_	
120-11	23497-23504	regions	_	
120-12	23505-23514	resulting	_	
120-13	23515-23517	in	_	
120-14	23518-23519	a	_	
120-15	23520-23521	‘	_	
120-16	23521-23526	heard	_	
120-17	23526-23527	’	_	
120-18	23528-23538	experience	_	
120-19	23539-23541	or	_	
120-20	23542-23545	one	_	
120-21	23546-23556	associated	_	
120-22	23557-23561	with	_	
120-23	23562-23568	memory	_	
120-24	23568-23569	,	_	
120-25	23570-23572	as	_	
120-26	23573-23576	our	_	
120-27	23577-23584	symptom	_	
120-28	23585-23592	capture	_	
120-29	23593-23600	results	_	
120-30	23601-23608	confirm	_	
120-31	23609-23619	activation	_	
120-32	23620-23622	in	_	
120-33	23623-23626	the	_	
120-34	23627-23635	superior	_	
120-35	23636-23644	temporal	_	
120-36	23645-23651	cortex	_	
120-37	23651-23652	,	_	
120-38	23653-23656	and	_	
120-39	23657-23672	parahippocampal	_	
120-40	23673-23678	areas	_	
120-41	23679-23685	during	_	
120-42	23686-23689	AVH	_	
120-43	23690-23696	itself	_	
120-44	23696-23697	.	_	

#Text=We also found increased FC in FEP with AVH between the left insula and the bilateral posterior cerebellum; and between the left claustrum and the left posterior cerebellum.
121-1	23698-23700	We	_	
121-2	23701-23705	also	_	
121-3	23706-23711	found	_	
121-4	23712-23721	increased	_	
121-5	23722-23724	FC	_	
121-6	23725-23727	in	_	
121-7	23728-23731	FEP	_	
121-8	23732-23736	with	_	
121-9	23737-23740	AVH	_	
121-10	23741-23748	between	_	
121-11	23749-23752	the	_	
121-12	23753-23757	left	_	
121-13	23758-23764	insula	_	
121-14	23765-23768	and	_	
121-15	23769-23772	the	_	
121-16	23773-23782	bilateral	_	
121-17	23783-23792	posterior	_	
121-18	23793-23803	cerebellum	_	
121-19	23803-23804	;	_	
121-20	23805-23808	and	_	
121-21	23809-23816	between	_	
121-22	23817-23820	the	_	
121-23	23821-23825	left	_	
121-24	23826-23835	claustrum	_	
121-25	23836-23839	and	_	
121-26	23840-23843	the	_	
121-27	23844-23848	left	_	
121-28	23849-23858	posterior	_	
121-29	23859-23869	cerebellum	_	
121-30	23869-23870	.	_	

#Text=Additionally, we found reduced sb-FC between the left claustrum and the left insula in FEP with AVH in comparison to HC, which has not been reported previously.
122-1	23871-23883	Additionally	_	
122-2	23883-23884	,	_	
122-3	23885-23887	we	_	
122-4	23888-23893	found	_	
122-5	23894-23901	reduced	_	
122-6	23902-23907	sb-FC	_	
122-7	23908-23915	between	_	
122-8	23916-23919	the	_	
122-9	23920-23924	left	_	
122-10	23925-23934	claustrum	_	
122-11	23935-23938	and	_	
122-12	23939-23942	the	_	
122-13	23943-23947	left	_	
122-14	23948-23954	insula	_	
122-15	23955-23957	in	_	
122-16	23958-23961	FEP	_	
122-17	23962-23966	with	_	
122-18	23967-23970	AVH	_	
122-19	23971-23973	in	_	
122-20	23974-23984	comparison	_	
122-21	23985-23987	to	_	
122-22	23988-23990	HC	_	
122-23	23990-23991	,	_	
122-24	23992-23997	which	_	
122-25	23998-24001	has	_	
122-26	24002-24005	not	_	
122-27	24006-24010	been	_	
122-28	24011-24019	reported	_	
122-29	24020-24030	previously	_	
122-30	24030-24031	.	_	

#Text=The claustrum has been reported to be activated specifically during AVH.
123-1	24032-24035	The	_	
123-2	24036-24045	claustrum	_	
123-3	24046-24049	has	_	
123-4	24050-24054	been	_	
123-5	24055-24063	reported	_	
123-6	24064-24066	to	_	
123-7	24067-24069	be	_	
123-8	24070-24079	activated	_	
123-9	24080-24092	specifically	_	
123-10	24093-24099	during	_	
123-11	24100-24103	AVH	_	
123-12	24103-24104	.	_	

#Text=The role of the claustrum includes sensory binding, modulation of selective attention, synchrony detection, and modulation and switching between intrinsic networks.
124-1	24105-24108	The	_	
124-2	24109-24113	role	_	
124-3	24114-24116	of	_	
124-4	24117-24120	the	_	
124-5	24121-24130	claustrum	_	
124-6	24131-24139	includes	_	
124-7	24140-24147	sensory	_	
124-8	24148-24155	binding	_	
124-9	24155-24156	,	_	
124-10	24157-24167	modulation	_	
124-11	24168-24170	of	_	
124-12	24171-24180	selective	_	
124-13	24181-24190	attention	_	
124-14	24190-24191	,	_	
124-15	24192-24201	synchrony	_	
124-16	24202-24211	detection	_	
124-17	24211-24212	,	_	
124-18	24213-24216	and	_	
124-19	24217-24227	modulation	_	
124-20	24228-24231	and	_	
124-21	24232-24241	switching	_	
124-22	24242-24249	between	_	
124-23	24250-24259	intrinsic	_	
124-24	24260-24268	networks	_	
124-25	24268-24269	.	_	

#Text=Reduced FC between the claustrum and the insula may indicate a reduced input of multi-sensory integrated information from claustrum to insula, which may impact on proximal salience appraisal.
125-1	24270-24277	Reduced	_	
125-2	24278-24280	FC	_	
125-3	24281-24288	between	_	
125-4	24289-24292	the	_	
125-5	24293-24302	claustrum	_	
125-6	24303-24306	and	_	
125-7	24307-24310	the	_	
125-8	24311-24317	insula	_	
125-9	24318-24321	may	_	
125-10	24322-24330	indicate	_	
125-11	24331-24332	a	_	
125-12	24333-24340	reduced	_	
125-13	24341-24346	input	_	
125-14	24347-24349	of	_	
125-15	24350-24363	multi-sensory	_	
125-16	24364-24374	integrated	_	
125-17	24375-24386	information	_	
125-18	24387-24391	from	_	
125-19	24392-24401	claustrum	_	
125-20	24402-24404	to	_	
125-21	24405-24411	insula	_	
125-22	24411-24412	,	_	
125-23	24413-24418	which	_	
125-24	24419-24422	may	_	
125-25	24423-24429	impact	_	
125-26	24430-24432	on	_	
125-27	24433-24441	proximal	_	
125-28	24442-24450	salience	_	
125-29	24451-24460	appraisal	_	
125-30	24460-24461	.	_	

#Text=Contrary to our findings, Clos et al. previously found reduced connectivity in several brain regions in patients with AVH including between right cerebellum and left thalamus.
126-1	24462-24470	Contrary	_	
126-2	24471-24473	to	_	
126-3	24474-24477	our	_	
126-4	24478-24486	findings	_	
126-5	24486-24487	,	_	
126-6	24488-24492	Clos	_	
126-7	24493-24495	et	_	
126-8	24496-24498	al	_	
126-9	24498-24499	.	_	
126-10	24500-24510	previously	_	
126-11	24511-24516	found	_	
126-12	24517-24524	reduced	_	
126-13	24525-24537	connectivity	_	
126-14	24538-24540	in	_	
126-15	24541-24548	several	_	
126-16	24549-24554	brain	_	
126-17	24555-24562	regions	_	
126-18	24563-24565	in	_	
126-19	24566-24574	patients	_	
126-20	24575-24579	with	_	
126-21	24580-24583	AVH	_	
126-22	24584-24593	including	_	
126-23	24594-24601	between	_	
126-24	24602-24607	right	_	
126-25	24608-24618	cerebellum	_	
126-26	24619-24622	and	_	
126-27	24623-24627	left	_	
126-28	24628-24636	thalamus	_	
126-29	24636-24637	.	_	

#Text=However this may be the result of different methodology (which involved replicating voice experience with playing recorded speech-like sounds) and choice of seed placement.
127-1	24638-24645	However	_	
127-2	24646-24650	this	_	
127-3	24651-24654	may	_	
127-4	24655-24657	be	_	
127-5	24658-24661	the	_	
127-6	24662-24668	result	_	
127-7	24669-24671	of	_	
127-8	24672-24681	different	_	
127-9	24682-24693	methodology	_	
127-10	24694-24695	(	_	
127-11	24695-24700	which	_	
127-12	24701-24709	involved	_	
127-13	24710-24721	replicating	_	
127-14	24722-24727	voice	_	
127-15	24728-24738	experience	_	
127-16	24739-24743	with	_	
127-17	24744-24751	playing	_	
127-18	24752-24760	recorded	_	
127-19	24761-24772	speech-like	_	
127-20	24773-24779	sounds	_	
127-21	24779-24780	)	_	
127-22	24781-24784	and	_	
127-23	24785-24791	choice	_	
127-24	24792-24794	of	_	
127-25	24795-24799	seed	_	
127-26	24800-24809	placement	_	
127-27	24809-24810	.	_	

#Text=Our findings suggest a greater role for the insula in AVH which, along with anterior cingulate cortex and ventral striatum, has been shown to be an important brain region involved in prediction error coding.
128-1	24811-24814	Our	_	
128-2	24815-24823	findings	_	
128-3	24824-24831	suggest	_	
128-4	24832-24833	a	_	
128-5	24834-24841	greater	_	
128-6	24842-24846	role	_	
128-7	24847-24850	for	_	
128-8	24851-24854	the	_	
128-9	24855-24861	insula	_	
128-10	24862-24864	in	_	
128-11	24865-24868	AVH	_	
128-12	24869-24874	which	_	
128-13	24874-24875	,	_	
128-14	24876-24881	along	_	
128-15	24882-24886	with	_	
128-16	24887-24895	anterior	_	
128-17	24896-24905	cingulate	_	
128-18	24906-24912	cortex	_	
128-19	24913-24916	and	_	
128-20	24917-24924	ventral	_	
128-21	24925-24933	striatum	_	
128-22	24933-24934	,	_	
128-23	24935-24938	has	_	
128-24	24939-24943	been	_	
128-25	24944-24949	shown	_	
128-26	24950-24952	to	_	
128-27	24953-24955	be	_	
128-28	24956-24958	an	_	
128-29	24959-24968	important	_	
128-30	24969-24974	brain	_	
128-31	24975-24981	region	_	
128-32	24982-24990	involved	_	
128-33	24991-24993	in	_	
128-34	24994-25004	prediction	_	
128-35	25005-25010	error	_	
128-36	25011-25017	coding	_	
128-37	25017-25018	.	_	

#Text=Aberrant predictive coding error could be a mechanism by which the SN dysfunction leads to AVH.
129-1	25019-25027	Aberrant	_	
129-2	25028-25038	predictive	_	
129-3	25039-25045	coding	_	
129-4	25046-25051	error	_	
129-5	25052-25057	could	_	
129-6	25058-25060	be	_	
129-7	25061-25062	a	_	
129-8	25063-25072	mechanism	_	
129-9	25073-25075	by	_	
129-10	25076-25081	which	_	
129-11	25082-25085	the	_	
129-12	25086-25088	SN	_	
129-13	25089-25100	dysfunction	_	
129-14	25101-25106	leads	_	
129-15	25107-25109	to	_	
129-16	25110-25113	AVH	_	
129-17	25113-25114	.	_	

#Text=Timing, sensory prediction and learning are involved in perceptual processes, are key functions of the cerebellum which may have aberrant FC in patients with AVH.
130-1	25115-25121	Timing	_	
130-2	25121-25122	,	_	
130-3	25123-25130	sensory	_	
130-4	25131-25141	prediction	_	
130-5	25142-25145	and	_	
130-6	25146-25154	learning	_	
130-7	25155-25158	are	_	
130-8	25159-25167	involved	_	
130-9	25168-25170	in	_	
130-10	25171-25181	perceptual	_	
130-11	25182-25191	processes	_	
130-12	25191-25192	,	_	
130-13	25193-25196	are	_	
130-14	25197-25200	key	_	
130-15	25201-25210	functions	_	
130-16	25211-25213	of	_	
130-17	25214-25217	the	_	
130-18	25218-25228	cerebellum	_	
130-19	25229-25234	which	_	
130-20	25235-25238	may	_	
130-21	25239-25243	have	_	
130-22	25244-25252	aberrant	_	
130-23	25253-25255	FC	_	
130-24	25256-25258	in	_	
130-25	25259-25267	patients	_	
130-26	25268-25272	with	_	
130-27	25273-25276	AVH	_	
130-28	25276-25277	.	_	

#Text=The cerebellum is part of several intrinsic brain networks including the SN and the DMN, and our results add to the evidence for dysconnectivity involving the cerebellum in the generation of AVH.
131-1	25278-25281	The	_	
131-2	25282-25292	cerebellum	_	
131-3	25293-25295	is	_	
131-4	25296-25300	part	_	
131-5	25301-25303	of	_	
131-6	25304-25311	several	_	
131-7	25312-25321	intrinsic	_	
131-8	25322-25327	brain	_	
131-9	25328-25336	networks	_	
131-10	25337-25346	including	_	
131-11	25347-25350	the	_	
131-12	25351-25353	SN	_	
131-13	25354-25357	and	_	
131-14	25358-25361	the	_	
131-15	25362-25365	DMN	_	
131-16	25365-25366	,	_	
131-17	25367-25370	and	_	
131-18	25371-25374	our	_	
131-19	25375-25382	results	_	
131-20	25383-25386	add	_	
131-21	25387-25389	to	_	
131-22	25390-25393	the	_	
131-23	25394-25402	evidence	_	
131-24	25403-25406	for	_	
131-25	25407-25422	dysconnectivity	_	
131-26	25423-25432	involving	_	
131-27	25433-25436	the	_	
131-28	25437-25447	cerebellum	_	
131-29	25448-25450	in	_	
131-30	25451-25454	the	_	
131-31	25455-25465	generation	_	
131-32	25466-25468	of	_	
131-33	25469-25472	AVH	_	
131-34	25472-25473	.	_	

#Text=We tentatively propose a unitary model of AVH, building on previous literature and our preliminary findings, with aberrant connectivity between the SN and DMN essential in AVH generation.
132-1	25474-25476	We	_	
132-2	25477-25488	tentatively	_	
132-3	25489-25496	propose	_	
132-4	25497-25498	a	_	
132-5	25499-25506	unitary	_	
132-6	25507-25512	model	_	
132-7	25513-25515	of	_	
132-8	25516-25519	AVH	_	
132-9	25519-25520	,	_	
132-10	25521-25529	building	_	
132-11	25530-25532	on	_	
132-12	25533-25541	previous	_	
132-13	25542-25552	literature	_	
132-14	25553-25556	and	_	
132-15	25557-25560	our	_	
132-16	25561-25572	preliminary	_	
132-17	25573-25581	findings	_	
132-18	25581-25582	,	_	
132-19	25583-25587	with	_	
132-20	25588-25596	aberrant	_	
132-21	25597-25609	connectivity	_	
132-22	25610-25617	between	_	
132-23	25618-25621	the	_	
132-24	25622-25624	SN	_	
132-25	25625-25628	and	_	
132-26	25629-25632	DMN	_	
132-27	25633-25642	essential	_	
132-28	25643-25645	in	_	
132-29	25646-25649	AVH	_	
132-30	25650-25660	generation	_	
132-31	25660-25661	.	_	

#Text=The SN is necessary to initiate and modify sensory information and action and mediates the switching between the DMN and the task positive network.
133-1	25662-25665	The	_	
133-2	25666-25668	SN	_	
133-3	25669-25671	is	_	
133-4	25672-25681	necessary	_	
133-5	25682-25684	to	_	
133-6	25685-25693	initiate	_	
133-7	25694-25697	and	_	
133-8	25698-25704	modify	_	
133-9	25705-25712	sensory	_	
133-10	25713-25724	information	_	
133-11	25725-25728	and	_	
133-12	25729-25735	action	_	
133-13	25736-25739	and	_	
133-14	25740-25748	mediates	_	
133-15	25749-25752	the	_	
133-16	25753-25762	switching	_	
133-17	25763-25770	between	_	
133-18	25771-25774	the	_	
133-19	25775-25778	DMN	_	
133-20	25779-25782	and	_	
133-21	25783-25786	the	_	
133-22	25787-25791	task	_	
133-23	25792-25800	positive	_	
133-24	25801-25808	network	_	
133-25	25808-25809	.	_	

#Text=In this model, insula dysfunction is essential in the generation of AVH via evaluation of stimuli and attribution of salience to them.
134-1	25810-25812	In	_	
134-2	25813-25817	this	_	
134-3	25818-25823	model	_	
134-4	25823-25824	,	_	
134-5	25825-25831	insula	_	
134-6	25832-25843	dysfunction	_	
134-7	25844-25846	is	_	
134-8	25847-25856	essential	_	
134-9	25857-25859	in	_	
134-10	25860-25863	the	_	
134-11	25864-25874	generation	_	
134-12	25875-25877	of	_	
134-13	25878-25881	AVH	_	
134-14	25882-25885	via	_	
134-15	25886-25896	evaluation	_	
134-16	25897-25899	of	_	
134-17	25900-25907	stimuli	_	
134-18	25908-25911	and	_	
134-19	25912-25923	attribution	_	
134-20	25924-25926	of	_	
134-21	25927-25935	salience	_	
134-22	25936-25938	to	_	
134-23	25939-25943	them	_	
134-24	25943-25944	.	_	

#Text=Aberrant activity within the claustrum–insula complex may be involved in impaired proximal salience appraisal leading to AVH, with compensatory activity in other areas, including the auditory network and areas involved in auditory processing, language and memory, and areas involved network dysconnectivity in predictive coding (cerebellum).
135-1	25945-25953	Aberrant	_	
135-2	25954-25962	activity	_	
135-3	25963-25969	within	_	
135-4	25970-25973	the	_	
135-5	25974-25990	claustrum–insula	_	
135-6	25991-25998	complex	_	
135-7	25999-26002	may	_	
135-8	26003-26005	be	_	
135-9	26006-26014	involved	_	
135-10	26015-26017	in	_	
135-11	26018-26026	impaired	_	
135-12	26027-26035	proximal	_	
135-13	26036-26044	salience	_	
135-14	26045-26054	appraisal	_	
135-15	26055-26062	leading	_	
135-16	26063-26065	to	_	
135-17	26066-26069	AVH	_	
135-18	26069-26070	,	_	
135-19	26071-26075	with	_	
135-20	26076-26088	compensatory	_	
135-21	26089-26097	activity	_	
135-22	26098-26100	in	_	
135-23	26101-26106	other	_	
135-24	26107-26112	areas	_	
135-25	26112-26113	,	_	
135-26	26114-26123	including	_	
135-27	26124-26127	the	_	
135-28	26128-26136	auditory	_	
135-29	26137-26144	network	_	
135-30	26145-26148	and	_	
135-31	26149-26154	areas	_	
135-32	26155-26163	involved	_	
135-33	26164-26166	in	_	
135-34	26167-26175	auditory	_	
135-35	26176-26186	processing	_	
135-36	26186-26187	,	_	
135-37	26188-26196	language	_	
135-38	26197-26200	and	_	
135-39	26201-26207	memory	_	
135-40	26207-26208	,	_	
135-41	26209-26212	and	_	
135-42	26213-26218	areas	_	
135-43	26219-26227	involved	_	
135-44	26228-26235	network	_	
135-45	26236-26251	dysconnectivity	_	
135-46	26252-26254	in	_	
135-47	26255-26265	predictive	_	
135-48	26266-26272	coding	_	
135-49	26273-26274	(	_	
135-50	26274-26284	cerebellum	_	
135-51	26284-26285	)	_	
135-52	26285-26286	.	_	

#Text=This model could incorporate the abnormal integration, source monitoring and prediction error theories.
136-1	26287-26291	This	_	
136-2	26292-26297	model	_	
136-3	26298-26303	could	_	
136-4	26304-26315	incorporate	_	
136-5	26316-26319	the	_	
136-6	26320-26328	abnormal	_	
136-7	26329-26340	integration	_	
136-8	26340-26341	,	_	
136-9	26342-26348	source	_	
136-10	26349-26359	monitoring	_	
136-11	26360-26363	and	_	
136-12	26364-26374	prediction	_	
136-13	26375-26380	error	_	
136-14	26381-26389	theories	_	
136-15	26389-26390	.	_	

#Text=Future studies would be needed to elucidate the temporal relationship this model suggests.
137-1	26391-26397	Future	_	
137-2	26398-26405	studies	_	
137-3	26406-26411	would	_	
137-4	26412-26414	be	_	
137-5	26415-26421	needed	_	
137-6	26422-26424	to	_	
137-7	26425-26434	elucidate	_	
137-8	26435-26438	the	_	
137-9	26439-26447	temporal	_	
137-10	26448-26460	relationship	_	
137-11	26461-26465	this	_	
137-12	26466-26471	model	_	
137-13	26472-26480	suggests	_	
137-14	26480-26481	.	_	

#Text=The results of this present study and any model suggested should be interpreted with caution due to clear limitations.
138-1	26482-26485	The	_	
138-2	26486-26493	results	_	
138-3	26494-26496	of	_	
138-4	26497-26501	this	_	
138-5	26502-26509	present	_	
138-6	26510-26515	study	_	
138-7	26516-26519	and	_	
138-8	26520-26523	any	_	
138-9	26524-26529	model	_	
138-10	26530-26539	suggested	_	
138-11	26540-26546	should	_	
138-12	26547-26549	be	_	
138-13	26550-26561	interpreted	_	
138-14	26562-26566	with	_	
138-15	26567-26574	caution	_	
138-16	26575-26578	due	_	
138-17	26579-26581	to	_	
138-18	26582-26587	clear	_	
138-19	26588-26599	limitations	_	
138-20	26599-26600	.	_	

#Text=These include primarily the small sample size, particularly of participants included in the symptom capture analysis, however this is comparable with previous fMRI symptom capture studies in chronic schizophrenia, which number 1–18, and reflect the challenge of capturing AVH in real time .
139-1	26601-26606	These	_	
139-2	26607-26614	include	_	
139-3	26615-26624	primarily	_	
139-4	26625-26628	the	_	
139-5	26629-26634	small	_	
139-6	26635-26641	sample	_	
139-7	26642-26646	size	_	
139-8	26646-26647	,	_	
139-9	26648-26660	particularly	_	
139-10	26661-26663	of	_	
139-11	26664-26676	participants	_	
139-12	26677-26685	included	_	
139-13	26686-26688	in	_	
139-14	26689-26692	the	_	
139-15	26693-26700	symptom	_	
139-16	26701-26708	capture	_	
139-17	26709-26717	analysis	_	
139-18	26717-26718	,	_	
139-19	26719-26726	however	_	
139-20	26727-26731	this	_	
139-21	26732-26734	is	_	
139-22	26735-26745	comparable	_	
139-23	26746-26750	with	_	
139-24	26751-26759	previous	_	
139-25	26760-26764	fMRI	_	
139-26	26765-26772	symptom	_	
139-27	26773-26780	capture	_	
139-28	26781-26788	studies	_	
139-29	26789-26791	in	_	
139-30	26792-26799	chronic	_	
139-31	26800-26813	schizophrenia	_	
139-32	26813-26814	,	_	
139-33	26815-26820	which	_	
139-34	26821-26827	number	_	
139-35	26828-26829	1	_	
139-36	26829-26830	–	_	
139-37	26830-26832	18	_	
139-38	26832-26833	,	_	
139-39	26834-26837	and	_	
139-40	26838-26845	reflect	_	
139-41	26846-26849	the	_	
139-42	26850-26859	challenge	_	
139-43	26860-26862	of	_	
139-44	26863-26872	capturing	_	
139-45	26873-26876	AVH	_	
139-46	26877-26879	in	_	
139-47	26880-26884	real	_	
139-48	26885-26889	time	_	
139-49	26890-26891	.	_	

#Text=We have been cautious in interpretation of our results therein.
140-1	26892-26894	We	_	
140-2	26895-26899	have	_	
140-3	26900-26904	been	_	
140-4	26905-26913	cautious	_	
140-5	26914-26916	in	_	
140-6	26917-26931	interpretation	_	
140-7	26932-26934	of	_	
140-8	26935-26938	our	_	
140-9	26939-26946	results	_	
140-10	26947-26954	therein	_	
140-11	26954-26955	.	_	

#Text=In addition, not all of the participants experienced hallucinations during the symptom capture part of the study and thus it is possible that these participants had different brain regions active during their AVH that were not captured in our seed placement for sb-FC.
141-1	26956-26958	In	_	
141-2	26959-26967	addition	_	
141-3	26967-26968	,	_	
141-4	26969-26972	not	_	
141-5	26973-26976	all	_	
141-6	26977-26979	of	_	
141-7	26980-26983	the	_	
141-8	26984-26996	participants	_	
141-9	26997-27008	experienced	_	
141-10	27009-27023	hallucinations	_	
141-11	27024-27030	during	_	
141-12	27031-27034	the	_	
141-13	27035-27042	symptom	_	
141-14	27043-27050	capture	_	
141-15	27051-27055	part	_	
141-16	27056-27058	of	_	
141-17	27059-27062	the	_	
141-18	27063-27068	study	_	
141-19	27069-27072	and	_	
141-20	27073-27077	thus	_	
141-21	27078-27080	it	_	
141-22	27081-27083	is	_	
141-23	27084-27092	possible	_	
141-24	27093-27097	that	_	
141-25	27098-27103	these	_	
141-26	27104-27116	participants	_	
141-27	27117-27120	had	_	
141-28	27121-27130	different	_	
141-29	27131-27136	brain	_	
141-30	27137-27144	regions	_	
141-31	27145-27151	active	_	
141-32	27152-27158	during	_	
141-33	27159-27164	their	_	
141-34	27165-27168	AVH	_	
141-35	27169-27173	that	_	
141-36	27174-27178	were	_	
141-37	27179-27182	not	_	
141-38	27183-27191	captured	_	
141-39	27192-27194	in	_	
141-40	27195-27198	our	_	
141-41	27199-27203	seed	_	
141-42	27204-27213	placement	_	
141-43	27214-27217	for	_	
141-44	27218-27223	sb-FC	_	
141-45	27223-27224	.	_	

#Text=Patients included in the symptom capture analysis had a cumulative median duration of AVH of 127 s (out of 600 s of scan time).
142-1	27225-27233	Patients	_	
142-2	27234-27242	included	_	
142-3	27243-27245	in	_	
142-4	27246-27249	the	_	
142-5	27250-27257	symptom	_	
142-6	27258-27265	capture	_	
142-7	27266-27274	analysis	_	
142-8	27275-27278	had	_	
142-9	27279-27280	a	_	
142-10	27281-27291	cumulative	_	
142-11	27292-27298	median	_	
142-12	27299-27307	duration	_	
142-13	27308-27310	of	_	
142-14	27311-27314	AVH	_	
142-15	27315-27317	of	_	
142-16	27318-27321	127	_	
142-17	27322-27323	s	_	
142-18	27324-27325	(	_	
142-19	27325-27328	out	_	
142-20	27329-27331	of	_	
142-21	27332-27335	600	_	
142-22	27336-27337	s	_	
142-23	27338-27340	of	_	
142-24	27341-27345	scan	_	
142-25	27346-27350	time	_	
142-26	27350-27351	)	_	
142-27	27351-27352	.	_	

#Text=This along with our less stringent use of uncorrected cluster level significance of p < 0.01 may suggest that this study was underpowered with a potential for type 2 error.
143-1	27353-27357	This	_	
143-2	27358-27363	along	_	
143-3	27364-27368	with	_	
143-4	27369-27372	our	_	
143-5	27373-27377	less	_	
143-6	27378-27387	stringent	_	
143-7	27388-27391	use	_	
143-8	27392-27394	of	_	
143-9	27395-27406	uncorrected	_	
143-10	27407-27414	cluster	_	
143-11	27415-27420	level	_	
143-12	27421-27433	significance	_	
143-13	27434-27436	of	_	
143-14	27437-27438	p	_	
143-15	27439-27440	<	_	
143-16	27441-27445	0.01	_	
143-17	27446-27449	may	_	
143-18	27450-27457	suggest	_	
143-19	27458-27462	that	_	
143-20	27463-27467	this	_	
143-21	27468-27473	study	_	
143-22	27474-27477	was	_	
143-23	27478-27490	underpowered	_	
143-24	27491-27495	with	_	
143-25	27496-27497	a	_	
143-26	27498-27507	potential	_	
143-27	27508-27511	for	_	
143-28	27512-27516	type	_	
143-29	27517-27518	2	_	
143-30	27519-27524	error	_	
143-31	27524-27525	.	_	

#Text=Notwithstanding, the results of the symptom capture have identified similar areas as the meta-analysis by Jardri et al. which provides some validity to the results from the symptom capture analysis and suggest the changes seen in chronic schizophrenia are also present early in the course of illness.
144-1	27526-27541	Notwithstanding	_	
144-2	27541-27542	,	_	
144-3	27543-27546	the	_	
144-4	27547-27554	results	_	
144-5	27555-27557	of	_	
144-6	27558-27561	the	_	
144-7	27562-27569	symptom	_	
144-8	27570-27577	capture	_	
144-9	27578-27582	have	_	
144-10	27583-27593	identified	_	
144-11	27594-27601	similar	_	
144-12	27602-27607	areas	_	
144-13	27608-27610	as	_	
144-14	27611-27614	the	_	
144-15	27615-27628	meta-analysis	_	
144-16	27629-27631	by	_	
144-17	27632-27638	Jardri	_	
144-18	27639-27641	et	_	
144-19	27642-27644	al	_	
144-20	27644-27645	.	_	
144-21	27646-27651	which	_	
144-22	27652-27660	provides	_	
144-23	27661-27665	some	_	
144-24	27666-27674	validity	_	
144-25	27675-27677	to	_	
144-26	27678-27681	the	_	
144-27	27682-27689	results	_	
144-28	27690-27694	from	_	
144-29	27695-27698	the	_	
144-30	27699-27706	symptom	_	
144-31	27707-27714	capture	_	
144-32	27715-27723	analysis	_	
144-33	27724-27727	and	_	
144-34	27728-27735	suggest	_	
144-35	27736-27739	the	_	
144-36	27740-27747	changes	_	
144-37	27748-27752	seen	_	
144-38	27753-27755	in	_	
144-39	27756-27763	chronic	_	
144-40	27764-27777	schizophrenia	_	
144-41	27778-27781	are	_	
144-42	27782-27786	also	_	
144-43	27787-27794	present	_	
144-44	27795-27800	early	_	
144-45	27801-27803	in	_	
144-46	27804-27807	the	_	
144-47	27808-27814	course	_	
144-48	27815-27817	of	_	
144-49	27818-27825	illness	_	
144-50	27825-27826	.	_	

#Text=Future studies should include a clinical control group of patients with psychosis who are not experiencing AVH to definitively establish the specificity of results to AVH rather than other group characteristics.
145-1	27827-27833	Future	_	
145-2	27834-27841	studies	_	
145-3	27842-27848	should	_	
145-4	27849-27856	include	_	
145-5	27857-27858	a	_	
145-6	27859-27867	clinical	_	
145-7	27868-27875	control	_	
145-8	27876-27881	group	_	
145-9	27882-27884	of	_	
145-10	27885-27893	patients	_	
145-11	27894-27898	with	_	
145-12	27899-27908	psychosis	_	
145-13	27909-27912	who	_	
145-14	27913-27916	are	_	
145-15	27917-27920	not	_	
145-16	27921-27933	experiencing	_	
145-17	27934-27937	AVH	_	
145-18	27938-27940	to	_	
145-19	27941-27953	definitively	_	
145-20	27954-27963	establish	_	
145-21	27964-27967	the	_	
145-22	27968-27979	specificity	_	
145-23	27980-27982	of	_	
145-24	27983-27990	results	_	
145-25	27991-27993	to	_	
145-26	27994-27997	AVH	_	
145-27	27998-28004	rather	_	
145-28	28005-28009	than	_	
145-29	28010-28015	other	_	
145-30	28016-28021	group	_	
145-31	28022-28037	characteristics	_	
145-32	28037-28038	.	_	

#Text=Using seed regions generated during symptom capture provide validity to a regions’ involvement in AVH, however with 15 seeds being used for sb-FC analysis, there is a possibility of type 1 error.
146-1	28039-28044	Using	_	
146-2	28045-28049	seed	_	
146-3	28050-28057	regions	_	
146-4	28058-28067	generated	_	
146-5	28068-28074	during	_	
146-6	28075-28082	symptom	_	
146-7	28083-28090	capture	_	
146-8	28091-28098	provide	_	
146-9	28099-28107	validity	_	
146-10	28108-28110	to	_	
146-11	28111-28112	a	_	
146-12	28113-28120	regions	_	
146-13	28120-28121	’	_	
146-14	28122-28133	involvement	_	
146-15	28134-28136	in	_	
146-16	28137-28140	AVH	_	
146-17	28140-28141	,	_	
146-18	28142-28149	however	_	
146-19	28150-28154	with	_	
146-20	28155-28157	15	_	
146-21	28158-28163	seeds	_	
146-22	28164-28169	being	_	
146-23	28170-28174	used	_	
146-24	28175-28178	for	_	
146-25	28179-28184	sb-FC	_	
146-26	28185-28193	analysis	_	
146-27	28193-28194	,	_	
146-28	28195-28200	there	_	
146-29	28201-28203	is	_	
146-30	28204-28205	a	_	
146-31	28206-28217	possibility	_	
146-32	28218-28220	of	_	
146-33	28221-28225	type	_	
146-34	28226-28227	1	_	
146-35	28228-28233	error	_	
146-36	28233-28234	.	_	

#Text=To give some address to this we have corrected for multiple comparisons using family-wise error correction within each analysis.
147-1	28235-28237	To	_	
147-2	28238-28242	give	_	
147-3	28243-28247	some	_	
147-4	28248-28255	address	_	
147-5	28256-28258	to	_	
147-6	28259-28263	this	_	
147-7	28264-28266	we	_	
147-8	28267-28271	have	_	
147-9	28272-28281	corrected	_	
147-10	28282-28285	for	_	
147-11	28286-28294	multiple	_	
147-12	28295-28306	comparisons	_	
147-13	28307-28312	using	_	
147-14	28313-28324	family-wise	_	
147-15	28325-28330	error	_	
147-16	28331-28341	correction	_	
147-17	28342-28348	within	_	
147-18	28349-28353	each	_	
147-19	28354-28362	analysis	_	
147-20	28362-28363	.	_	

#Text=Finally, although we have found no correlation with our FC results and medication, given the majority of participants were medicated cannot rule out effects entirely.
148-1	28364-28371	Finally	_	
148-2	28371-28372	,	_	
148-3	28373-28381	although	_	
148-4	28382-28384	we	_	
148-5	28385-28389	have	_	
148-6	28390-28395	found	_	
148-7	28396-28398	no	_	
148-8	28399-28410	correlation	_	
148-9	28411-28415	with	_	
148-10	28416-28419	our	_	
148-11	28420-28422	FC	_	
148-12	28423-28430	results	_	
148-13	28431-28434	and	_	
148-14	28435-28445	medication	_	
148-15	28445-28446	,	_	
148-16	28447-28452	given	_	
148-17	28453-28456	the	_	
148-18	28457-28465	majority	_	
148-19	28466-28468	of	_	
148-20	28469-28481	participants	_	
148-21	28482-28486	were	_	
148-22	28487-28496	medicated	_	
148-23	28497-28503	cannot	_	
148-24	28504-28508	rule	_	
148-25	28509-28512	out	_	
148-26	28513-28520	effects	_	
148-27	28521-28529	entirely	_	
148-28	28529-28530	.	_	

#Text=In summary, in FEP patients with frequent AVH and reduced confounds of long duration of treatment, repeated episodes or length of illness, there was some evidence of aberrant FC between the SN and the DMN; the SN and the cerebellum; and the SN and the claustrum.
149-1	28531-28533	In	_	
149-2	28534-28541	summary	_	
149-3	28541-28542	,	_	
149-4	28543-28545	in	_	
149-5	28546-28549	FEP	_	
149-6	28550-28558	patients	_	
149-7	28559-28563	with	_	
149-8	28564-28572	frequent	_	
149-9	28573-28576	AVH	_	
149-10	28577-28580	and	_	
149-11	28581-28588	reduced	_	
149-12	28589-28598	confounds	_	
149-13	28599-28601	of	_	
149-14	28602-28606	long	_	
149-15	28607-28615	duration	_	
149-16	28616-28618	of	_	
149-17	28619-28628	treatment	_	
149-18	28628-28629	,	_	
149-19	28630-28638	repeated	_	
149-20	28639-28647	episodes	_	
149-21	28648-28650	or	_	
149-22	28651-28657	length	_	
149-23	28658-28660	of	_	
149-24	28661-28668	illness	_	
149-25	28668-28669	,	_	
149-26	28670-28675	there	_	
149-27	28676-28679	was	_	
149-28	28680-28684	some	_	
149-29	28685-28693	evidence	_	
149-30	28694-28696	of	_	
149-31	28697-28705	aberrant	_	
149-32	28706-28708	FC	_	
149-33	28709-28716	between	_	
149-34	28717-28720	the	_	
149-35	28721-28723	SN	_	
149-36	28724-28727	and	_	
149-37	28728-28731	the	_	
149-38	28732-28735	DMN	_	
149-39	28735-28736	;	_	
149-40	28737-28740	the	_	
149-41	28741-28743	SN	_	
149-42	28744-28747	and	_	
149-43	28748-28751	the	_	
149-44	28752-28762	cerebellum	_	
149-45	28762-28763	;	_	
149-46	28764-28767	and	_	
149-47	28768-28771	the	_	
149-48	28772-28774	SN	_	
149-49	28775-28778	and	_	
149-50	28779-28782	the	_	
149-51	28783-28792	claustrum	_	
149-52	28792-28793	.	_	

#Text=This may provide some basis of a unified mechanism for the generation of AVH, with the claustrum/ insula as a novel target area of interest.
150-1	28794-28798	This	_	
150-2	28799-28802	may	_	
150-3	28803-28810	provide	_	
150-4	28811-28815	some	_	
150-5	28816-28821	basis	_	
150-6	28822-28824	of	_	
150-7	28825-28826	a	_	
150-8	28827-28834	unified	_	
150-9	28835-28844	mechanism	_	
150-10	28845-28848	for	_	
150-11	28849-28852	the	_	
150-12	28853-28863	generation	_	
150-13	28864-28866	of	_	
150-14	28867-28870	AVH	_	
150-15	28870-28871	,	_	
150-16	28872-28876	with	_	
150-17	28877-28880	the	_	
150-18	28881-28890	claustrum	_	
150-19	28890-28891	/	_	
150-20	28892-28898	insula	_	
150-21	28899-28901	as	_	
150-22	28902-28903	a	_	
150-23	28904-28909	novel	_	
150-24	28910-28916	target	_	
150-25	28917-28921	area	_	
150-26	28922-28924	of	_	
150-27	28925-28933	interest	_	
150-28	28933-28934	.	_	

#Text=Future research should focus on the strength and directionality of connectivity between these regions and the temporal relationship between this and auditory processing, language and memory areas to explore the specificity of this aberrant FC to the detailed and varied experience of voice hearing.
151-1	28935-28941	Future	_	
151-2	28942-28950	research	_	
151-3	28951-28957	should	_	
151-4	28958-28963	focus	_	
151-5	28964-28966	on	_	
151-6	28967-28970	the	_	
151-7	28971-28979	strength	_	
151-8	28980-28983	and	_	
151-9	28984-28998	directionality	_	
151-10	28999-29001	of	_	
151-11	29002-29014	connectivity	_	
151-12	29015-29022	between	_	
151-13	29023-29028	these	_	
151-14	29029-29036	regions	_	
151-15	29037-29040	and	_	
151-16	29041-29044	the	_	
151-17	29045-29053	temporal	_	
151-18	29054-29066	relationship	_	
151-19	29067-29074	between	_	
151-20	29075-29079	this	_	
151-21	29080-29083	and	_	
151-22	29084-29092	auditory	_	
151-23	29093-29103	processing	_	
151-24	29103-29104	,	_	
151-25	29105-29113	language	_	
151-26	29114-29117	and	_	
151-27	29118-29124	memory	_	
151-28	29125-29130	areas	_	
151-29	29131-29133	to	_	
151-30	29134-29141	explore	_	
151-31	29142-29145	the	_	
151-32	29146-29157	specificity	_	
151-33	29158-29160	of	_	
151-34	29161-29165	this	_	
151-35	29166-29174	aberrant	_	
151-36	29175-29177	FC	_	
151-37	29178-29180	to	_	
151-38	29181-29184	the	_	
151-39	29185-29193	detailed	_	
151-40	29194-29197	and	_	
151-41	29198-29204	varied	_	
151-42	29205-29215	experience	_	
151-43	29216-29218	of	_	
151-44	29219-29224	voice	_	
151-45	29225-29232	hearing	_	
151-46	29232-29233	.	_	

#Text=Electronic supplementary material
#Text=Joint last authors: Stephen J Wood, Rachel Upthegrove.
152-1	29234-29244	Electronic	_	
152-2	29245-29258	supplementary	_	
152-3	29259-29267	material	_	
152-4	29268-29273	Joint	_	
152-5	29274-29278	last	_	
152-6	29279-29286	authors	_	
152-7	29286-29287	:	_	
152-8	29288-29295	Stephen	_	
152-9	29296-29297	J	_	
152-10	29298-29302	Wood	_	
152-11	29302-29303	,	_	
152-12	29304-29310	Rachel	_	
152-13	29311-29321	Upthegrove	_	
152-14	29321-29322	.	_	

#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-018-0118-6).
153-1	29323-29333	Electronic	_	
153-2	29334-29347	supplementary	_	
153-3	29348-29356	material	_	
153-4	29357-29370	Supplementary	_	
153-5	29371-29382	Information	_	
153-6	29383-29394	accompanies	_	
153-7	29395-29399	this	_	
153-8	29400-29405	paper	_	
153-9	29406-29408	at	_	
153-10	29409-29410	(	_	
153-11	29410-29417	10.1038	_	
153-12	29417-29418	/	_	
153-13	29418-29424	s41398	_	
153-14	29424-29425	-	_	
153-15	29425-29428	018	_	
153-16	29428-29429	-	_	
153-17	29429-29433	0118	_	
153-18	29433-29434	-	_	
153-19	29434-29435	6	_	
153-20	29435-29436	)	_	
153-21	29436-29437	.	_	

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
154-1	29438-29449	Publisher's	_	
154-2	29450-29454	note	_	
154-3	29454-29455	:	_	
154-4	29456-29464	Springer	_	
154-5	29465-29471	Nature	_	
154-6	29472-29479	remains	_	
154-7	29480-29487	neutral	_	
154-8	29488-29492	with	_	
154-9	29493-29499	regard	_	
154-10	29500-29502	to	_	
154-11	29503-29517	jurisdictional	_	
154-12	29518-29524	claims	_	
154-13	29525-29527	in	_	
154-14	29528-29537	published	_	
154-15	29538-29542	maps	_	
154-16	29543-29546	and	_	
154-17	29547-29560	institutional	_	
154-18	29561-29573	affiliations	_	
154-19	29573-29574	.	_	

#Text=Conflict of interest
#Text=The authors declare that they have no conflict of interest.
155-1	29575-29583	Conflict	_	
155-2	29584-29586	of	_	
155-3	29587-29595	interest	_	
155-4	29596-29599	The	_	
155-5	29600-29607	authors	_	
155-6	29608-29615	declare	_	
155-7	29616-29620	that	_	
155-8	29621-29625	they	_	
155-9	29626-29630	have	_	
155-10	29631-29633	no	_	
155-11	29634-29642	conflict	_	
155-12	29643-29645	of	_	
155-13	29646-29654	interest	_	
155-14	29654-29655	.	_	

#Text=References
#Text=Schizophrenia: the characteristic symptoms
#Text=The evolution of depression and suicidality in first episode psychosis
#Text=Auditory and non-auditory hallucinations in first-episode psychosis: differential associations with diverse clinical features
#Text=Auditory Hallucinations and the Brain’s Resting-State Networks: findings and methodological observations
#Text=Hearing voices in the resting brain: a review of intrinsic functional connectivity research on auditory verbal hallucinations
#Text=Interaction of language, auditory and memory brain networks in auditory verbal hallucinations
#Text=Mechanisms of Auditory Verbal Hallucination in Schizophrenia
#Text=The role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations
#Text=The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations
#Text=Auditory hallucinations in schizophrenia: intrusive thoughts and forgotten memories
#Text=Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations
#Text=Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia
#Text=Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis
#Text=Quantitative meta-analysis on state and trait aspects of auditory verbal hallucinations in schizophrenia
#Text=Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neurochemistry and beyond
#Text=How can the brain’s resting state activity generate hallucinations?
156-1	29656-29666	References	_	
156-2	29667-29680	Schizophrenia	_	
156-3	29680-29681	:	_	
156-4	29682-29685	the	_	
156-5	29686-29700	characteristic	_	
156-6	29701-29709	symptoms	_	
156-7	29710-29713	The	_	
156-8	29714-29723	evolution	_	
156-9	29724-29726	of	_	
156-10	29727-29737	depression	_	
156-11	29738-29741	and	_	
156-12	29742-29753	suicidality	_	
156-13	29754-29756	in	_	
156-14	29757-29762	first	_	
156-15	29763-29770	episode	_	
156-16	29771-29780	psychosis	_	
156-17	29781-29789	Auditory	_	
156-18	29790-29793	and	_	
156-19	29794-29806	non-auditory	_	
156-20	29807-29821	hallucinations	_	
156-21	29822-29824	in	_	
156-22	29825-29838	first-episode	_	
156-23	29839-29848	psychosis	_	
156-24	29848-29849	:	_	
156-25	29850-29862	differential	_	
156-26	29863-29875	associations	_	
156-27	29876-29880	with	_	
156-28	29881-29888	diverse	_	
156-29	29889-29897	clinical	_	
156-30	29898-29906	features	_	
156-31	29907-29915	Auditory	_	
156-32	29916-29930	Hallucinations	_	
156-33	29931-29934	and	_	
156-34	29935-29938	the	_	
156-35	29939-29944	Brain	_	
156-36	29944-29945	’	_	
156-37	29945-29946	s	_	
156-38	29947-29960	Resting-State	_	
156-39	29961-29969	Networks	_	
156-40	29969-29970	:	_	
156-41	29971-29979	findings	_	
156-42	29980-29983	and	_	
156-43	29984-29998	methodological	_	
156-44	29999-30011	observations	_	
156-45	30012-30019	Hearing	_	
156-46	30020-30026	voices	_	
156-47	30027-30029	in	_	
156-48	30030-30033	the	_	
156-49	30034-30041	resting	_	
156-50	30042-30047	brain	_	
156-51	30047-30048	:	_	
156-52	30049-30050	a	_	
156-53	30051-30057	review	_	
156-54	30058-30060	of	_	
156-55	30061-30070	intrinsic	_	
156-56	30071-30081	functional	_	
156-57	30082-30094	connectivity	_	
156-58	30095-30103	research	_	
156-59	30104-30106	on	_	
156-60	30107-30115	auditory	_	
156-61	30116-30122	verbal	_	
156-62	30123-30137	hallucinations	_	
156-63	30138-30149	Interaction	_	
156-64	30150-30152	of	_	
156-65	30153-30161	language	_	
156-66	30161-30162	,	_	
156-67	30163-30171	auditory	_	
156-68	30172-30175	and	_	
156-69	30176-30182	memory	_	
156-70	30183-30188	brain	_	
156-71	30189-30197	networks	_	
156-72	30198-30200	in	_	
156-73	30201-30209	auditory	_	
156-74	30210-30216	verbal	_	
156-75	30217-30231	hallucinations	_	
156-76	30232-30242	Mechanisms	_	
156-77	30243-30245	of	_	
156-78	30246-30254	Auditory	_	
156-79	30255-30261	Verbal	_	
156-80	30262-30275	Hallucination	_	
156-81	30276-30278	in	_	
156-82	30279-30292	Schizophrenia	_	
156-83	30293-30296	The	_	
156-84	30297-30301	role	_	
156-85	30302-30304	of	_	
156-86	30305-30308	the	_	
156-87	30309-30316	primary	_	
156-88	30317-30325	auditory	_	
156-89	30326-30332	cortex	_	
156-90	30333-30335	in	_	
156-91	30336-30339	the	_	
156-92	30340-30346	neural	_	
156-93	30347-30356	mechanism	_	
156-94	30357-30359	of	_	
156-95	30360-30368	auditory	_	
156-96	30369-30375	verbal	_	
156-97	30376-30390	hallucinations	_	
156-98	30391-30394	The	_	
156-99	30395-30408	hallucinating	_	
156-100	30409-30414	brain	_	
156-101	30414-30415	:	_	
156-102	30416-30417	a	_	
156-103	30418-30424	review	_	
156-104	30425-30427	of	_	
156-105	30428-30438	structural	_	
156-106	30439-30442	and	_	
156-107	30443-30453	functional	_	
156-108	30454-30466	neuroimaging	_	
156-109	30467-30474	studies	_	
156-110	30475-30477	of	_	
156-111	30478-30492	hallucinations	_	
156-112	30493-30501	Auditory	_	
156-113	30502-30516	hallucinations	_	
156-114	30517-30519	in	_	
156-115	30520-30533	schizophrenia	_	
156-116	30533-30534	:	_	
156-117	30535-30544	intrusive	_	
156-118	30545-30553	thoughts	_	
156-119	30554-30557	and	_	
156-120	30558-30567	forgotten	_	
156-121	30568-30576	memories	_	
156-122	30577-30585	Abnormal	_	
156-123	30586-30596	monitoring	_	
156-124	30597-30599	of	_	
156-125	30600-30605	inner	_	
156-126	30606-30612	speech	_	
156-127	30612-30613	:	_	
156-128	30614-30615	a	_	
156-129	30616-30629	physiological	_	
156-130	30630-30635	basis	_	
156-131	30636-30639	for	_	
156-132	30640-30648	auditory	_	
156-133	30649-30663	hallucinations	_	
156-134	30664-30674	Perceiving	_	
156-135	30675-30677	is	_	
156-136	30678-30687	believing	_	
156-137	30687-30688	:	_	
156-138	30689-30690	a	_	
156-139	30691-30699	Bayesian	_	
156-140	30700-30708	approach	_	
156-141	30709-30711	to	_	
156-142	30712-30722	explaining	_	
156-143	30723-30726	the	_	
156-144	30727-30735	positive	_	
156-145	30736-30744	symptoms	_	
156-146	30745-30747	of	_	
156-147	30748-30761	schizophrenia	_	
156-148	30762-30770	Cortical	_	
156-149	30771-30782	activations	_	
156-150	30783-30789	during	_	
156-151	30790-30798	auditory	_	
156-152	30799-30805	verbal	_	
156-153	30806-30820	hallucinations	_	
156-154	30821-30823	in	_	
156-155	30824-30837	schizophrenia	_	
156-156	30837-30838	:	_	
156-157	30839-30840	a	_	
156-158	30841-30857	coordinate-based	_	
156-159	30858-30871	meta-analysis	_	
156-160	30872-30884	Quantitative	_	
156-161	30885-30898	meta-analysis	_	
156-162	30899-30901	on	_	
156-163	30902-30907	state	_	
156-164	30908-30911	and	_	
156-165	30912-30917	trait	_	
156-166	30918-30925	aspects	_	
156-167	30926-30928	of	_	
156-168	30929-30937	auditory	_	
156-169	30938-30944	verbal	_	
156-170	30945-30959	hallucinations	_	
156-171	30960-30962	in	_	
156-172	30963-30976	schizophrenia	_	
156-173	30977-30989	Neuroimaging	_	
156-174	30990-30998	auditory	_	
156-175	30999-31013	hallucinations	_	
156-176	31014-31016	in	_	
156-177	31017-31030	schizophrenia	_	
156-178	31030-31031	:	_	
156-179	31032-31036	from	_	
156-180	31037-31049	neuroanatomy	_	
156-181	31050-31052	to	_	
156-182	31053-31067	neurochemistry	_	
156-183	31068-31071	and	_	
156-184	31072-31078	beyond	_	
156-185	31079-31082	How	_	
156-186	31083-31086	can	_	
156-187	31087-31090	the	_	
156-188	31091-31096	brain	_	
156-189	31096-31097	’	_	
156-190	31097-31098	s	_	
156-191	31099-31106	resting	_	
156-192	31107-31112	state	_	
156-193	31113-31121	activity	_	
156-194	31122-31130	generate	_	
156-195	31131-31145	hallucinations	_	
156-196	31145-31146	?	_	

#Text=A ‘resting state hypothesis’ of auditory verbal hallucinations
#Text=The neurodynamic organization of modality-dependent hallucinations
#Text=Does the salience network play a cardinal role in psychosis?
157-1	31147-31148	A	_	
157-2	31149-31150	‘	_	
157-3	31150-31157	resting	_	
157-4	31158-31163	state	_	
157-5	31164-31174	hypothesis	_	
157-6	31174-31175	’	_	
157-7	31176-31178	of	_	
157-8	31179-31187	auditory	_	
157-9	31188-31194	verbal	_	
157-10	31195-31209	hallucinations	_	
157-11	31210-31213	The	_	
157-12	31214-31226	neurodynamic	_	
157-13	31227-31239	organization	_	
157-14	31240-31242	of	_	
157-15	31243-31261	modality-dependent	_	
157-16	31262-31276	hallucinations	_	
157-17	31277-31281	Does	_	
157-18	31282-31285	the	_	
157-19	31286-31294	salience	_	
157-20	31295-31302	network	_	
157-21	31303-31307	play	_	
157-22	31308-31309	a	_	
157-23	31310-31318	cardinal	_	
157-24	31319-31323	role	_	
157-25	31324-31326	in	_	
157-26	31327-31336	psychosis	_	
157-27	31336-31337	?	_	

#Text=An emerging hypothesis of insular dysfunction
#Text=Network dynamics during the different stages of hallucinations in schizophrenia
#Text=Are auditory hallucinations related to the brain’s resting state activity?
158-1	31338-31340	An	_	
158-2	31341-31349	emerging	_	
158-3	31350-31360	hypothesis	_	
158-4	31361-31363	of	_	
158-5	31364-31371	insular	_	
158-6	31372-31383	dysfunction	_	
158-7	31384-31391	Network	_	
158-8	31392-31400	dynamics	_	
158-9	31401-31407	during	_	
158-10	31408-31411	the	_	
158-11	31412-31421	different	_	
158-12	31422-31428	stages	_	
158-13	31429-31431	of	_	
158-14	31432-31446	hallucinations	_	
158-15	31447-31449	in	_	
158-16	31450-31463	schizophrenia	_	
158-17	31464-31467	Are	_	
158-18	31468-31476	auditory	_	
158-19	31477-31491	hallucinations	_	
158-20	31492-31499	related	_	
158-21	31500-31502	to	_	
158-22	31503-31506	the	_	
158-23	31507-31512	brain	_	
158-24	31512-31513	’	_	
158-25	31513-31514	s	_	
158-26	31515-31522	resting	_	
158-27	31523-31528	state	_	
158-28	31529-31537	activity	_	
158-29	31537-31538	?	_	

#Text=A ‘Neurophenomenal Resting State Hypothesis’
#Text=Functional connectivity of left Heschl’s gyrus in vulnerability to auditory hallucinations in schizophrenia
#Text=Aberrant connectivity of areas for decoding degraded speech in patients with auditory verbal hallucinations
#Text=Resting state functional connectivity in patients with chronic hallucinations
#Text=Aberrant resting-state connectivity in non-psychotic individuals with auditory hallucinations
#Text=Elevated functional connectivity along a corticostriatal loop and the mechanism of auditory/verbal hallucinations in patients with schizophrenia
#Text=Putamen-related regional and network functional deficits in first-episode schizophrenia with auditory verbal hallucinations
#Text=Auditory hallucinations in schizophrenia are associated with reduced functional connectivity of the temporo-parietal area
#Text=Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations
#Text=Understanding auditory verbal hallucinations: a systematic review of current evidence
#Text=
#Text=The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
#Text=The revised Beliefs About Voices Questionnaire (BAVQ-R)
#Text=Persistent auditory hallucinations and their relationship to delusions and mood
#Text=The power and omnipotence of voices: subordination and entrapment by voices and significant others
#Text=Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS)
#Text=DPARSF: a MATLAB toolbox for ‘pipeline’ data analysis of resting-state fMRI
#Text=Methods and software for fMRI analysis of clinical subjects
#Text=Movement-related effects in fMRI time-series
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=A component based noise correction method (CompCor) for BOLD and perfusion based fMRI
#Text=A fast diffeomorphic image registration algorithm
#Text=Dissociable intrinsic connectivity networks for salience processing and executive control
#Text=A default mode of brain function
#Text=Functional connectivity in the resting brain: a network analysis of the default mode hypothesis
#Text=Functional connectivity of default mode network components: correlation, anticorrelation, and causality
#Text=A computational morphometric MRI study of schizophrenia: effects of hallucinations
#Text=Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis
#Text=Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies
#Text=The influence of stimulus detection on activation patterns during auditory hallucinations
#Text=What is the function of the claustrum?
159-1	31539-31540	A	_	
159-2	31541-31542	‘	_	
159-3	31542-31557	Neurophenomenal	_	
159-4	31558-31565	Resting	_	
159-5	31566-31571	State	_	
159-6	31572-31582	Hypothesis	_	
159-7	31582-31583	’	_	
159-8	31584-31594	Functional	_	
159-9	31595-31607	connectivity	_	
159-10	31608-31610	of	_	
159-11	31611-31615	left	_	
159-12	31616-31622	Heschl	_	
159-13	31622-31623	’	_	
159-14	31623-31624	s	_	
159-15	31625-31630	gyrus	_	
159-16	31631-31633	in	_	
159-17	31634-31647	vulnerability	_	
159-18	31648-31650	to	_	
159-19	31651-31659	auditory	_	
159-20	31660-31674	hallucinations	_	
159-21	31675-31677	in	_	
159-22	31678-31691	schizophrenia	_	
159-23	31692-31700	Aberrant	_	
159-24	31701-31713	connectivity	_	
159-25	31714-31716	of	_	
159-26	31717-31722	areas	_	
159-27	31723-31726	for	_	
159-28	31727-31735	decoding	_	
159-29	31736-31744	degraded	_	
159-30	31745-31751	speech	_	
159-31	31752-31754	in	_	
159-32	31755-31763	patients	_	
159-33	31764-31768	with	_	
159-34	31769-31777	auditory	_	
159-35	31778-31784	verbal	_	
159-36	31785-31799	hallucinations	_	
159-37	31800-31807	Resting	_	
159-38	31808-31813	state	_	
159-39	31814-31824	functional	_	
159-40	31825-31837	connectivity	_	
159-41	31838-31840	in	_	
159-42	31841-31849	patients	_	
159-43	31850-31854	with	_	
159-44	31855-31862	chronic	_	
159-45	31863-31877	hallucinations	_	
159-46	31878-31886	Aberrant	_	
159-47	31887-31900	resting-state	_	
159-48	31901-31913	connectivity	_	
159-49	31914-31916	in	_	
159-50	31917-31930	non-psychotic	_	
159-51	31931-31942	individuals	_	
159-52	31943-31947	with	_	
159-53	31948-31956	auditory	_	
159-54	31957-31971	hallucinations	_	
159-55	31972-31980	Elevated	_	
159-56	31981-31991	functional	_	
159-57	31992-32004	connectivity	_	
159-58	32005-32010	along	_	
159-59	32011-32012	a	_	
159-60	32013-32028	corticostriatal	_	
159-61	32029-32033	loop	_	
159-62	32034-32037	and	_	
159-63	32038-32041	the	_	
159-64	32042-32051	mechanism	_	
159-65	32052-32054	of	_	
159-66	32055-32063	auditory	_	
159-67	32063-32064	/	_	
159-68	32064-32070	verbal	_	
159-69	32071-32085	hallucinations	_	
159-70	32086-32088	in	_	
159-71	32089-32097	patients	_	
159-72	32098-32102	with	_	
159-73	32103-32116	schizophrenia	_	
159-74	32117-32132	Putamen-related	_	
159-75	32133-32141	regional	_	
159-76	32142-32145	and	_	
159-77	32146-32153	network	_	
159-78	32154-32164	functional	_	
159-79	32165-32173	deficits	_	
159-80	32174-32176	in	_	
159-81	32177-32190	first-episode	_	
159-82	32191-32204	schizophrenia	_	
159-83	32205-32209	with	_	
159-84	32210-32218	auditory	_	
159-85	32219-32225	verbal	_	
159-86	32226-32240	hallucinations	_	
159-87	32241-32249	Auditory	_	
159-88	32250-32264	hallucinations	_	
159-89	32265-32267	in	_	
159-90	32268-32281	schizophrenia	_	
159-91	32282-32285	are	_	
159-92	32286-32296	associated	_	
159-93	32297-32301	with	_	
159-94	32302-32309	reduced	_	
159-95	32310-32320	functional	_	
159-96	32321-32333	connectivity	_	
159-97	32334-32336	of	_	
159-98	32337-32340	the	_	
159-99	32341-32357	temporo-parietal	_	
159-100	32358-32362	area	_	
159-101	32363-32376	Resting-state	_	
159-102	32377-32387	functional	_	
159-103	32388-32400	connectivity	_	
159-104	32401-32412	alterations	_	
159-105	32413-32415	in	_	
159-106	32416-32419	the	_	
159-107	32420-32427	default	_	
159-108	32428-32435	network	_	
159-109	32436-32438	of	_	
159-110	32439-32452	schizophrenia	_	
159-111	32453-32461	patients	_	
159-112	32462-32466	with	_	
159-113	32467-32477	persistent	_	
159-114	32478-32486	auditory	_	
159-115	32487-32493	verbal	_	
159-116	32494-32508	hallucinations	_	
159-117	32509-32522	Understanding	_	
159-118	32523-32531	auditory	_	
159-119	32532-32538	verbal	_	
159-120	32539-32553	hallucinations	_	
159-121	32553-32554	:	_	
159-122	32555-32556	a	_	
159-123	32557-32567	systematic	_	
159-124	32568-32574	review	_	
159-125	32575-32577	of	_	
159-126	32578-32585	current	_	
159-127	32586-32594	evidence	_	
159-128	32596-32599	The	_	
159-129	32600-32618	Mini-International	_	
159-130	32619-32635	Neuropsychiatric	_	
159-131	32636-32645	Interview	_	
159-132	32646-32647	(	_	
159-133	32647-32654	M.I.N.I	_	
159-134	32654-32655	.	_	
159-135	32655-32656	)	_	
159-136	32656-32657	:	_	
159-137	32658-32661	the	_	
159-138	32662-32673	development	_	
159-139	32674-32677	and	_	
159-140	32678-32688	validation	_	
159-141	32689-32691	of	_	
159-142	32692-32693	a	_	
159-143	32694-32704	structured	_	
159-144	32705-32715	diagnostic	_	
159-145	32716-32727	psychiatric	_	
159-146	32728-32737	interview	_	
159-147	32738-32741	for	_	
159-148	32742-32748	DSM-IV	_	
159-149	32749-32752	and	_	
159-150	32753-32756	ICD	_	
159-151	32756-32757	-	_	
159-152	32757-32759	10	_	
159-153	32760-32763	The	_	
159-154	32764-32771	revised	_	
159-155	32772-32779	Beliefs	_	
159-156	32780-32785	About	_	
159-157	32786-32792	Voices	_	
159-158	32793-32806	Questionnaire	_	
159-159	32807-32808	(	_	
159-160	32808-32814	BAVQ-R	_	
159-161	32814-32815	)	_	
159-162	32816-32826	Persistent	_	
159-163	32827-32835	auditory	_	
159-164	32836-32850	hallucinations	_	
159-165	32851-32854	and	_	
159-166	32855-32860	their	_	
159-167	32861-32873	relationship	_	
159-168	32874-32876	to	_	
159-169	32877-32886	delusions	_	
159-170	32887-32890	and	_	
159-171	32891-32895	mood	_	
159-172	32896-32899	The	_	
159-173	32900-32905	power	_	
159-174	32906-32909	and	_	
159-175	32910-32921	omnipotence	_	
159-176	32922-32924	of	_	
159-177	32925-32931	voices	_	
159-178	32931-32932	:	_	
159-179	32933-32946	subordination	_	
159-180	32947-32950	and	_	
159-181	32951-32961	entrapment	_	
159-182	32962-32964	by	_	
159-183	32965-32971	voices	_	
159-184	32972-32975	and	_	
159-185	32976-32987	significant	_	
159-186	32988-32994	others	_	
159-187	32995-33001	Scales	_	
159-188	33002-33004	to	_	
159-189	33005-33012	measure	_	
159-190	33013-33023	dimensions	_	
159-191	33024-33026	of	_	
159-192	33027-33041	hallucinations	_	
159-193	33042-33045	and	_	
159-194	33046-33055	delusions	_	
159-195	33055-33056	:	_	
159-196	33057-33060	the	_	
159-197	33061-33070	psychotic	_	
159-198	33071-33078	symptom	_	
159-199	33079-33085	rating	_	
159-200	33086-33092	scales	_	
159-201	33093-33094	(	_	
159-202	33094-33101	PSYRATS	_	
159-203	33101-33102	)	_	
159-204	33103-33109	DPARSF	_	
159-205	33109-33110	:	_	
159-206	33111-33112	a	_	
159-207	33113-33119	MATLAB	_	
159-208	33120-33127	toolbox	_	
159-209	33128-33131	for	_	
159-210	33132-33133	‘	_	
159-211	33133-33141	pipeline	_	
159-212	33141-33142	’	_	
159-213	33143-33147	data	_	
159-214	33148-33156	analysis	_	
159-215	33157-33159	of	_	
159-216	33160-33173	resting-state	_	
159-217	33174-33178	fMRI	_	
159-218	33179-33186	Methods	_	
159-219	33187-33190	and	_	
159-220	33191-33199	software	_	
159-221	33200-33203	for	_	
159-222	33204-33208	fMRI	_	
159-223	33209-33217	analysis	_	
159-224	33218-33220	of	_	
159-225	33221-33229	clinical	_	
159-226	33230-33238	subjects	_	
159-227	33239-33255	Movement-related	_	
159-228	33256-33263	effects	_	
159-229	33264-33266	in	_	
159-230	33267-33271	fMRI	_	
159-231	33272-33283	time-series	_	
159-232	33284-33292	Spurious	_	
159-233	33293-33296	but	_	
159-234	33297-33307	systematic	_	
159-235	33308-33320	correlations	_	
159-236	33321-33323	in	_	
159-237	33324-33334	functional	_	
159-238	33335-33347	connectivity	_	
159-239	33348-33351	MRI	_	
159-240	33352-33360	networks	_	
159-241	33361-33366	arise	_	
159-242	33367-33371	from	_	
159-243	33372-33379	subject	_	
159-244	33380-33386	motion	_	
159-245	33387-33388	A	_	
159-246	33389-33398	component	_	
159-247	33399-33404	based	_	
159-248	33405-33410	noise	_	
159-249	33411-33421	correction	_	
159-250	33422-33428	method	_	
159-251	33429-33430	(	_	
159-252	33430-33437	CompCor	_	
159-253	33437-33438	)	_	
159-254	33439-33442	for	_	
159-255	33443-33447	BOLD	_	
159-256	33448-33451	and	_	
159-257	33452-33461	perfusion	_	
159-258	33462-33467	based	_	
159-259	33468-33472	fMRI	_	
159-260	33473-33474	A	_	
159-261	33475-33479	fast	_	
159-262	33480-33493	diffeomorphic	_	
159-263	33494-33499	image	_	
159-264	33500-33512	registration	_	
159-265	33513-33522	algorithm	_	
159-266	33523-33534	Dissociable	_	
159-267	33535-33544	intrinsic	_	
159-268	33545-33557	connectivity	_	
159-269	33558-33566	networks	_	
159-270	33567-33570	for	_	
159-271	33571-33579	salience	_	
159-272	33580-33590	processing	_	
159-273	33591-33594	and	_	
159-274	33595-33604	executive	_	
159-275	33605-33612	control	_	
159-276	33613-33614	A	_	
159-277	33615-33622	default	_	
159-278	33623-33627	mode	_	
159-279	33628-33630	of	_	
159-280	33631-33636	brain	_	
159-281	33637-33645	function	_	
159-282	33646-33656	Functional	_	
159-283	33657-33669	connectivity	_	
159-284	33670-33672	in	_	
159-285	33673-33676	the	_	
159-286	33677-33684	resting	_	
159-287	33685-33690	brain	_	
159-288	33690-33691	:	_	
159-289	33692-33693	a	_	
159-290	33694-33701	network	_	
159-291	33702-33710	analysis	_	
159-292	33711-33713	of	_	
159-293	33714-33717	the	_	
159-294	33718-33725	default	_	
159-295	33726-33730	mode	_	
159-296	33731-33741	hypothesis	_	
159-297	33742-33752	Functional	_	
159-298	33753-33765	connectivity	_	
159-299	33766-33768	of	_	
159-300	33769-33776	default	_	
159-301	33777-33781	mode	_	
159-302	33782-33789	network	_	
159-303	33790-33800	components	_	
159-304	33800-33801	:	_	
159-305	33802-33813	correlation	_	
159-306	33813-33814	,	_	
159-307	33815-33830	anticorrelation	_	
159-308	33830-33831	,	_	
159-309	33832-33835	and	_	
159-310	33836-33845	causality	_	
159-311	33846-33847	A	_	
159-312	33848-33861	computational	_	
159-313	33862-33874	morphometric	_	
159-314	33875-33878	MRI	_	
159-315	33879-33884	study	_	
159-316	33885-33887	of	_	
159-317	33888-33901	schizophrenia	_	
159-318	33901-33902	:	_	
159-319	33903-33910	effects	_	
159-320	33911-33913	of	_	
159-321	33914-33928	hallucinations	_	
159-322	33929-33939	Structural	_	
159-323	33940-33950	correlates	_	
159-324	33951-33953	of	_	
159-325	33954-33962	auditory	_	
159-326	33963-33977	hallucinations	_	
159-327	33978-33980	in	_	
159-328	33981-33994	schizophrenia	_	
159-329	33994-33995	:	_	
159-330	33996-33997	a	_	
159-331	33998-34011	meta-analysis	_	
159-332	34012-34024	Neuroanatomy	_	
159-333	34025-34027	of	_	
159-334	34028-34036	auditory	_	
159-335	34037-34043	verbal	_	
159-336	34044-34058	hallucinations	_	
159-337	34059-34061	in	_	
159-338	34062-34075	schizophrenia	_	
159-339	34075-34076	:	_	
159-340	34077-34078	a	_	
159-341	34079-34091	quantitative	_	
159-342	34092-34105	meta-analysis	_	
159-343	34106-34108	of	_	
159-344	34109-34120	voxel-based	_	
159-345	34121-34132	morphometry	_	
159-346	34133-34140	studies	_	
159-347	34141-34144	The	_	
159-348	34145-34154	influence	_	
159-349	34155-34157	of	_	
159-350	34158-34166	stimulus	_	
159-351	34167-34176	detection	_	
159-352	34177-34179	on	_	
159-353	34180-34190	activation	_	
159-354	34191-34199	patterns	_	
159-355	34200-34206	during	_	
159-356	34207-34215	auditory	_	
159-357	34216-34230	hallucinations	_	
159-358	34231-34235	What	_	
159-359	34236-34238	is	_	
159-360	34239-34242	the	_	
159-361	34243-34251	function	_	
159-362	34252-34254	of	_	
159-363	34255-34258	the	_	
159-364	34259-34268	claustrum	_	
159-365	34268-34269	?	_	

#Text=Attention: the claustrum
#Text=Hypotheses relating to the function of the claustrum
#Text=A new perspective on delusional states—evidence for claustrum involvement
#Text=Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
#Text=Temporal prediction errors modulate cingulate-insular coupling
#Text=Seeking a unified framework for cerebellar function and dysfunction: from circuit operations to cognition
#Text=Consensus paper: the role of the cerebellum in perceptual processes
#Text=Distinct cerebellar contributions to intrinsic connectivity networks
#Text=Saliency, switching, attention and control: a network model of insula function
#Text=A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks
160-1	34270-34279	Attention	_	
160-2	34279-34280	:	_	
160-3	34281-34284	the	_	
160-4	34285-34294	claustrum	_	
160-5	34295-34305	Hypotheses	_	
160-6	34306-34314	relating	_	
160-7	34315-34317	to	_	
160-8	34318-34321	the	_	
160-9	34322-34330	function	_	
160-10	34331-34333	of	_	
160-11	34334-34337	the	_	
160-12	34338-34347	claustrum	_	
160-13	34348-34349	A	_	
160-14	34350-34353	new	_	
160-15	34354-34365	perspective	_	
160-16	34366-34368	on	_	
160-17	34369-34379	delusional	_	
160-18	34380-34395	states—evidence	_	
160-19	34396-34399	for	_	
160-20	34400-34409	claustrum	_	
160-21	34410-34421	involvement	_	
160-22	34422-34440	Dopamine-dependent	_	
160-23	34441-34451	prediction	_	
160-24	34452-34458	errors	_	
160-25	34459-34467	underpin	_	
160-26	34468-34482	reward-seeking	_	
160-27	34483-34492	behaviour	_	
160-28	34493-34495	in	_	
160-29	34496-34502	humans	_	
160-30	34503-34511	Temporal	_	
160-31	34512-34522	prediction	_	
160-32	34523-34529	errors	_	
160-33	34530-34538	modulate	_	
160-34	34539-34556	cingulate-insular	_	
160-35	34557-34565	coupling	_	
160-36	34566-34573	Seeking	_	
160-37	34574-34575	a	_	
160-38	34576-34583	unified	_	
160-39	34584-34593	framework	_	
160-40	34594-34597	for	_	
160-41	34598-34608	cerebellar	_	
160-42	34609-34617	function	_	
160-43	34618-34621	and	_	
160-44	34622-34633	dysfunction	_	
160-45	34633-34634	:	_	
160-46	34635-34639	from	_	
160-47	34640-34647	circuit	_	
160-48	34648-34658	operations	_	
160-49	34659-34661	to	_	
160-50	34662-34671	cognition	_	
160-51	34672-34681	Consensus	_	
160-52	34682-34687	paper	_	
160-53	34687-34688	:	_	
160-54	34689-34692	the	_	
160-55	34693-34697	role	_	
160-56	34698-34700	of	_	
160-57	34701-34704	the	_	
160-58	34705-34715	cerebellum	_	
160-59	34716-34718	in	_	
160-60	34719-34729	perceptual	_	
160-61	34730-34739	processes	_	
160-62	34740-34748	Distinct	_	
160-63	34749-34759	cerebellar	_	
160-64	34760-34773	contributions	_	
160-65	34774-34776	to	_	
160-66	34777-34786	intrinsic	_	
160-67	34787-34799	connectivity	_	
160-68	34800-34808	networks	_	
160-69	34809-34817	Saliency	_	
160-70	34817-34818	,	_	
160-71	34819-34828	switching	_	
160-72	34828-34829	,	_	
160-73	34830-34839	attention	_	
160-74	34840-34843	and	_	
160-75	34844-34851	control	_	
160-76	34851-34852	:	_	
160-77	34853-34854	a	_	
160-78	34855-34862	network	_	
160-79	34863-34868	model	_	
160-80	34869-34871	of	_	
160-81	34872-34878	insula	_	
160-82	34879-34887	function	_	
160-83	34888-34889	A	_	
160-84	34890-34898	critical	_	
160-85	34899-34903	role	_	
160-86	34904-34907	for	_	
160-87	34908-34911	the	_	
160-88	34912-34917	right	_	
160-89	34918-34932	fronto-insular	_	
160-90	34933-34939	cortex	_	
160-91	34940-34942	in	_	
160-92	34943-34952	switching	_	
160-93	34953-34960	between	_	
160-94	34961-34978	central-executive	_	
160-95	34979-34982	and	_	
160-96	34983-34995	default-mode	_	
160-97	34996-35004	networks	_	
